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Over the recent years, venlafaxine has become the predominant antidepressant drug 
detected in municipal wastewater effluents (MWWE) and aquatic systems. However, very 
little is known about the effect of this drug in the aquatic environment on non-target 
organisms, including fish. Venlafaxine is a pharmaceutical compound designed to inhibit 
serotonin and norepinephrine reuptake, thereby increasing the synaptic availability of these 
neurotransmitters. In teleosts, the key aspect of stress adaptation involves the activation of 
the hypothalamus-pituitary-interrenal (HPI) axis, leading to the production of cortisol. Given 
that monoamine neurotransmitters (serotonin, norepinephrine, and dopamine) are involved in 
the regulation of a wide range of neuroendocrine responses, including stress axis function, 
my primary hypothesis was that venlafaxine acts as a neuroendocrine disruptor impacting the 
functioning of the corticosteroid stress axis in rainbow trout (Oncorhynchus mykiss). This 
hypothesis was tested through a series of in vivo exposure studies, as well as in vitro 
experiments, using environmentally relevant levels of venlafaxine, in order to tease out 
potential mode of action of this drug on target tissues involved in HPI axis functioning.  
The results suggest that venlafaxine alters monoamine neurotransmitter levels and 
their turnover rates in a region-specific manner in trout brain, and that the midbrain is the 
prime target. The monoamine changes may be responsible for the downstream effects on 
neuroendocrine responses coordinated in the hypothalamus, as this region receives 
monoaminergic inputs from the midbrain. The functional relevance of the above finding was 
confirmed by showing that venlafaxine exposure disrupted the neuroendocrine responses 
associated with social stress and appetite regulation. Functional downstream effects of HPI 
axis dysfunction were further confirmed by subjecting the fish to a handling disturbance, 
which revealed that the highly conserved cortisol and glucose responses to stressors were 
disrupted by venlafaxine. Also, there were tissue-specific effects of venlafaxine exposure on 
metabolic capacities, including enhanced gluconeogenesis and amino acid catabolism in the 
liver (a key glucose producing tissue), and alterations in the glycolytic capacity and sodium 
potassium ATPase activity in the gill (a key glucose utilizing tissue).  
 
 v 
The results suggest that the mode of action of venlafaxine may involve disruption of 
each target tissue involved in the HPI axis functioning. In vitro mechanistic studies indicated 
that hypothalamus functioning is disrupted by venlafaxine and this may involve effects 
mediated by serotonergic pathways. The reduced phosphorylation of cAMP response element 
binding protein (CREB) suggests that venlafaxine may impact downstream signalling 
cascades that are CREB-dependent. The transcript changes observed with venlafaxine in the 
hypothalamus include changes in mRNA levels of key genes involved in appetite regulation 
and stress response, including corticotropin releasing factor (CRF) and neuropeptide Y 
(NPY). At the pituitary level, venlafaxine impaired adrenocorticotropic hormone (ACTH) 
production, and this involved disruption of corticotropin releasing factor-receptor type 1 
(CRF-R1), which is a key sensor for CRF stimulation. At the interrenal tissue level, the 
responsiveness of steroidogenic cells to ACTH stimulation was altered by venlafaxine and 
the mode of action appears to involve pathways upstream of the intracellular cAMP 
production. Also, cortisol biosynthetic capacity was disrupted by venlafaxine and this was 
accompanied by changes in transcript abundances of steroidogenic acute regulatory protein 
and cytochrome P450 side chain cleavage in the interrenal tissue.  
Taken together, the results demonstrate for the first time that the antidepressant 
venlafaxine, a human pharmaceutical contaminating aquatic systems, disrupts 
neuroendocrine responses and affects stress, feeding and metabolic responses in rainbow 
trout. The mode of action may include disruptions in brain monoamine levels and pathways 
involved in CREB signalling, while the exact mechanism of action remains to be elucidated.  
Exposure of fish to this pharmaceutical drug adversely affects the highly conserved adaptive 
responses that are essential to cope with subsequent stressors, and may translate into reduced 
fitness over the long-term. The findings underscore the necessity to understand the 
mechanisms of action of chemicals present in MWWE, and develop and utilize effective risk 
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Over the last two decades, pharmaceuticals became recognized as an important source 
of environmental contamination. Many drugs are only partially removed by wastewater 
treatment process, and often remain biochemically active upon reaching the ecosystem. 
Human consumption of antidepressant drugs has been on the rise, and venlafaxine has 
become a predominant antidepressant detected in aquatic environments across North 
America and Europe. Main therapeutic properties of this psychotropic drug are based upon 
modulation of important monoamine neurotransmitters, serotonin and norepinephrine, in the 
human brain. Many drug targets, including neurotransmitter systems and neuroendocrine 
pathways, are highly conserved among vertebrates, suggesting that fish are likely to be 
affected by environmental drug exposure. Monoamine neurotransmitters are intimately 
interconnected with the neuroendocrine pathways that regulate various physiological and 
behavioural stress response mechanisms. Stress response is an essential adaptive mechanism 
that allows an animal to meet increased energy demands associated with stressor exposure 
and to regain homeostasis. In fish, a non-target organism for human pharmaceuticals, 
alterations of monoamine levels by antidepressants, including venlafaxine, may disrupt 
neuroendocrine components of the hypothalamus-pituitary-interrenal (HPI) axis, leading to 
impact on downstream physiological and/or behavioural responses. This chapter provides 
insights into the main concepts addressed throughout this thesis in order to establish potential 
links between environmental exposure to this pharmaceutical and stress physiology in fish, 
and highlight a relative lack of knowledge in this area.   
1.2 Pharmaceuticals in the aquatic environment 
Municipal wastewater effluent (MWWE) is a primary source introducing 
pharmaceutical contamination in the aquatic environment (Chambers et al., 1997). 
Inadequacy of wastewater treatment methods combined with low environmental 
degradability leads to environmental pollution with pharmaceutical compounds and their 
metabolites, which often remain biochemically active upon reaching the ecosystem 
(Corcoran et al., 2010).  
The issue of environmental contamination with pharmaceutical agents did not receive 
much attention until the 1990s (Henschel et al., 1997; Purdom et al., 1994), when it was 
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discovered that many compounds can exhibit biological effects and have an ability to 
interfere with ecosystems in trace concentrations, as low as few nanograms per litre (Halling-
Sørensen et al., 1998). Development of analytical methods for detection and quantification of 
pharmaceutical residues in environmental samples (Gros et al., 2006; Ternes, 2001) allowed 
conducting accurate assessments of contamination levels. The rise in pharmaceutical 
consumption world-wide has resulted in an increasing deposition of these drugs into the 
aquatic environment (Corcoran et al., 2010). Pharmaceutical contamination is of major 
concern in regards to its impact on ecosystem health, especially because so little is known 
about its effect on non-target organisms, including fish.  
Human pharmaceutical groups that are commonly detected in the environment 
include analgesics, antibiotics, β-blockers, lipid-regulators, anti-inflammatories, 
contraceptives and psychiatric drugs (e.g. anxiolytics, sedatives, antidepressants) (Jones et 
al., 2001). In most cases pharmaceuticals are characterized by highly specific modes of 
action to reduce potential toxicity, a high degree of stability and prolonged activity to 
minimize dosing requirements and ensure sufficient therapeutic activity before elimination 
(Winter et al., 2010). 
A large number of potential target sites for pharmaceutical agents are evolutionarily 
conserved across the animal kingdom (e.g. neurotransmitter systems, metabolic pathways, 
signalling pathways, etc.), therefore, many compounds that are designed to affect humans or 
livestock are likely to be biologically active in non-target wildlife species (Gunnarsson et al., 
2008; Corcoran et al., 2010). As a result, inadvertent exposure of non-target organisms, such 
as fish, to active pharmaceutical components may lead to adverse effects that may translate 
into reduced fitness and reproduction (Santos et al., 2010). From an ecotoxicological 
standpoint, it is important to study the effects of the MWWE mixtures on aquatic organisms 
in order assess overall exposure impact. In addition, it is also essential to investigate effects 
of individual pharmaceutical components of such complex effluent mixtures in order to 
elucidate their mechanisms of action in non-target species. 
1.2.1 Antidepressant drugs 
Over the last two decades, antidepressant drugs have become a significant source of 
aquatic contamination due to a constantly increasing human consumption. Antidepressant 
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drugs are in the top ten list of pharmaceutical classes ranked by global sales, and 
antidepressants comprise a large portion of worldwide medicinal prescriptions (IMS Health, 
2010). Selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake 
inhibitors (SNRIs) are the most common classes of antidepressants that are used to treat 
depression, anxiety, obsessive-compulsive disorders, and panic disorders (Silverstone, 2004). 
SSRIs (e.g. fluoxetine, sertraline, citalopram) selectively inhibit presynaptic neuronal 
reuptake of serotonin (5-HT), while SNRIs (e.g. duloxetine, venlafaxine) block 5-HT and 
norepinephrine (NE) reuptake, thus increasing synaptic availability of these neurotransmitters 
(Horst and Preskorn, 1998) (Fig. 1-1). Interestingly, antidepressant effects of drugs with 5-
HT reuptake inhibiting properties appear only after 2-4 weeks of administration, despite the 
fact that reuptake inhibition happens immediately (Celada et al., 2004; Gardier et al., 1996). 
Acute administration of SSRIs leads to a rapid elevation of extracellular 5-HT levels due to 
reuptake inhibition, and is then followed by activation of an intrinsic negative feedback 
mechanism that controls presynaptic neuronal firing. This mechanism involves 
somatodendritic 5-HT1A autoreceptors on presynaptic neurons. However, chronic treatment 
leads to desensitization of these autoreceptors and normalizes firing rate of presynaptic 5-HT 
neurons, while postsynaptic 5-HT1A receptors become sensitized in the forebrain areas (Blier 
and Abbott, 2001; Hjorth et al., 2000). Consequently, long-term treatment with SSRIs results 
in amplification of 5-HT neurotransmission and onset of the antidepressant effects. However, 
there is no conclusive evidence confirming 5-HT autoreceptors desensitization by SNRI 
drugs (Roseboom and Kalin, 2000). 
History of the antidepressant drugs [reviewed in (Janowsky, 2004)] goes back to the 
late 1950s. Introduction of monoamine oxidase inhibitors (MAOIs) and the tricyclic 
antidepressants revolutionized the treatment of depression. Due to undesirable side effects of 
MAOIs (e.g. induction of hypertensive crisis), their popularity decreased, while tricyclic 
antidepressants (e.g. imipramine, desipramine) gained popularity. In the late 1980s SSRIs 
were introduced on the market (beginning with fluoxetine) and soon after, commercialization 
of similar compounds followed (paroxetine, sertraline, fluvoxamine). SSRIs soon replaced 
tricyclic antidepressants due to their characteristics, which offered reduced side effects in 
comparison to the tricyclic compounds (i.e. lack of lack of anticholinergic effects, reduced 
toxicity in overdose). In the mid-1990s, SRNIs were introduced (serotonergic and 
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Figure 1-1. Diagram representing pharmacological mechanism of serotonin and 
norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine. When pre-synaptic nerve 
terminals of serotonergic and noradrenergic neurons are depolarized, serotonin (5-HT) and 
norepinephrine (NE) are released into the synaptic cleft and subsequently bind to their 
corresponding receptors on a post-synaptic cell. Venlafaxine blocks 5-HT and NE re-uptake 
transporters, which take up these neurotransmitters back into the presynaptic terminals, 
leading to increasing concentrations of these neurotransmitter in the synapse. 
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1.2.2 Pharmacological profile of venlafaxine 
Over the last decade, venlafaxine, also known under the brand name Effexor (first 
introduced by Wyeth Pharmaceuticals, Inc.), became one of the most frequently prescribed 
antidepressant drugs due to its faster therapeutic onset and fewer side effects in patients 
(Horst and Preskorn, 1998). According to IMS Health (2011), venlafaxine was number seven 
on the list of most dispensed medications in 2010 in Canada. Although it is a dual reuptake 
inhibitor, it has a stronger effect on 5-HT reuptake compared to NE (Roseboom and Kalin, 
2000). This drug also has a relatively weak effect on dopamine (DA) reuptake (Roseboom 
and Kalin, 2000). Venlafaxine can modulate DA levels in a region-specific manner, although 
the underlying mechanism may be a reflection of alteration in NE levels, since noradrenergic 
neurons modulate mesolimbic and mesocortical DA systems (Muneoka et al., 2009; 
Liprando et al., 2004). Venlafaxine undergoes first-pass metabolism in liver, particularly by 
the CYP2D6 isoenzyme (Thase and Sloan, 2009). Its major metabolite is O-
desmethylvenlafaxine, which has a similar potency to the parent compound for inhibiting 
neurotransmitter reuptake, and it contributes significantly to the overall antidepressant 
efficacy of the drug (Roseboom and Kalin, 2000). Renal elimination of venlafaxine and its 
metabolites is the primary route of excretion for these compounds; clearance rate O-
desmethylvenlafaxine (10 h half-life) is slower than that of venlafaxine (4 h half-life) (Thase 
and Sloan, 2009). 
1.2.3 Environmental presence of venlafaxine 
Environmental values of venlafaxine were reported as high as 2.19 μg/L in MWWE 
(St. Paul, MN, USA) and 1.31 μg/L in the effluent-dominated creek (Pecan Creek, Denton, 
TX) (Schultz and Furlong, 2008). A recent study reported the occurrence of these compounds 
in different German rivers and streams at concentrations ranging from 18-122 ng/L for 
venlafaxine, and 23-743 ng/L for O-desmethylvenlafaxine (Rúa-Gomez and Püttmann, 
2012). 
Metcalfe et al. (2010) reported that locally, in the Grand River watershed (ON, 
CAN), venlafaxine and its metabolite were present in significantly higher concentrations 
compared to other antidepressants/metabolites in the untreated and treated MWWE, as well 
as in the receiving waters as far as 17 km downstream of a municipal wastewater treatment 
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plant. The removal rates for these compounds from the MWWE were around 40%. 
Concentrations of venlafaxine and O-desmethylvenlafaxine were measured at 0.253 µg/L and 
0.486 µg/L, respectively, in MWWE collected downstream of the tertiary sewage treatment 
plant in Guelph, ON, CAN (Ings, 2011). In general, removal rates for venlafaxine and its 
major metabolite were shown to be inefficient, leading to their continual discharge in waters 
(Rúa-Gomez and Püttmann, 2012; Schultz et al., 2010; Metcalfe et al., 2010). Indirect 
photodegradation appears to be the dominant degradation process responsible for removal of 
these pharmaceuticals from the environment, and the half-lives of venlafaxine and O-
desmethylvenlafaxine determined from the field experiment were 51 and 18 h, respectively 
(Rúa-Gómez and Püttmann, 2013).   
1.2.4 Effects of antidepressants on non-target species 
Despite the overwhelming evidence of environmental contamination with 
antidepressant drugs, relatively little research has been carried out to elucidate their potential 
effects as well as their mechanisms of action on non-target animals, including fish. The 
majority of research in this field has been focused on fluoxetine (also known under the trade 
name Prozac, originally marketed by Eli Lilly & Co.), which was marketed as the first SSRI 
drug in 1987 (Mennigen et al., 2011). It remains one of the most commonly prescribed 
antidepressants and frequently detected in the environment (Oakes et al., 2010). Fluoxetine 
and norfluoxetine show a high degree of bioaccumulation in fish relative to other 
antidepressants, especially in the neural tissue (Schultz et al., 2010). Studies demonstrated 
that fluoxetine reduces fish growth and feeding in fathead minnows (Pimephales promelas) 
(Stanley et al., 2007), increases circulating estradiol levels in females of Japanese medaka 
(Oryzias latipes) (Brooks et al., 2003), affects ovarian steroid hormone levels and gene 
expression in zebrafish (Danio rerio) (Lister et al., 2009), decreases food intake, weight and 
disrupts reproductive physiology in goldfish (Carassius auratus) (Mennigen et al., 2010; 
Mennigen et al., 2009), and diminishes aggressive behaviours in Siamese fighting fish (Betta 
splendens) (Dzieweczynski and Hebert, 2012). Another environmental concern regarding 
pharmaceutical exposure arises from the fact that some compounds may have synergistic or 
additive effects due to similarities in their pharmacological modes of action. For example, 
Christensen et al. (2007) have demonstrated that several SSRIs produced additive toxic 
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effects on the tested algae and crustacean species. However, there is no data available on 
possible additive or synergistic effects of antidepressants from the SNRI class, such as 
venlafaxine and duloxetine.  
Despite the growing environmental relevance of venlafaxine, only a small number of 
studies have examined the effect of this drug in fish. In trout hepatocytes in vitro, high 
concentrations of venlafaxine (100 and 1000 nM) attenuated the epinephrine-stimulated 
glucose production and this involved inhibition of β-adrenoreceptor signalling (Ings et al., 
2012). Genome analysis in fathead minnows exposed to pharmacological concentration of 
venlafaxine revealed upregulation of several genes involved in neural development and 
signalling (Thomas et al., 2012). Painter et al. (2009) demonstrated that environmentally 
relevant concentrations of venlafaxine adversely affect predator avoidance behaviour in 
larval fathead minnows. Assessments of venlafaxine levels in the neural tissue of fish suggest 
that this drug does not bioaccumulate during environmental exposures (Schultz et al., 2011; 
Schultz et al., 2010). Fathead minnows exposed to environmentally relevant concentration 
(305 and 1104 ng/L) of venlafaxine suffered significant mortality after a 21-day exposure 
(Schultz et al., 2011). A study based on a 6-day exposure of hybrid striped bass (Morone 
saxatilis x Morone chrysops) to venlafaxine (35-500 μg/L range) showed a significant 
reduction in total brain 5-HT levels and increased length of time needed to capture pray 
(Bisesi et al., 2014). Together, the picture that is emerging from these studies is that 
venlafaxine may be acting as a neuroendocrine disruptor in fish. As corticosteroid response 
to stressor is a highly conserved adaptive response in vertebrates to reestablish homeostasis, 
any impact on this neuroendocrine stress response by the drug may lead to reduced fitness.  
1.3 Stress response in fish 
In fish, as in other vertebrates, stress involves disturbance of the homeostatic 
equilibrium of the organism by stressors, which may include intrinsic or extrinsic stimuli 
(chemical, physical, or biological) (von Holst, 1998; Vijayan et al., 2010). In order to regain 
homeostasis, fish exhibit an adaptive response that consists of a suite of coordinated 
physiological and behavioural reactions, referred to as the stress response (Vijayan et al., 
2010). Such adjustments ultimately result in altered digestive, respiratory, metabolic, 
osmoregulatory, immune and reproductive functions in order to re-establish the internal 
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milieu (Sapolsky et al., 2000). Physiological responses to acute stress are generally 
categorized into the primary (neuroendocrine/endocrine activation), secondary (biochemical 
and physiological adjustments) and tertiary responses (population level changes).   
 The primary response (Fig. 1-2) involves a rapid increase in tone of the sympathetic 
nervous system and activation of the hypothalamic-sympathetic-chromaffin cell axis (HSC), 
also known as the fight-or-flight response (Mommsen et al., 1999). HSC axis activation leads 
to the release of catecholamines, epinephrine (E) and norepinephrine (NE), into the general 
circulation from the chromaffin cells (Vijayan et al., 2010). Chromaffin cells are clustered 
within the anterior (head) kidney region around post-cardinal vein along with glucocorticoid-
producing interrenal cells (Hontela and Vijayan, 2009; Wendelaar Bonga, 1997). Release of 
catecholamines is essential for adjustment of cardiovascular and respiratory systems for 
enhanced blood oxygen transport, and mobilization of energy substrates to meet increased 
energy demands that accompany stress (Reid et al., 1998; Wendelaar Bonga, 1997). The 
activation of the hypothalamus-pituitary-interrenal axis (HPI), which is analogous to 
mammalian hypothalamic-pituitary-adrenal axis (HPA), is delayed (within minutes) relative 
to catecholamine secretion. Activation of the HPI axis leads to the release of cortisol, the 
primary glucocorticoid hormone in teleosts, which is synthesized by the steroidogenic cells 
dispersed within the interrenal tissue (Vijayan et al., 2010). Fish, unlike mammals, do not 
have a discrete adrenal gland and the interrenal tissue is distributed mostly in the head kidney 
region (Wendelaar Bonga, 1997; Mommsen et al., 1999). Cortisol mediates essential 
physiological adaptations to stress, including regulation of energy metabolism, hydromineral 













Figure 1-2. The stress axis in teleost fish. Upon perception of stress stimuli, immediate 
neuroendocrine response is activated.  Rapid activation of the hypothalamic-sympathetic-
chromaffin cell (HSC) axis leads to increased sympathetic nerve firing and release of 
catecholamines (epinephrine and norepinephrine) from chromaffin cells in the head kidney 
region into the general circulation. Activation of the hypothalamus-pituitary-interrenal axis 
(HPI) involved release of corticotropin-releasing factor (CRF) from hypothalamus, which 
stimulates corticotroph cells of the anterior pituitary to secrete adrenocorticotropic hormone 
(ACTH) into the general circulation. ACTH acts on the interrenal cells of the head kidney to 
increase cortisol production and output into the bloodstream. Cortisol release is regulated by 
a negative feedback mechanism. Overall, the stress hormones (catecholamines and cortisol) 
will initiate a series of physiological adjustments that allow an animal to re-establish 
homeostasis. Green arrows indicate secretion; red lines indicate negative feedback inhibition. 






















The secondary stress response mediated by catecholamines and glucocorticoids 
results in a series of physiological adjustments (e.g. metabolism, cellular changes, acid-base 
and hydromineral balance, immune function), enhancing delivery of energy substrates to 
tissues with higher energy demands (Barton, 2002; Mommsen et al., 1999). In addition, 
tertiary response may occur, involving changes at the whole-animal and populations levels 
(Barton, 2002; Iwama, 1998). For instance, prolonged stress response may lead to exhaustion 
associated with reallocation of energy resources away from critical processes to cope with 
stress. This may lead to negative consequences, including decreased growth and 
reproduction, increased disease susceptibility and mortality (Barton, 2002; Iwama, 1998).   
1.4 Hypothalamus-pituitary-interrenal axis (HPI) 
As stated earlier, activation of the HPI axis, resulting in the synthesis and release of 
glucocorticoid hormone cortisol, is an integral component of stress response (Fig. 1-3A). The 
following section describes in detail elements of the teleost HPI axis, as well as the 
neuroendocrine and endocrine responses involving the hypothalamus, pituitary and interrenal 
tissue. 
1.4.1 Hypothalamus 
Activation of the HPI axis is initiated at the level of hypothalamus, a brain region that 
receives and integrates inputs transmitted from central and peripheral nervous systems. The 
first step in the HPI axis activation leads to the release of the neuropeptide, corticotropin 
releasing factor (CRF), from the hypothalamic neurosecretory cells into the anterior pituitary 
(Fig. 1-3A). CRF stimulates secretion of the adrenocorticotropic hormone (ACTH) by 
corticotroph cells in the anterior pituitary (rostral pars distalis) (Mommsen et al., 1999; 
Wendelaar Bonga, 1997). In mammals, CRF is delivered to the anterior pituitary via intrinsic 
hypophyseal circulatory portal system (Chrousos, 1998). Teleosts, in contrast, do not have 
such hypophyseal portal system and axon projections of the hypothalamic neurosecretory 
cells make direct synaptic contacts with the pituitary corticotrophs (Bernier et al., 2009). 
CRF-producing neurons originating in the nucleus preopticus (NPO), analogous to the 
mammalian paraventricular nucleus (PVN), are known to play a pivotal role in stress-
mediated ACTH secretion (Flik et al., 2006). CRF bioavailability is regulated by CRF 
binding protein (CRF-BP) (Bernier et al., 2008; Bernier, 2006).  This neuropeptide mediates 
 
 14 
its effects via two types of receptors in teleosts: CRF-R1 and CRF-R2 (Pohl et al., 2001). 
CRF-R1 plays an important role in the stress axis, while CRF-R2 is involved in a broad range 
of physiological and behavioural responses (e.g. feeding, learning, vascular tone) (Flik et al., 
2006). Even though CRF is a major player of stress-induced ACTH secretion in fish, other 
hypothalamic neuropeptides, including arginine vasotocin and urotensin, are also involved in 




























Figure 1-3. Overview of the major components of the teleost hypothalamus-pituitary-
interrenal axis (HPI) and associated signalling cascades (A). Sagittal view of the brain shows 
enlarged preoptic and hypothalamic brain areas along with pituitary gland. Corticotropin-
releasing-factor (CRF)-producing neurons originating from the nucleus preopticus (NPO) 
make synaptic connections with the corticotroph cells in the rostral pars distalis (RPD) of the 
pituitary. CRF release from NPO-originating neurons leads to activation of CRF-R1 and 
CRF-R2 (receptor 1 and 2) signalling in the corticotrophs, leading to secretion of 
adrenocorticotropic hormone (ACTH) into the bloodstream. In the interrenal cells (in head 
kidney region), ACTH initiates cortisol synthesis via melanocortin type 2 receptor (MC2R) 
signalling. Upon reaching target tissues, cortisol mediates its genomic effects via 
glucocorticoid and mineralocorticoid receptors (GR and MR, respectively), and rapid non-
genomic action by membrane-associated mechanisms. Representation of cortisol biosynthetic 
pathway (taking place in the interrenal cells) showing enzymatic reactions occurring within 
the mitochondrial compartment (inside shaded area) and cytosolic compartment (outside 
shaded area) (B). Once cholesterol is transported to the inner mitochondrial membrane by 
steroidogenic acute regulatory protein (StAR), it gets converted to pregnenolone by 
cytochrome P450 side chain cleavage enzyme (P450scc), which serves as a substrate for a 
series of reactions catalyzed by 17-α-hydroxylase (P450c17), 3β-hydroxysteroid 
dehydrogenase (3β-HSD), steroid 21-hydroxylase (P450c21), and 11-β-hydroxylase 
















1.4.2 Pituitary gland 
Pituitary corticotroph cells produce ACTH from a precursor peptide pro-
opiomelanocortin (POMC) and release it into the general circulation (Mommsen et al., 1999; 
Wendelaar Bonga, 1997). In vertebrates, POMC is a precursor for several biologically active 
peptides, including the opioid, β-endorphin, and the melanocortin-related peptides, ACTH, α-
melanocyte stimulating hormone (α-MSH), β-MSH, and γ-MSH (Tanaka, 2003). Proteolytic 
cleavage of large POMC peptide is catalyzed by prohormone convertases (PC) in a tissue-
specific manner. In the corticotrophs, the major products of POMC cleavage by PC1 include 
ACTH and β-lipotrophic hormone. Salmonids possess two copies of POMC genes, POMC A 
and POMC B, which arose from a genome duplication event (Salbert et al., 1992). Both gene 
products are found in the pituitary, and expression of the different POMC transcripts could 
vary with life-history stage or in response to environmental conditions (Leder and 
Silverstein, 2006). 
1.4.3 Interrenal tissue 
The sequence of events in the interrenal tissue involves the binding of ACTH to 
melanocortin 2 receptor (MC2R), leading to the activation of cortisol biosynthetic pathway 
(Aluru and Vijayan, 2008). MC2R is a G-protein-coupled receptor belonging to the family of 
melanocortin receptors (MCRs). ACTH binding to MC2R activates adenylate cyclase and 
cAMP signalling cascade, leading to initiation of cholesterol delivery to the inner 
mitochondrial membrane, followed by a series of enzymatic reactions (Vijayan et al., 2010).  
Steroidogenic acute regulatory protein (StAR) mediates transport of cholesterol to the inner 
mitochondrial membrane (Sierra, 2004), and this step is often considered as the rate-limiting 
step in steroid synthesis. Also, peripheral-type benzodiazepine receptor (PBR) is known to 
facilitate mitochondrial cholesterol trafficking (Papadopoulos, 2004), but its precise role in 
fish remains unclear.  The first enzymatic reaction involves conversion of cholesterol to 
pregnenolone by cytochrome P450 side chain cleavage (P450scc) and pregnenolone serves as 
a precursor for all biological steroids. A detailed pathway of cortisol biosynthesis is 
presented in Fig. 1-3B. Although several pituitary and extra pituitary hormones (e.g. α-MSH, 
β-endorphin) are involved in regulation of cortisol secretion, ACTH is the primary 
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secretogogue for cortisol secretion in fish (Vijayan et al., 2010; Bernier et al., 2009; 
Wendelaar Bonga, 1997; Mommsen et al., 1999).  
1.4.4 Plasma cortisol response 
Cortisol response to acute stressor is a well-established physiological response and 
commonly used as an indicator of stress in fish. Acute stressor exposure causes a transient 
surge in plasma cortisol concentrations, followed by a decline to basal levels over a 24 h 
period (Vijayan et al., 2010). Plasma levels of cortisol are dependent upon the net effect of 
its production and clearance, and hormonal clearance is usually determined by a combination 
of several factors, including binding proteins, target tissue receptors, uptake and catabolism 
(Mommsen et al., 1999). Mammals are known to have cortisol binding globulin (CBG) 
regulating the amount of free plasma cortisol (i.e. bioavailable form) (Gayrard et al., 1996), 
while there is no evidence of CBG in the plasma of fish (Mommsen et al., 1999). Both 
sensitivity of the stress axis and amplitude of cortisol output are influenced by genetic, 
developmental and environmental factors, as well as the intensity and duration of the 
stressors (Vijayan et al., 2010; Barton, 2002). For example, strain differences in cortisol 
responsiveness to stressors have been demonstrated and used to establish high- and low-
responsive rainbow trout lines by selective breeding (Pottinger and Carrick, 1999). Under 
non-stressed conditions, basal cortisol levels are influenced by circadian rhythms for 
maintenance of normal physiological functions (Wendelaar Bonga, 1997). In addition, 
seasonal rhythms, reproductive state and gonadal steroids also affect basal and stress-induced 
cortisol levels (Norris, 2000).  Measurement of plasma cortisol levels provides a great tool 
for assessment of acute stress in fish. Since catecholamine response is very rapid and occurs 
immediately when animals are handled, measuring resting (basal) plasma levels is very 
difficult. In contrast, stress-induced cortisol release is slightly delayed, and resting levels can 
be accurately measured when animals are anaesthetised and sampled quickly (Vijayan et al., 
2010).  
1.4.5 Cortisol signalling 
Genomic signalling of cortisol and its negative feedback regulations are mediated by 
intracellular corticosteroid receptors, glucocorticoid (GR) and mineralocorticoid (MR), 
which are ligand-dependent transcription factors (Aluru and Vijayan, 2009). In brief, 
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classical GR signalling (Fig. 1-4) is initiated by binding of cortisol to cytosolic GR. Upon 
binding, molecular chaperones that are associated with GR in the cytoplasm are released. A 
homodimer of activated GR forms in the cytoplasm, and following translocation into the 
nucleus, it binds to  a glucocorticoid response element (GRE) within a promoter region of a 
glucocorticoid-responsive gene leading to alterations in gene expression (Prunet et al., 2006). 
In addition to its ability to bind to GR, cortisol also has high affinity for MR (10-fold higher 
than GR) (Greenwood et al., 2003).  Mammals have another natural ligand for MR, 
aldosterone, a hormone involved in the control of hydromineral balance. Cortisol is usually 
inactivated in MR-specific tissues by the enzyme 11β-hydroxysteroid dehydrogenase type 2 
(11βHSD2), permitting aldosterone binding and mediation of its effects (Pascual-Le Tallec 
and Lombes, 2005). Teleosts do not produce aldosterone and it is not clear whether MR has 
another natural ligand, although there is some evidence that another circulating 
corticosteroid, 11-deoxycorticosterone, may be a candidate (Sturm et al., 2005).   
Rainbow trout, like most teleosts, possess two GR isoforms, encoded by GR1 and 
GR2 genes (Alsop and Vijayan, 2008). These receptor isoforms have different properties: 
GR2 has greater transactivational activity and higher binding affinity for cortisol than GR1. 
GR2 is sensitive to lower cortisol concentrations than GR1, and the latter receptor type is 
thought to be activated by stressor-induced levels of cortisol (Sturm et al., 2011; Prunet et 
al., 2006). Suppression of cortisol secretion by the negative feedback mechanisms is an 
important component of proper HPI axis functioning. Prolonged elevation of glucocorticoids 
can result in detrimental effects, including suppression of reproduction, immune response, 
and growth (Norris, 2000; Wendelaar Bonga, 1997). This neuroendocrine feedback loop 
involves cortisol inhibition of hypothalamic CRF and pituitary ACTH secretion. In fish, a 
recent study demonstrated that the central and peripheral GR signalling is essential for the 
negative feedback regulation of plasma cortisol levels (Alderman et al., 2012). 
 In addition to the classical genomic signalling mechanisms, all steroid hormones, 
including glucocorticoids, are known to exhibit rapid effects on various physiological 
processes (Borski, 2000). These rapid effects are known to be independent of gene 
transcription and are mediated by membrane-associated mechanisms. For example, it has 
been shown that in vitro exposure to cortisol rapidly alters fluidity, surface topography, and 
elasticity of hepatic plasma membranes in rainbow trout (Dindia et al., 2012). Cortisol-
 
 20 
mediated membrane alterations have been shown to be associated with activation of 
intracellular stress signalling pathways, including increased phosphorylation of extracellular 
signal-related kinases as well as several putative protein kinase A (PKA) and protein kinase 
C (PKC) substrate proteins (Dindia et al., 2013). However, most of the studies on cortisol 
signalling in fish have focused on genomic signalling by GR activation, while the 































Figure 1-4. Schematic diagram of classical (genomic) glucocorticoid receptor (GR) 
signalling. Cortisol diffuses through plasma membrane due to its lipophilic nature. In cytosol, 
cortisol binds GR, which is thought to be bound by molecular chaperones in teleosts. Cortisol 
binding leads to disassociation of molecular chaperones and subsequent homodimerization of 
the activated receptor. This complex then translocates into the nucleus, where it acts as a 
transcription factor regulating expression of target genes via binding to the glucocorticoid 
response elements (GREs).  
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1.4.6 Metabolic effects of cortisol 
Stress in energy demanding, and the primary role of cortisol is to mobilize energy 
substrates to fuel metabolic demands associated with stress (Mommsen et al., 1999). While 
catecholamines are involved in the fight-or-flight response by increasing glucose production 
via glycogenolysis (breaking down glycogen stores), cortisol plays a role in the longer-term 
glucose maintenance (Vijayan et al., 2010; Mommsen et al., 1999). The metabolic effects of 
cortisol during stress are aimed at increasing rates of gluconeogenesis − production of 
glucose from non-carbohydrate substrates, glycolysis, which may be critical to cope with 
increased liver energy demand, and proteolysis and lipolysis (Vijayan et al., 2010; Mommsen 
et al., 1999).  Previous studies in fish have demonstrated that both stress and cortisol elevate 
transcript abundances and/or enzymatic activity of the key gluconeogenic enzyme, 
phosphoenolpyruvate carboxykinase (PEPCK), which catalyzes the rate-limiting step in 
gluconeogenesis (conversion of oxaloacetate into phosphoenolpyruvate) and the enzymes 
involved in amino acid catabolism, alanine aminotransferase (AlaAT) and aspartate 
aminotransferase (AspAT), providing important source of substrates for liver 
gluconeogenesis  (Gravel and Vijayan, 2007; Wiseman et al., 2007; Vijayan et al., 2003; 
Vijayan et al., 1994). In addition, cortisol has been associated with upregulation of the 
glycolytic enzymes, including hexokinase, pyruvate kinase, and lactate dehydrogenase 
(Gravel and Vijayan, 2007; Vijayan et al., 1994). Stress-induced glucose response is an 
essential evolutionarily conserved physiological mechanism that allows an organism to 
regain homeostasis. Impairment of this adaptive response by exogenous means, such as 
exposure to certain water contaminants, may affect energy metabolism and result in 
decreased capacity to cope with other environmental stressors. 
1.5 Neural inputs regulating stress axis activation 
In contrast to mammals, the sensory components of the stress axis are less studied in 
fish, although there seems to be a high degree of homology in the brain circuitry and 
neurotransmitter mechanisms regulating stress axis in all vertebrates. In mammals, neuronal 
circuits involved in activation and regulation of the HPA axis have been well documented 
(Carrasco and Van de Kar, 2003; Herman and Cullinan, 1997). Multiple brain structures and 
a variety of neurotransmitters are involved in coordination of the stress responses. Interaction 
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between the stress-sensitive pathways and the neuroendocrine neurons of the hypothalamic 
PVN plays a key role in the HPA axis activation (Van de Kar and Blair, 1999). For example, 
secretion of CRF is known to be regulated by ascending aminergic input from the locus 
coeruleus by NE and raphe nuclei by 5-HT, extra hypothalamic neurons secreting dopamine 
(DA) from the medial zona incerta of the subthalamus, GABAergic neurons originating from 
the posterior bed nucleus of the stria terminalis (Choi et al., 2007; Herman and Cullinan, 
1997; Van de Kar and Blair, 1999). Monoamine neurotransmitters (5-HT, NE and DA) play 
an important role in integrating autonomic, behavioural and neuroendocrine pathways 
coordinating stress response (Cerdá-Reverter and Canosa, 2009; Winberg et al., 1997; Ortega 
et al., 2005).  
1.6 Monoamines 
Monoamines are important neurotransmitters and neuromodulators in the central 
nervous system of vertebrates involved in the mediation of physiological and behavioural 
stress responses. They consist of the indoleamine, 5-HT, and the catecholamines, DA and NE 
(Purves et al., 2008). The catecholamines are synthesised from the amino acid precursor 
tyrosine, while 5-HT is synthesised from tryptophan. Effects of monoamine 
neurotransmitters are terminated following the reuptake into presynaptic nerve terminals or 
surrounding glial cells. Monoamine oxidases (MAOs) play an important role in the 
inactivation of monoamine compounds (Purves et al., 2008). The major metabolite of 5-HT 
catabolism is 5-hydroxyindoleacetic acid (5-HIAA) (Winberg and Nilsson, 1993; Øverli, 
2001). In DA metabolism, 3,4-dihydroxyphenylacetic acid (DOPAC) is the main 
deamination product, which can also be processed into 3-methoxytyramine (3-MT) and 
homovanilic acid (HVA), depending on species-specific distribution of the metabolising 
enzymes (Winberg and Nilsson, 1993). Major metabolite of NE is considered to be 3-
methoxy-4-hydroxyphenylglycol (MHPG) (Øverli, 2001; Winberg and Nilsson, 1993). 
Ratios of monoamine metabolites to their respective parent compounds are often used as 
index of neural activity, since decreased metabolite production suggests decreased turnover 
of the parent neurotransmitter (Fillenz, 1993; Winberg and Nilsson, 1993).  
The monoamines act on a variety of pre- and postsynaptic receptors in the brain and 
specificity of their function is determined by differences in distribution of receptor subtypes. 
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In vertebrates, at least five DA receptor subtypes have been identified, which are usually 
referred as D1-like (D1, D5) and D2-like (D2, D3, D4) (Callier et al., 2003). Also, five 
adrenergic receptors have been characterized in mammals: α1, α 2, β1, β2 and β3 (Purves et al., 
2008). Serotonergic system shows the highest receptor divergence. Seven families of 5-HT 
receptors have been identified (5-HT1-5-HT7), comprising 14 structurally and 
pharmacologically distinct subgroups (Hoyer et al., 2002). Relatively little is known about 
monoamine receptor subtypes in the teleost brain. Overall, neuroanatomical organization of 
most monoaminergic pathways is well conserved in vertebrates. Monoaminergic neurons 
compose a very small fraction of neurons in the vertebrate brain; however, their divergent 
projections establish strong influence in many brain areas.  
1.6.1 Role of monoamines in HPI axis regulation 
While the mechanisms leading to the hypothalamic activation during stress in teleosts 
are not well understood, monoamine neurotransmitters, 5-HT, NE and DA, play a central role 
in the regulation of the stress axis (Cerdá-Reverter and Canosa, 2009; Øverli et al., 2005; 
Winberg et al., 1997; Winberg and Nilsson, 1993). In the vertebrate brain, a variety of 
neuronal inputs converge on the CRF-neurosecretory cells. The brain noradrenergic system 
was shown to be involved in the stress response in mammals, and numerous stressors may 
induce the NE-dependent release of CRF (Dunn et al., 2004; Pacak et al., 1995). It is well 
established that 5-HT induces CRF release from the hypothalamic neurosecretory cells 
(Chaouloff, 1993). Evidence suggests that in fish 5-HT also plays a key role in the HPI axis 
activation and downstream cortisol production (Winberg et al., 1997). The stimulatory role 
of NE and 5-HT on CRH release in vitro has been reported in tilapia (Oreochromis 
mossambicus) (Pepels et al., 2004). Studies suggest that DA may be involved in the 
inhibitory modulation of pituitary corticotrophs, for instance, in goldfish injections with DA 
antagonists induced hypertrophy of corticotroph cells and stimulated ACTH release 
(Olivereau et al., 1988). Physiological evidence from in vitro superfusion study with pituitary 
pars distalis of common carp (Cyprinus carpio) suggested that CRF can only stimulate 
ACTH release in the presence of mild dopaminergic inhibitory tonus (Metz et al., 2004).  
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1.6.2 Role of serotonin subtype 1A receptor (5-HT1A) in HPI axis regulation 
Involvement of 5-HT in the HPA axis regulation has been relatively well studied in 
mammals. The 5-HT1A receptor has long been identified as a key link mediating serotonergic 
effects on the stress axis (Goel et al., 2014; Pitchot et al., 2001; Lorens and Van de Kar, 
1987). Relatively little is known about 5-HT receptor subtypes in the teleost brain; however, 
studies done in Arctic charr (Salvelinus alpinus) provided evidence for the presence of a 
multitude of 5-HT receptors in the brain, especially one that has a pharmacological profile 
strikingly similar to 5-HT1A in mammals (Winberg and Nilsson, 1996). In addition, several 
studies in teleost fish provided substantial evidence demonstrating involvement of 5-HT1A 
receptor in the HPI axis regulation axis (Medeiros et al., 2014; Höglund et al., 2002; 
Winberg et al., 1997). Work conducted on cannulated rainbow trout showed a dose-
dependent increase in plasma cortisol levels with the administration of a selective 5-HT1A 
receptor agonist, 8-hydroxy-N,N-dipropyl-2-aminotetralin (8-OH-DPAT) (Winberg et al., 
1997) . Interestingly, Höglund et al. (2002) observed that 8-OH-DPAT had a stimulatory 
effect on the HPI axis activation in unstressed fish (equipped with a permanent i.p. catheter), 
whereas stressed fish (handled for i.p. injections) showed a suppressive effect of 8-OH-
DPAT on the HPI axis. The authors suggested that 5-HT1A receptors may act both as post-
synaptic receptors and pre-synaptic autoreceptors in fish (Höglund et al., 2002). A study 
conducted in the Gulf toadfish (Opsanus beta) with cortisol-releasing oil implants provided 
evidence of cortisol-mediated downregulation 5-HT1A transcripts via GR-mediated 
mechanisms (Medeiros and McDonald, 2013). Collectively, this evidence demonstrates that 
5-HT1A receptor is the key player involved in mediation of serotonergic effects on the HPI 
axis regulation in teleosts.  
1.6.3 Serotonin in the head kidney 
Presence of 5-HT in the adrenal gland has been demonstrated 
(immunohistochemically and biochemically) in various vertebrate species (Contesse et al., 
2000). 5-HT has also been localized in the head kidney of several fish species (Reid et al., 
1998). In rainbow trout, 5-HT is stored in high concentrations in the anterior region of the 
post-cardinal vein within the head kidney and it can mediate release of catecholamines from 
the chromaffin cells (Fritsche et al., 1993). Similarly, in Atlantic hagfish (Myxine glutinosa), 
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evidence suggests that 5-HT is stored in a separate population of cells within the head kidney 
region, whereas Atlantic cod (Gadus morhua) and European eel (Anguilla anguilla) release 
serotonin from the chromaffin cells (Bernier and Perry, 1996; Reid et al., 1995).  Moreover, 
5-HT can induce corticosteroid secretion from the adrenocortical cells via paracrine action in 
many vertebrate species (Contesse et al., 2000). Recent studies in teleost fish showed that 5-
HT can directly stimulate cortisol secretion from the interrenal tissue, and most likely several 
5-HT receptor subtypes are involved in this response (Lim et al., 2013; Medeiros and 
McDonald, 2012). Therefore, findings of the above mentioned studies suggest that cells 
within the head kidney region are involved in paracrine interactions, where 5-HT possibly 
plays a role in a local positive feedback mechanism facilitating endocrine responses of the 
catecholamine- and cortisol-secreting cells during acute stress. 
1.7 Behavioural links to monoamines and stress 
In fish, like in other vertebrates, behavioural and physiological stress responses are 
intimately linked by a central control mechanism in the brain, where monoamine 
neurotransmitters play a central role in coordination of these responses (Øverli et al., 2005). 
For example, monoamines affect behavioural responses involved in feeding and aggression, 
which are usually associated with social rank establishment (Huber, 2005; Winberg and 
Nilsson, 1993). It is not surprising to see that exposure to antidepressant drugs alters 
behavioural responses in fish, including changes in aggressive behaviour or predator 
avoidance, due to effects exerted upon monoaminergic systems (Painter et al., 2009; 
Perreault et al., 2003). 
Salmonid fish tend to form social hierarchies in groups of two or more (Gilmour et 
al., 2005b; Øverli et al., 2005). Dominant individuals display agonistic behaviours and are 
able to acquire more food. Behavioural differences in coping styles are associated with 
important differences in physiological and neuroendocrine responses. For instance, 
subordinate fish have been characterized by increased brain serotonergic activity and higher 
plasma cortisol levels, whereas dominant fish have increased brain dopaminergic activity and 
lower cortisol levels (Doyon et al., 2003; Pottinger and Carrick, 2001; Sloman et al., 2000; 
Summers et al., 2005). Behavioural responses attributed to specific monoaminergic profiles 
undoubtedly demonstrate a link between monoamines and the stress axis. Changes in 
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monoaminergic activity result in altered functioning of the HPI axis, reflected in changes in 
CRF and POMC gene expression levels (Doyon et al., 2003; Winberg and Lepage, 1998), 
interrenal activity and cortisol production (DiBattista et al., 2005; Øverli et al., 2004; Noakes 
and Leatherland, 1977). Overall, behavioural responses and their associated stress effects 
constitute prominent targets for antidepressant-mediated effects in fish.   
1.8 Food intake control and interactions with the stress axis 
Regulation of food intake in vertebrates is a complex process involving interactions 
between brain neuronal circuits and peripheral systems. The brain produces key factors that 
either induce (orexigenic) or inhibit (anorexigenic) food intake (Volkoff et al., 2005).  For 
instance, neuropeptide Y (NPY), orexins, galanin and β-endorphin have orexigenic 
properties, while CRF-related peptides, 5-HT, bombesin, cholecystokinin, tachykinins have 
anorexigenic properties (Lin et al., 2000; Volkoff et al., 2005). Hypothalamus plays a central 
role in food intake control and a complex neuronal network integrates sensory information 
arising from peripheral signals of appetite, satiation, and long-term energy-balance (Kalra et 
al., 1999). The HPI axis interacts with appetite regulation and exposure to environmental, 
social or physical stressors inhibits feeding behaviour in fish (Bernier and Peter, 2001). 
Evidence from mammalian studies demonstrated that substances that stimulate serotonergic 
neurotransmission inhibit food intake (Dryden et al., 1996; Anelli et al., 1992). 5-HT appears 
to have similar properties in fish. For example, administration of a 5-HT-releasing agent 
induced a short-term inhibition of food intake in rainbow trout (Ruibal et al., 2002). CRF has 
been shown to be an important mediator of appetite-suppressing effects associated with 
stress. CRF-administration inhibited food intake in a dose-related manner in goldfish 
(Bernier and Peter, 2001). Moreover, pharmacologically removing negative feedback action 
of cortisol by treatment with the GR antagonist, RU-486, or cortisol synthesis inhibitor, 
metyrapone, led to a dose-dependent food intake reduction (Bernier and Peter, 2001). In 
mammals, the important appetite regulator NPY is involved in complex interactions with the 
HPA axis (Krysiak et al., 1999). In fish, evidence suggests that NPY may participate in 
activation of the HPI axis in trout, possibly through interaction with CRF (Doyon et al., 
2003). Overall, these findings demonstrate that there are reciprocal interactions between 
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neuroendocrine responses associated with the appetite regulation and mediators of the stress 
response in fish.  
 
1.9 Thesis objectives 
The major objectives of this thesis were to examine the impact of environmental 
levels of venlafaxine exposure on fish stress axis functioning and to identify possible modes 
of action of this drug. The research objectives were based on the primary hypothesis that 
Venlafaxine is a neuroendocrine disruptor in juvenile rainbow trout (Oncorhynchus mykiss), 
impairing the functioning of downstream responses including stress and feeding responses. 
Testing of this hypothesis was accomplished through a series of in vivo exposure studies in a 
controlled laboratory setting, as well as in vitro experiments to examine the mode of action of 
this drug on target tissues involved in HPI axis functioning.  
The specific research objectives were to assess whether: 
1. Venlafaxine exposure disrupts brain monoamine levels and neuroendocrine responses 
to stress in rainbow trout (Chapter 2). 
2. Exposure to venlafaxine impacts the metabolic capacity of rainbow trout to a 
secondary acute stressor (Chapter 3). 
3. Venlafaxine exposure impacts the functioning of the HPI axis to a secondary stressor 
(Chapter 4). 
4. Venlafaxine affects multiple neuroendocrine components of the HPI axis at the tissue 
level (Chapter 5). 
Overall representation of the main biological aspects examined in this thesis is presented in 








Figure 1-5. Graphic representation of the main biological aspects examined in this thesis in 
order to assess impact of waterborne venlafaxine exposure on juvenile rainbow trout. Image 
on the left demonstrates neuroendocrine responses that are regulated by monoamines. Image 
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Venlafaxine, a serotonin-norepinephrine reuptake inhibitor, is a widely prescribed 
antidepressant drug routinely detected in the aquatic environment. However, little is known 
about the impact that this pharmaceutical may have on the physiology of non-target 
organisms. We tested the hypothesis that venlafaxine perturbs brain monoamine levels and 
disrupts molecular responses essential for stress coping and feeding activity in fish. Juvenile 
rainbow trout (Oncorhynchus mykiss) were exposed to waterborne venlafaxine (0.2 and 1.0 
μg/L) for seven days. This drug elevated brain norepinephrine, serotonin and dopamine 
levels in a region-specific manner. There were also region-specific elevations in expression 
levels of genes involved in stress and feeding responses, including corticotropin releasing 
factor, pro-opiomelanocortin B, and glucose transporter type 2 in the brains of venlafaxine-
exposed fish. We also conducted a behavioural experiment following venlafaxine exposure 
with paired trout demonstrating that plasma cortisol levels were higher in the subordinate fish 
from the drug-exposed group compared to the control group. Total feed consumed per day 
was reduced in the venlafaxine group, although there were no significant drug treatment 
effects within each social rank. Collectively, our results demonstrate that venlafaxine is a 
neuroendocrine disruptor that can impact feeding response and response to a social stressor 
in rainbow trout. We propose the midbrain region of the trout brain is a key target for 
venlafaxine impact and the mode of action involves alterations in monoamine content. 
2.2 INTRODUCTION 
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) are the most common classes of antidepressants that are used to 
treat depression, anxiety, obsessive-compulsive disorders, and panic disorders (Silverstone, 
2004). They selectively inhibit presynaptic neuronal reuptake of serotonin (5-HT) and/or 
norepinephrine (NE), thereby increasing synaptic availability of these monoamines. One of 
the most frequently prescribed antidepressant drugs in recent years is the SNRI venlafaxine 
(Horst and Preskorn, 1998). Consequently, this drug along with its major metabolite O-
desmethylvenlafaxine is detectable in our waterways at parts per million levels (Metcalfe et 
al., 2010). Municipal wastewater effluent (MWWE) is the primary source introducing 
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pharmaceuticals, including venlafaxine, in the aquatic environment (Chambers et al., 1997), 
but little is known about the impact of this drug on non-target aquatic species, including fish.  
The mode of action of venlafaxine has not been established in non-target organisms, 
but this drug is primarily designed to modulate brain 5-HT and NE signalling (Horst and 
Preskorn, 1998). In teleosts, brain 5-HT, NE and dopamine (DA) play a very important role 
in the regulation of motivated behavioural responses, including establishing social 
hierarchies and feed acquisition (Huber, 2005; Winberg and Nilsson, 1993). For instance, 
trout form social hierarchies in groups of two or more (Øverli et al., 2005; Gilmour et al., 
2005b), and dominant individuals usually acquire more food, display agonistic behaviours 
and have lower plasma cortisol levels compared to subordinate fish (Doyon et al., 2003; 
Pottinger and Carrick, 2001; Sloman et al., 2000). These behavioural responses are 
associated with altered monoaminergic activity, leading to altered hypothalamus-pituitary-
interrenal (HPI) axis functioning and cortisol production (DiBattista et al., 2005; Øverli et 
al., 2004; Winberg and Nilsson, 1993; Noakes and Leatherland, 1977). 
In teleosts, the HPI axis activation involves the release of corticotropin releasing 
factor (CRF) by hypothalamic neurons, which stimulates the corticotroph cells of the 
pituitary to secrete adrenocorticotropic hormone, ACTH, a peptide produced post-
translationally from pro-opiomelanocortin (POMC) (Mommsen et al., 1999). ACTH 
stimulates cortisol biosynthesis in the interrenal cells, and the secreted cortisol mediates its 
physiological actions via glucocorticoid and mineralocorticoid receptors (GR and MR) 
(Vijayan et al., 2010). While the mechanism leading to the neuroendocrine regulation of 
stress in teleosts is not well understood, studies suggest a role for 5-HT, NE and dopamine 
(DA) in the regulation of the cortisol response to stressors (Cerdá-Reverter and Canosa, 
2009). For instance, serotonergic activity stimulates the release of CRF from the 
hypothalamus and activates the HPI axis function leading to cortisol production in fish 
(Winberg et al., 1997). There is also evidence of NE and DA involvement in the control of 
HPI axis activity (Pepels et al., 2004; Olivereau et al., 1988), although the mechanisms are 
less clear. 
Given that venlafaxine may impact brain monoamine levels, we hypothesized that 
environmentally relevant levels of this drug will perturb the molecular response to stress and 
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appetite regulation in rainbow trout (Oncorhynchus mykiss). To this end, trout were exposed 
to waterborne venlafaxine at environmentally relevant levels for seven days and brain 
monoamine levels, including 5-HT, DA and NE and their major metabolite levels (only of 5-
HT and DA) were measured in different brain regions. Also, the molecular markers of stress 
and appetite regulation, including CRF and its binding protein, CRF-BP (Bernier, 2006; Flik 
et al., 2006), POMC (Xu et al., 2011; Leder and Silverstein, 2006), glucose transporter type 2 
(GLUT2) (Polakof et al., 2007; Polakof et al., 2011), and neuropeptide Y(NPY) (Volkoff et 
al., 2005; Lin et al., 2000), were analyzed in different brain regions. The functional impact of 
venlafaxine exposure on behaviour and stress response was monitored by carrying out a 
social pairing experiment and measuring food acquisition as marker of appetite, as well as 
plasma glucose and cortisol levels as indicators of stress response in the dominant and 
subordinate fish. 
2.3 MATERIALS AND METHODS 
2.3.1 Animals 
Immature rainbow trout were obtained from Rainbow Springs Hatchery (Thamesford, 
ON, CAN). Fish were maintained at the University of Waterloo Aquatic Facility (Waterloo, 
ON, Can) in a continuous supply of aerated well water under a 12 h-light and 12 h-dark cycle 
in a 2000L tank at ~13.5 °C. Fish were fed once daily to satiety with commercial trout chow 
(Martin Feed Mills, Elmira, ON, CAN). All experimental protocols were approved by the 
University of Waterloo Animal Care Committee and conducted in accordance with the 
Canadian Council for Animal Care guidelines. 
2.3.2 Experimental protocol: brain responses 
Groups of 10 trout (89 ± 6 g) were randomly assigned to three 120 L tanks. They 
were acclimated for two weeks to static water conditions with 40% water exchange daily. 
Fish were fed once daily as mentioned above. Following acclimation, fish were exposed to 
three experimental treatments for 7 days: control (no drug), 0.2 μg/L and 1.0 μg/L 
venlafaxine (venlafaxine hydrochloride; Sigma Aldrich, St. Louis, MO, USA). Venlafaxine 
was dissolved in water and its experimental dosage was maintained by re-administering the 
drug with each tank water exchange. Exposure concentrations were chosen to approximate 
 
 34 
environmental levels of venlafaxine (Metcalfe et al., 2010; Schultz and Furlong, 2008). Food 
was withheld during the 7-day drug exposure period. Water samples were collected daily 
from each treatment tank after a 2 h equilibration period in 20 mL glass scintillation vials and 
frozen at -20°C until further analysis of venlafaxine concentrations.  
On the day of sampling, trout were euthanized with an overdose of 2-phenoxyethanol 
(1:1000 dilution; Sigma Aldrich, St. Louis, MO, USA). Fish were bled by caudal severance 
into sterile centrifuge tubes containing 40 μl of 10 mg/mL EDTA in physiological saline. 
Plasma was collected following blood centrifugation (6000 × g for 10 min) for cortisol and 
glucose analyses. Each brain was quickly removed, placed on a chilled petri dish and 
dissected into seven regions, including hypothalamus (Hyp), telencephalon (Tel), preoptic 
area (POA), optic tectum (OT), midbrain (MB), cerebellum (Cer) and hindbrain (HB) (Fig. 
A1-A; Appendix A); pituitaries (Pit) were also collected. All samples were snap frozen on 
dry ice and then stored at -80 °C until processed for further analyses.  
2.3.3 Experimental protocol: behavioural response 
A total of 24 trout (30 ± 2 g) were divided equally among four 30 L tanks. Following 
acclimation, two tanks received control treatment and two tanks received 1.0 µg/L 
venlafaxine treatment, administered as above, for a 7-day period. Fish were food-deprived 
during the exposure period. Following exposure, trout were transferred into 10 L flow-
through tanks (no drug exposure) in approximately size-matched pairs for a total of six tanks 
of paired fish per treatment. Either the dorsal or ventral caudal fin tip was clipped to 
distinguish between individuals of each pair for visual tracking.  Each pair of fish were fed 
10 pellets (21.5 ± 1.0 mg) 4 h after transfer (day 1) and were observed live and video 
recorded (Sony Handycam HDR-CX550V) for 10 min. Fish were given all 10 pellets at once 
and the share eaten by each fish was noted. At the end of 10 min, any uneaten food was 
removed from the tank. This feeding protocol was repeated again on days 2 and 3 for a total 
of three feeding trials. Additionally, agonistic interactions were also assessed by counting the 
number of attacks by the dominant fish, and food acquisition and agonistic interactions were 
used as markers to separate the dominant and subordinate fish (Gilmour et al., 2005a; Øverli 
et al., 2005).  The day following the last feeding trial, all pairs were euthanized with an 
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overdose of 2-phenoxyethanol as above, and plasma was collected for cortisol and glucose 
analyses.  
2.3.4 Venlafaxine analysis 
Water samples from the first exposure experiment were analysed to ensure that 
nominal drug concentrations were maintained in our static exposure system. We selected six 
samples from both venlafaxine tanks (from days 2-7 of the exposure period for 0.2 and 1.0 
μg/L treatments), and three samples from the control tank (from days 2, 5, and 7) for analysis 
of venlafaxine concentrations. Solid phase extraction (SPE) was used to extract venlafaxine 
from the water samples (15 mL) using Oasis HLB cartridges (6 mL, 500 mg, Waters 
Corporation, Millford, MA,USA) as previously described (Rahman et al., 2010). Samples 
were spiked with 100 μL of 100 μg/L of deuterated venlafaxine prior to extraction to 
compensate for possible matrix effects from the analysis.  Dried extracts were reconstituted 
with 500 µL of methanol plus internal standards (Lorazapam and Chloramphenicol) and 
stored at -20°C until analysis. 
Analysis of SPE extracts was completed using a 1200 Agilent liquid chromatograph 
with a Sciex API 3200 QTRAP mass spectrometer with electrospray ionization using 
multiple reaction monitoring (MRM) as previously described (Rahman et al., 2010). The ion 
transition monitored in MRM was 278/58 for venlafaxine and 284/64 for d6-venlafaxine.  
The method detection limit (DL) was 1 ng/L.  Venlafaxine calibration curve was analyzed to 
confirm peak shape, retention time and peak area. Each sample was injected once at a 
volume of 20 µL.  Matrix spikes were completed and showed recoveries between 106-117%.  
Method blanks were also completed and showed no analyte. 
2.3.5 Plasma analysis 
Plasma cortisol levels for the brain response experiment were measured using 
3
H 
cortisol radioimmunoassay as described previously (McMaster et al., 1995). Cortisol 
antibody was obtained from MP Biomedicals (Solon, OH, USA) and tritiated cortisol was 
purchased from GE Healthcare (Waukesha, WI, USA). Plasma cortisol levels for the 
behavioural response study were measured using a commercially available cortisol ELISA 
(Neogen, Lexington KY, USA) as described previously (Nesan and Vijayan, 2012). Plasma 
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glucose levels were measured enzymatically by the hexokinase and glucose-6-phosphate 
dehydrogenase enzymatic method (Bergmeyer et al., 1974).  
2.3.6 Brain monoamine analysis 
Fish (n = 5 per treatment) from the brain response study were used for monoamine 
analyses. Seven rainbow trout brain regions (Hyp, POA, Tel, MB, HB, OT) and Pit (Fig. A1-
A; Appendix A) were analysed for 5-HT, DA, their major oxidative metabolites 5-HIAA and 
DOPAC, respectively, and NE contents. High performance liquid chromatography with 
electrochemical detection (HPLC-EC) was used as previously described (Gesto et al., 2006) 
with some modifications and HPLC system specifications were identical. The mobile phase 
was composed of 63.9 mM NaH2PO4, 0.1 mM Na2EDTA, 0.80 mM sodium 1-
octanesulfonate and 15.3 % (v/v) methanol (pH 2.95), and was filtered (0.20 µm filter, 
Millipore, Bedford, USA) and degasified at vacuum before use. Analytical run time was 15 
minutes at an isocratic flow rate of 1.0 mL·min
-1
 at room temperature. Detection limit for the 
amines and their metabolites was between 0.5 and 1.5 pg per injection, with a signal-to-noise 
ratio of 2. Acquisition and integration of chromatograms were performed using the 
ChromNAV version 1.12 software (Jasco Corp., Tokyo, Japan).  
Tissues were weighed and then homogenized by ultrasonic disruption in 0.15 mL 
(Pit), 0.5 mL (Hyp, Tel, POA), or 1 mL (Cer, OT, MB, HB) of mobile phase. Homogenates 
were then centrifuged (16000 × g, 10 min) and supernatants diluted with mobile phase prior 
to HPLC analysis. Dilutions were 1:1 (supernatant: mobile phase) for Hyp, Tel and Pit; 1:2 
for POA, Cer, MB and HB; 1:4 for OT. Data were normalized to the protein content of the 
samples, which was measured with the bicinchoninic acid method (Smith et al., 1985). The 
5-HIAA/5-HT and DOPAC/DA ratios were calculated since they are often used as indices of 
the turnover rates of their respective parent neurotransmitters, 5-HT and DA. 
2.3.7 Transcript abundance 
As most changes in the brain monoamine concentrations were seen in the 1.0 μg/L 
venlafaxine group compared to control, quantitative real-time RT-PCR (qPCR) analysis was 
carried out only in this venlafaxine group (0.2 μg/L group omitted). Total RNA was extracted 
from the brain regions and pituitary glands of the fish used in the brain response experiment 
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(n = 5 per treatment) using TRIzol reagent (Invitrogen Corp., San Diego, CA, USA) 
according to the manufacturer’s instructions. One µg RNA was treated with DNase I 
(Qiagen, Mississauga, ON, CAN) to remove genomic DNA contamination prior to cDNA 
synthesis using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturers’ protocols. 
Transcript levels of some key genes involved in the HPI axis function and energy 
homeostasis were measured by qPCR in triplicates using gene-specific primers (Table 2-1) as 
previously described (Aluru and Vijayan, 2007), with one modification of PCR conditions 
for NPY (Conde-Sieira et al., 2010). A relative standard curve method was used to determine 
relative transcript abundances according to established protocols (Sathiyaa and Vijayan, 
2003).  All data were normalized to EF1α expression since it was unchanged by treatments. 
All gene expression levels are shown as percent of the control of the Hyp region.  
Transcript abundances of CRF and CRF-BP were analyzed in the Hyp and POA, two 
brain regions involved in the HPI axis regulation and primary expression areas for CRF and 
CRF-BP (Bernier et al., 2008; Flik et al., 2006). POMCA and POMCB gene expression 
levels were examined in the Pit (Leder and Silverstein, 2006), and additionally in the Hyp, 
MB and HB, areas associated with food intake/energy homeostasis (Grill and Hayes, 2012; 
Kalra et al., 1999). GLUT2 and NPY expression levels were analyzed in the Hyp, HB, and 
MB due to the same selection criteria as stated earlier.  
2.3.8 Statistical analysis 
All statistical analyses were performed using Sigmaplot 11 software (Systat Software 
Inc., San Jose, CA, USA) and data were expressed as mean ± standard error of mean (SEM). 
Data were log transformed, when necessary, to meet the assumptions of homogeneity of 
variance. For the monoamine analyses, treatment effects of venlafaxine in different brain 
regions were determined by one-way analysis of variance (ANOVA) followed by post-hoc 
Holm-Sidak test. In our transcript analyses, significant differences between control and 1.0 
μg/L venlafaxine treatments were assessed by Student’s t-test in selected regions. For the 
behavioural response experiment, the sum of the number of pellets eaten by each treatment 
group per day (12 fish) and by each social rank (6 fish) in each treatment group were 
determined for each feeding trial (n = 3 trials). The mean ± SEM of these values were used 
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for statistical analyses by Student’s t-test and two-way ANOVA with Tukey’s post-hoc test, 
respectively. Agonistic interactions were analyzed by Mann-Whitney rank sum test. Cortisol 
levels due to social stress were measured on the third day of social pairing experiment and 
were analyzed by two-way ANOVA followed by Tukey’s post-hoc test. In all cases, 






















Table 2-1. Sequences (forward and reverse), product sizes, accession numbers and annealing 
temperatures for oligonucleotide primers used in quantitative real-time RT-PCR. 





























NM_001124719.1 60 199 
R: 5'- CCTGCTGCCCTCCTCTACTGC-3' 
GLUT2 
F: 5’-GGCCATCTTCCTGTTTGTGT-3’ 




NM_001124266 58 247 
R: 5'-GTTCATCATATCTGGACTGTG-3' 
 
EF1α, elongation factor 1α; CRF, corticotropin-releasing factor; CRF-BP, corticotropin-releasing 
factor binding protein; POMCA and POMCB, pro-opiomelanocortin A and B; GLUT2, glucose 









2.4.1 Brain response study 
Venlafaxine concentrations 
The average water venlafaxine concentrations were 0.2583 ± 0.0075 μg/L and 1.0233 
± 0.0141 μg/L (n = 6) for the nominal 0.2 μg/L and 1.0 μg/L treatments, respectively. 
Therefore, drug concentrations were accurately maintained in our static exposure system. No 
venlafaxine was detected in the control treatment (< DL, n = 3). 
Plasma cortisol and glucose levels 
Venlafaxine treatment did not significantly affect plasma cortisol levels. Cortisol 
levels were 0.37± 0.1 ng/mL in the control group, and 0.57± 0.24 and 0.35 ± 0.15 ng/mL in 
the 0.2 μg/L and 1.0 μg/L venlafaxine groups, respectively. Plasma glucose levels were not 
significantly different in the control (3.94 ± 0.16 mM) and venlafaxine groups (3.67 ± 0.15 
and 3.61 ± 0.21 mM in 0.2 μg/L and 1.0 μg/L groups, respectively).  
Brain monoamine levels 
Levels of 5-HT, 5-HIAA, DA, DOPAC and NE were measured in seven brain regions 
and pituitary glands of rainbow trout. The ratios of 5-HIAA/5-HT and DOPAC/DA were 
used as indices of the turnover rates of 5-HT and DA. Statistically significant elevation of 5-
HT levels was detected in the MB of the 1.0 μg/L venlafaxine group, while no significant 
changes were detected in other brain regions (Fig. 2-1A). No significant changes were 
detected in the levels of 5-HIAA in any of the brain regions (Fig. A1-B; Appendix A). 
Treatment with 1.0 μg/L venlafaxine significantly reduced the 5-HIAA/5-HT ratio in the 
MB, but not other brain regions (Fig. 2-1B).  
Significant changes in the DA levels were also detected in the MB, where 1.0 μg/L 
venlafaxine group had higher DA than 0.2 μg/L venlafaxine, but neither venlafaxine group 
was found to be different from the control (Fig. 2-1C). There were no significant changes in 
DOPAC levels across the brain regions (Fig. A1-C; Appendix A). However, there were 
significant changes in DOPAC/DA ratio in the HB and MB regions (Fig. 2-1D). In the HB, 
both venlafaxine treatments decreased the ratio in comparison to the control. In the MB, 1.0 
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μg/L venlafaxine group had lower DOPAC/DA ratio than 0.2 μg/L venlafaxine treatment, but 
neither venlafaxine group was found to be different from the control. 
There was a significantly higher NE level in the MB region in 1.0 μg/L but not the 
0.2 μg/L venlafaxine treatment group (Fig. 2-1E). NE was not significantly different due to 






















Figure 2-1.  Brain monoamine levels: concentrations of 5-hydroxytryptamine, 5-HT (A) and 
its turnover rate (represented by the ratio of 5-hydroxyindoleacetic acid, 5-HIAA/5HT) (B), 
dopamine, DA (C), and its turnover rate (represented by the ratio of 3,4-
dihydroxyphenylacetic acid, DOPAC/DA) (D), and norepinephrine, NE (E) in rainbow trout 
brain following a 7-day venlafaxine exposure. Values represent means ± SEM (n = 5). 
Different letters indicate significant treatment effects within a given region (one-way 
ANOVA; P < 0.05). Abbreviations: hypothalamus (Hyp), telencephalon (Tel), preoptic area 




Transcriptional response  
CRF mRNA abundance was significantly higher in 1.0 μg/L venlafaxine group 
compared to the controls in the Hyp but not POA (Fig. 2-2A). There was no significant 
difference in CRF-BP transcript levels with venlafaxine in the Hyp or POA (Fig. A2-A; 
Appendix A). Exposure to venlafaxine significantly increased GLUT2 transcript levels in the 
MB, but not Hyp or HB, compared to the control group (Fig. 2-2B). Venlafaxine exposure 
significantly increased POMCB mRNA abundance in the HB, but not in the Pit, Hyp, or MB 
(Fig. 2-2C). There was no significant effect of venlafaxine exposure on mRNA levels of 
POMCA (Fig. A2-B; Appendix A) in the brain regions examined (Pit, Hyp, MB, and HB). 
Transcript abundance of NPY was not affected by venlafaxine in the Hyp, MB, or HB (Fig. 



























Figure 2-2.  Spatial brain gene expression: mRNA abundances of corticotropin-releasing 
factor, CRF (A), glucose transporter type 2, GLUT2 (B), and pro-opiomelanocortin B, 
POMCB (C) in different brain regions of rainbow trout brain following a 7-day venlafaxine 
exposure. Values were normalized to EF1α and represent percent hypothalamus control. Bars 
show means ± SEM (n = 5); asterisk indicates a significant treatment effect within a given 
region (Student’s t-test; P < 0.05). Abbreviations: hypothalamus (Hyp), preoptic area (POA), 
midbrain (MB), hindbrain (HB), and pituitary (Pit). 
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2.4.2 Behavioural response study 
Food acquisition and agonistic interactions 
Trout held in pairs formed social hierarchies, and food intake, agonistic behaviour 
and cortisol levels (assessed at the end of the pairing experiment) were used to assign social 
status. The dominant fish obtained majority of the food, displayed more agonistic behaviours 
and also had lower plasma cortisol levels compared to the subordinate fish. Agonistic 
interactions within pairs were limited in most cases. Although there was no significant 
differences in agonistic behaviours on day 1 (4 h post-transfer) or day 2 (24 h post-transfer) 
(Table 2-2), the highest frequency of attacks occurred on day 3 (or 48 h post-transfer), where 
the dominant fish exhibited higher number of attacks compared to the subordinates in both 
control and venlafaxine treatment groups, although no significant drug treatment effect was 
















Table 2-2. Agonistic behaviours displayed by each rainbow trout rank (dominant or 
subordinate) on days 1-3 of social pairing experiment conducted after a 7-day exposure to 1.0 
µg/L venlafaxine. Days 1, 2 and 3 correspond to 4, 24 and 48 h post-transfer from 
venlafaxine exposure system, respectively. Values in the table represent number of agonistic 
attacks, shown as means ± SEM. Significant differences between social ranks are indicated 
by different letters (P < 0.05, Mann-Whitney Rank Sum Test). No significant venlafaxine 








(n = 6) 
Subordinate 
(n = 6) 
Dominant 
(n = 5) 
Subordinate 
(n = 5) 
 Day 1 0.0 ± 0.00 0.0 ± 0.00 0.4 ± 0.40 0.6 ± 0.40 
 Day 2 0.2 ± 0.17 0.2 ± 0.17 4.4 ± 4.15 0.6 ± 0.40 
 Day 3 6.2 ± 3.59 
A
 0.3 ± 0.21 
B
 14.6 ± 8.32 
A

















Overall, food intake was reduced by venlafaxine, which is demonstrated by a 
significantly lower amount of total food pellets eaten by fish in the drug exposed group 
compared to the control over the 3-day feeding trial (Fig. 2-3A). When food acquisition data 
were examined by each social rank (dominant and subordinate) within each treatment group 
over the 3-day feeding trial period (Fig. 2-3B), there was no significant treatment effect on 
food acquisition.  
Plasma cortisol and glucose levels 
 Analysis of plasma cortisol levels measured 24 h after the final feeding session 
detected a significant interaction between venlafaxine treatment and social rank (Fig. 2-3C). 
In both treatment groups plasma cortisol levels were significantly higher in the subordinate 
individuals compared to the dominant individuals. Within the dominant social rank, there 
was no significant effect of drug exposure on plasma cortisol levels, whereas within the 
subordinate rank, venlafaxine exposure resulted in significantly higher circulating cortisol 
levels compared to the control group. Plasma glucose levels were measured 24 h following 
the final feeding session. No significant drug treatment or social rank effects were identified 













Figure 2-3. Behavioural response over a 3-day social pairing experiment in rainbow trout 
following a 7-day exposure to 1.0 μg/L venlafaxine (VEN). Food consumption by trout, 
represented as the total number of food pellets consumed per day by all fish in each treatment 
group (12 fish/group) (A); different letters indicate significant differences (P < 0.05, t-test). 
Food consumption in established social dyads shown as the total number of pellets consumed 
per day by the dominant (DOM) and subordinate (SUB) fish per day in each treatment group 
(B); different letters indicate significant differences (P < 0.05, 2-way ANOVA). In both food 
intake graphs bars represent means ± SEM, n = 3 feeding trials. Plasma cortisol levels in the 
DOM and SUB fish measured on the last day of experiment (day 3) (C); bars represent 
means ± SEM (n = 5-6 fish) and different letters indicate significant differences (P < 0.05, 2-
way ANOVA).  















































































Our results demonstrate for the first time that environmentally relevant concentrations 
of venlafaxine affect brain monoamine levels in rainbow trout. Since brain monoamines have 
hypophysiotropic functions and play important roles in integrating autonomic, behavioural 
and neuroendocrine responses (Cerdá-Reverter and Canosa, 2009; Winberg et al., 1997), the 
disruption in 5-HT, NE and DA levels by venlafaxine may affect several downstream 
pathways leading to disturbances in homeostasis. For instance, our findings demonstrate that 
venlafaxine exposure reduces food intake, and leads to an elevation in plasma cortisol levels 
in the socially stressed trout. This along with changes in mRNA abundances of genes 
involved in HPI axis functioning and appetite regulation suggests that neuroendocrine 
pathways involved in stress response and feeding are targets for venlafaxine impact in trout.  
 There was a clear spatial difference in 5-HT, DA and NE levels suggesting that the 
venlafaxine effect on the brain is region-specific. Our results suggest that the MB and HB 
regions are key targets for venlafaxine impact in rainbow trout, while the mechanism is 
unknown. The higher 5-HT and NE levels in the MB region in trout is in agreement with 
mammalian studies confirming these neurotransmitters as primary drug targets for 
venlafaxine. For instance, a 4-d treatment with venlafaxine increased 5-HT levels in the MB 
region and NE levels in the ventral tegmental area (associated with the MB) in rats (Muneoka 
et al., 2009). In our study, 1.0 μg/L venlafaxine treatment increased 5-HT levels in the MB 
without alterations in the concentration of its main metabolite, 5-HIAA. This suggests that 
venlafaxine treatment increased 5-HT production rate rather than its catabolism, thus 
lowering the turnover rate of this neurotransmitter, indicated by reduced 5-HIAA/5-HT ratio. 
For instance, 5-HIAA is formed in the presynaptic neurons after 5-HT reuptake by serotonin 
transporters (Winberg and Nilsson, 1993), so any disruption in the monoamine uptake will 
lead to changes in metabolite levels and 5-HIAA/5-HT ratio. In addition to a direct effect of 
venlafaxine on serotonergic neurons, the higher levels of NE may also modulate 5-HT levels. 
This is supported by the modulation of 5-HT levels in the mammalian MB, including raphe 
nuclei, by NE (Adell et al., 2002). It remains to be seen whether the observed changes in NE 
levels in the present study in the MB due to venlafaxine disrupt downstream serotonergic 
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pathways. The observed changes in DA levels in the MB region between the high and low 
venlafaxine group along with reduced turnover in the HB region suggest that DA dynamics is 
also disrupted by venlafaxine exposure in trout. It should be noted that evidence from 
mammalian studies suggest that venlafaxine can have a relatively weak effect on dopamine 
(DA) reuptake (Roseboom and Kalin, 2000), modulating DA levels in a region-specific 
manner; however, the underlying mechanism may be a reflection of alteration in NE levels, 
since noradrenergic neurons modulate certain DA systems (Muneoka et al., 2009; Liprando 
et al., 2004). 
 The MB and HB regions are abundant in cell bodies of 5-HT (Nieuwenhuys, Ten 
Donkelaar, and Nicholson 1998) and NE (Ekström et al., 1986) producing neurons, and their 
nerve projections are very divergent and reach most of the brain regions, including dense 
innervations to the POA and HYP. Also, the soma of dopaminergic neurons are contained 
mainly in the hypothalamus, telencephalon and pretectal areas, and in medulla oblongata, 
while their projections are widely distributed with the highest density of terminals in the Tel, 
POA and HYP regions (Meek et al., 1989). As serotonergic, noradrenergic and dopaminergic 
pathways innervate key areas of the brain involved in the integration of endocrine and 
metabolic signals to coordinate stress response and food intake, any disruption in the 
dynamics of these neurotransmitters may lead to homeostatic disturbances, including stress 
axis dysfunction (Pepels et al., 2004; Winberg et al., 1997). 
 Indeed, our gene expression data indicate changes to transcript levels of key markers of 
HPI axis functioning and appetite regulation in response to venlafaxine exposure. CRF is a 
neuroendocrine marker of stress activation (Flik et al., 2006) and appetite suppression 
(Bernier, 2006; Volkoff et al., 2005). Our study showed that CRF mRNA abundance was 
increased by venlafaxine in the HYP, the region of the brain that plays a central role in 
appetite regulation.  This, along with the higher abundance of POMCB mRNA, encoding 
peptides associated with energy homeostasis and appetite suppression (Xu et al., 2011; 
Volkoff et al., 2005), in the HB suggests a role for venlafaxine in impacting appetite 
regulation and stress response in trout. Furthermore, the higher transcript levels of GLUT2, a 
bidirectional glucose transporter that is a key component of the brain glucosensory system 
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and appetite regulation (Polakof et al., 2007), in the MB of trout by venlafaxine points to a 
dysregulation in feeding response. The change in GLUT2 mRNA level was not accompanied 
by concomitant changes in plasma glucose levels leading to the proposal that the disruption 
may be brain-specific. Together, the transcript changes observed in the brain suggests an 
anorexigenic role for venlafaxine, mediated in part by alterations in the brain monoamine 
levels. The impact of venlafaxine on appetite suppression, as indicated by the transcript 
changes, was confirmed by our feeding trials that clearly showed a reduced feed intake after 
a 7-d drug exposure in trout.  
 Brain monoamine neurotransmitters are thought to play a key role in the establishment 
of social ranks in fish (Winberg and Nilsson, 1993). For instance, subordinate fish have 
increased brain serotonergic activity along with higher cortisol levels and lower appetite 
compared to the dominant fish that have higher brain dopaminergic activity, lower cortisol 
levels and increased appetite (Summers et al., 2005). When we subjected the venlafaxine-
exposed fish to a social stressor, the dominant and subordinate hierarchies were clearly 
established as in the control group. As expected, the dominant fish consumed significantly 
more food than the subordinate fish in both treatment groups. However, the lack of 
venlafaxine effect on feed consumed based on social ranking may be due to the limited 
number of feeding trials. Interestingly, plasma cortisol level in the subordinate response to a 
social stressor was amplified in the drug exposed group. It is well known that there is a 
strong interplay between the serotonergic system and the stress axis. For instance, an acute 
stressor induces very rapid increases in brain serotonergic activity in trout, as well as in 
lizards, supporting the involvement of the serotonergic system as a primary activator of the 
stress response (Gesto et al., 2013; Emerson et al., 2000). Furthermore, elevation in cortisol 
levels increases serotonergic activity (DiBattista et al., 2005) and administration of a 5-HT 
receptor agonist significantly elevates cortisol levels (Winberg et al., 1997). This relationship 
also holds true during social stress in fish, as an increase in brain serotonergic activity 
corresponds to a reduction in aggressive behaviour, resulting in lower social rank (Winberg 
and Nilsson, 1993). For example, in the study based on a territorial reef fish species, 
aggression was reduced following a treatment with the SSRI fluoxetine due to modulation of 
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the serotonergic system by this drug (Perreault et al., 2003).   
Our finding that venlafaxine treatment leads to a regional increase in serotonergic 
activity combined with the fact that subordination stress itself leads to higher serotonergic 
activity, suggest that drug-exposed subordinate fish may experience hyperactivation of the 
HPI axis. Subordinate individuals are affected by chronically elevated cortisol levels leading 
to compromised health (Gilmour et al., 2005b), and our results suggest that such effects may 
be amplified in fish exposed to venlafaxine in the aquatic environment. Although aquatic 
species are usually exposed to numerous chemical compounds in complex mixtures, 
including MWWE, it is important to investigate the effects of these pharmaceutical drugs 
individually in order to elucidate their mechanisms of action on non-target species. For 
instance, inadvertent exposure of non-target organisms to active pharmaceutical compounds 
may lead to adverse effects that may translate into reduced fitness and reproduction. To this 
end, exposures to environmentally relevant concentrations of venlafaxine, fluoxetine and 
bupropion (individually or in mixtures) adversely affected predator avoidance behaviour in 
larval fathead minnows suggesting performance dysfunction (Painter et al., 2009). 
Consequently, the potential implications of venlafaxine and other relevant antidepressants on 
fish fitness do emphasize their ecological relevance and the necessity for a thorough 
understanding of their mode of action on non-target aquatic organisms for environmental 
effects monitoring.  
2.6 CONCLUSIONS 
Collectively, results of this study suggest that exposure to environmentally relevant 
venlafaxine concentrations affect monoamine and neuroendocrine responses pertaining to 
stress and appetite regulation in trout. Our findings indicate that the midbrain region may be 
a key target for venlafaxine impact and the mode of action may involve changes in 
monoamine content. Since this region contains numerous nuclei and nerve tracts that 
interconnect with rostral and caudal brain regions, any impact on the midbrain region may 
lead to downstream effects on endocrine and behavioural responses. Indeed, venlafaxine 
modulated the functioning of the HPI axis in the socially stressed rainbow trout resulting in 
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amplified cortisol response in the subordinate fish. Our results underscore a role for this 
antidepressant as a neuroendocrine disruptor in trout, and its exposure may lead to several 
downstream adverse effects in non-target animals.   
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The antidepressant venlafaxine is detected at parts per billion levels in tertiary-treated 
municipal wastewater effluent. However, the impact of this serotonin-norepinephrine 
reuptake inhibitor (SNRI) on non-target aquatic animals is poorly understood. We tested the 
hypothesis that environmentally relevant levels of venlafaxine disrupt the highly conserved 
cortisol and glucose response to stress in rainbow trout (Oncorhynchus mykiss). Juvenile 
trout were exposed to venlafaxine (0, 0.2 and 1.0 µg/L) in a static system with daily renewal 
for seven days. The fish were then subjected to an acute handling disturbance and sampled 
either prior to (0 h) or 1, 4 and 24 h after stressor exposure. Venlafaxine exposure did not 
affect the stressor-mediated transient elevation in plasma cortisol levels or target tissue 
glucocorticoid receptor expression. The drug exposure disrupted the interrenal steroidogenic 
capacity, including altered stressor-mediated changes in mRNA abundances of steroidogenic 
acute regulatory protein and cytochrome P450 side chain cleavage. Also, venlafaxine at the 
higher concentration increased the ACTH-induced cortisol production by head kidney tissue 
ex vivo. The stressor-induced transient elevations in plasma glucose levels were significantly 
reduced in the venlafaxine-exposed fish. This was not accompanied by changes in liver 
glycogen content, glucose transporter 2 mRNA levels or the glycolytic capacity, whereas the 
capacity for gluconeogenesis and amino acid catabolism were enhanced. Venlafaxine also 









 ATPase enzyme activity was 
reduced. Collectively, our results demonstrate that venlafaxine at levels detected in the 
aquatic environment impacts tissue metabolic capacities and may compromise the adaptive 
responses to an acute stressor in rainbow trout.  
3.2 INTRODUCTION 
Over the last two decades, pharmaceutical compounds have become a prominent 
source of environmental contamination and they are constantly being discharged into the 
aquatic environment through treated sewage effluent, leaching, and direct disposal (Daughton 
and Ternes, 1999). Pharmaceuticals are frequently detected in municipal wastewater effluents 
 
 56 
(MWWEs) and receiving waters (Corcoran et al., 2010; Metcalfe et al., 2010). Among 
antidepressant drugs, fluoxetine, a selective serotonin reuptake inhibitor (SSRI), is the most 
commonly studied in the aquatic environment and it has been shown to affect fish 
performance (Mennigen et al., 2011). Recently, the use of venlafaxine, a serotonin-
norepinephrine reuptake inhibitor (SNRI) antidepressant with improved therapeutic action 
and fewer side effects than fluoxetine (Horst and Preskorn, 1998) has been on the rise. At 
present, venlafaxine and its active metabolite O-desmethylvenlafaxine are among the highest 
detected antidepressants in tertiary-treated MWWEs (Metcalfe et al., 2010; Schultz et al., 
2010). Despite this, very little is known about the impact of this pharmaceutical drug on non-
target aquatic organisms, including fish. A recent study showed that exposure to tertiary-
treated MWWE, that also contains venlafaxine, impairs the cortisol and metabolic responses 
to an acute stressor in rainbow trout (Oncorhynchus mykiss) (Ings et al., 2011). 
The cortisol stress response is part of an evolutionarily conserved adaptive response 
that allows animals to restore homeostasis when challenged by stressors. To that end, cortisol 
and catecholamines induce several metabolic alterations to help to overcome the threat.  
Briefly, after exposure to a stressor, the primary fight or flight response involves the 
stimulation of the sympathetic division of the autonomic nervous system and results in 
increased production of catecholamines, especially epinephrine and norepinephrine, within 
seconds of stressor perception (Vijayan et al., 2010; Fabbri et al., 1998; Reid et al., 1998). 
Catecholamines activate alpha- and beta-adrenergic signalling leading to rapid cardiovascular 
adjustments and glycogen breakdown to enhance oxygen and glucose delivery to tissues, 
respectively (Vijayan et al., 2010; Reid et al., 1998). The activation of the hypothalamus-
pituitary-interrenal (HPI) axis lags behind the sympathetic response and begins with the 
release of corticotropin releasing factor (CRF) from the hypothalamus triggering 
adrenocorticotropic hormone (ACTH) release from the pituitary, which stimulates cortisol 
secretion from the interrenal cells of the head kidney (Vijayan et al., 2010). ACTH binding to 
melanocortin 2 receptors (MC2R) activates cAMP-signalling cascade, resulting in the 
initiation of cortisol biosynthetic pathway. The key rate determining steps in steroidogenesis 
involve the steroidogenic acute regulatory protein (StAR), which transports cholesterol from 
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the outer to the inner mitochondrial membrane, followed by conversion of cholesterol to 
pregnenolone by cytochrome P450 side chain cleavage (P450scc) (Aluru et al., 2005). The 
elevated cortisol levels in response to stress mediate the target effects, including energy 
substrate mobilization, by activating glucocorticoid receptor (GR) and/or mineralocorticoid 
receptor (MR) signalling (Bury and Sturm, 2007; Prunet et al., 2006). 
We have previously demonstrated that venlafaxine at environmental concentrations 
modulates levels of monoamine neurotransmitters in the midbrain and hindbrain regions of 
the rainbow trout brain [Chapter 2; Melnyk-Lamont et al. submitted]. Monoamine 
neurotransmitters (serotonin, norepinephrine and dopamine) are known to be involved in the 
regulation of the neuroendocrine components of the HPI axis (Cerdá-Reverter and Canosa, 
2009; Winberg et al., 1997). Consequently, venlafaxine-mediated changes in brain 
monoamine levels may lead to downstream effects on the HPI axis functioning, but this has 
not been tested before.  
In this study, the hypothesis tested was that venlafaxine at environmentally realistic 
levels impairs the adaptive cortisol and glucose responses to an acute stressor in fish. 
Rainbow trout were exposed to waterborne venlafaxine (0.2 and 1.0 µg/L) for seven days. 
The drug exposure was considered as the primary stressor, and these fish were then subjected 
to a handling disturbance, which constituted the secondary stressor. The concentration of 
venlafaxine used was based on the levels detected in the aquatic environment (Metcalfe et 
al., 2010). The impact of the drug on basal and stressor-stimulated steroid biosynthetic 
capacity in the interrenal tissue as well as target tissue metabolic capacities was assessed. At 
the interrenal level, StAR and P450scc transcript levels were measured along with plasma 
cortisol levels to assess cortisol biosynthetic capacity, as these are targets for xenobiotic 
impact (Sandhu and Vijayan, 2014; Arukwe, 2008; Aluru et al., 2005). In addition, we 
examined the capacity of head kidney tissue from venlafaxine-exposed fish to respond to 
ACTH challenge in vitro. Tissue metabolic capacity was assessed by measuring plasma 
glucose levels and liver glycogen content, glucose transporter type 2 (GLUT2) transcript 
levels and activities of enzymes involved in key metabolic pathways, including glycolysis 
[hexokinase (HK), glucokinase (GK), pyruvate kinase (PK) and lactate dehydrogenase 
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(LDH)], gluconeogenesis [phosphoenolpyruvate carboxykinase (PEPCK)] and amino acid 
catabolism [alanine aminotransferase (AlaAT) and aspartate aminotransferase (AspAT)] 
(Vijayan et al., 2006). Also, metabolic capacity of the gill, a key target tissue for glucose 




 ATPase activity and its protein 
expression, as well as activities of key glycolytic enzymes, including HK, PK and LDH 
(Soengas et al., 1995; Mommsen, 1984). In addition, brain and liver GR protein expression 
was used as a marker of target tissue responsiveness to cortisol (Vijayan et al., 2005).  
3.3 MATERIAL AND METHODS 
3.3.1 Animals 
Juvenile rainbow trout (average body mass 8.5 ± 2.5 g) were obtained from Rainbow 
Springs Hatchery (Thamesford, ON) and maintained in flow-through well water (13ºC, 400 
mg CaCO3/L, pH 8.0, Alsop et al. 2009). Fish were acclimated for two weeks in 2000 L 
tanks and lighting was on a 12 h day/night cycle. Fish were fed to satiety daily during the 
acclimation period with a commercial trout chow (Martin Feed Mills, Elmira, ON). 
3.3.2 Experimental design 
The study involved exposing trout to different concentrations of venlafaxine over a 
period of seven days. There were duplicate tanks (30 L) for each treatment and 16 fish in 
each tank. The tanks were continuously aerated and their water temperature maintained by 
leaving them in a larger tank (2000 L) with flow-through well water exactly as mentioned 
above. Fish were acclimated in the experimental setup tanks for one week prior to the 
exposure. During acclimation, the fish were fed to satiety (once daily) and the tanks were 
cleaned and 40% water replenished (12 L) daily. Fish were exposed to either 0 (control), 0.2 
or 1.0 µg/L nominal venlafaxine concentrations (venlafaxine hydrochloride; Sigma Aldrich, 
St. Louis, MO; dissolved in water). Food was withheld for the duration of the experiment and 
40% of water was replaced daily and supplemented with venlafaxine at the appropriate 
concentrations before addition to the fish tanks. Previous work in our laboratory 
demonstrated that this static exposure system with such daily water changes did accurately 
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maintain the expected nominal concentrations of venlafaxine [Chapter 2; Melnyk-Lamont et 
al., submitted]. Another study also conducted in a static system showed that venlafaxine 
concentrations remain stable over the exposure period similar to that used in the present 
study (Bisesi et al., 2014).  
Following the 7-d exposure, an initial group of fish were sampled (0 h) while the rest 
were subjected to an acute stressor (consisting of 30 s netting and 5 min crowding stressor at 
3 fish /L) and sampled at 1, 4 and 24 h post-handling disturbance. Sampling consisted of 
quickly netting four fish from each replicate tank (8 per treatment) at the respective time-
points. Fish were euthanized with an overdose of 2-phenoxyethanol (1:1000 dilution; Sigma-
Aldrich), weighed and bled by caudal severance into heparinized capillary tubes. The whole 
procedure took less than 5 minutes for each tank. The plasma was collected after 
centrifugation of the capillary tubes at approximately 5000 x g for four minutes and was 
stored in microfuge tubes at -80°C for later hormone and metabolite assay. Liver, gill, brain, 
and head kidney were removed and snap frozen on dry ice and were stored at -80 °C for later 
analysis. The experimental protocol was approved by the University of Waterloo Animal 
Care Committee and was conducted in accordance with the Canadian Council for Animal 
Care guidelines for the use of fish in research. 
3.3.3 Ex vivo head kidney study 
A follow-up study was conducted using head kidney tissues pieces from rainbow 
trout (average body mass 78 ± 3 g) in vivo exposed to venlafaxine treatments for a 7 day 
period as described earlier (control, 0.2 μg/L and 1.0 μg/L venlafaxine). The exposure was 
conducted in 120 L tanks to accommodate larger fish size (tank set-up as described in 
Chapter 2). At the end of the exposure period, fish were quickly sampled and the head kidney 
region (containing the interrenal cells) was quickly dissected from each fish (n = 6 
independent fish/ treatment group), and tissues were prepared using a well-established 
method (Sandhu and Vijayan, 2011; Aluru and Vijayan, 2006). Briefly, tissues were finely 
minced (~1 mm
3
 pieces) in chilled Petri dishes with modified Hank’s medium (136.9 mM 
NaCl, 5.4 mM KCl, 0.8 mM MgSO4∙7H20, 0.33 mM Na2HPO4∙7H2O, 0.44 mM KH2PO4, 5.0 
 
 60 
mM HEPES, 5 mM HEPES∙Na, 5mM NaHCO3, 5mM glucose, pH 7.63) and cleaned from 
blood clots. After rinsing, the tissue from each fish was distributed equally among treatment 
wells (500 μL of buffer with ~35-40 mg of tissue) in a sterile 24-well culture plate (Sarstedt, 
Newton, NC, USA). Following pre-incubation period for 2 h at 13 °C, medium was replaced 
with fresh aliquots containing the following treatments: control, 0.5 IU/mL ACTH (porcine 
ACTH
1–39
; Sigma-Aldrich), 0.5 mM 8-Bromo-cAMP (Sigma-Aldrich), and the tissues were 
incubated for 4 h as described previously (Sandhu and Vijayan, 2012). ACTH is the primary 
cortisol secretogogue in fish, while 8-Br-cAMP (analogue of cAMP) was used to determine 
if venlafaxine effect was upstream of cAMP signalling. Concentration of ACTH for in vitro 
treatment and the incubation period were chosen based on previous studies (Sandhu and 
Vijayan, 2011; Aluru and Vijayan, 2006). At the end of incubation period, samples were 
collected, quickly centrifuged (13,000 x g for 1 min), and the supernatant was collected and 
stored at -30
o
C for later cortisol determination.  
3.3.4 Plasma glucose and cortisol levels 
 Plasma glucose was measured colorimetrically according to Hancock et al. (2004). 
Briefly, samples and standards were loaded onto a 96-well plate, followed by 0.1 M, pH 7.4 
monobasic sodium phosphate buffer with phenol (1 mM) and 4-aminoantipyrine (2.5 mM). 
Glucose oxidase (10 U/ml) and peroxidase (10 U/ml) were added to initiate the reaction. 
Following 45 min incubation in the dark at room temperature, absorbance was read at 500 
nm using a microplate reader (VersaMax, Molecular Devices LLC, Sunnyvale, CA, USA). 
Plasma cortisol levels were determined using a commercially available competitive ELISA 
kit (Neogen, Lexington, KY, USA) according to the manufacturer’s instructions. Media 
cortisol concentrations from the head kidney ex vivo study were measured using 
3
H cortisol 
radioimmunoassay as described previously (Sandhu and Vijayan, 2011; Aluru and Vijayan, 
2006). 
3.3.5 Tissue preparation 
 Brain, liver and gill tissues were sonicated in ice cold 50 mM Tris buffer (pH 7.5) 
with protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Protein 
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concentrations of the samples were determined using the bicinchoninic acid (BCA) reagent 
(Sigma-Aldrich) with bovine serum albumin as the standard. For the enzyme assays, portions 
of liver and gill homogenates were aliquoted and stored in 50% glycerol buffer (50% 
glycerol, 21 mM Na2HPO4, 0.5 mM EDTA-Na, 0.2% BSA, 5 mM β-mercaptoethanol, pH 
7.5) at -20°C as described previously (Sandhu et al., 2014). For protein analysis, a portion of 
the homogenate was prepared for western blot analysis as described before (Dindia et al., 
2013).  
3.3.6 Glycogen and Enzyme Activity Measurements 
Glycogen content was determined in liver tissue, and the activity of several enzymes 
was measured in liver and gill tissue. Glycogen content was determined by measuring 
glucose levels in the homogenate before and after hydrolysis by amyloglucosidase (Sigma-
Aldrich) as described previously (Vijayan et al., 2006). Enzyme activities in liver and gill 
were determined by continuous UV spectroscopy at 340 nm at 22°C using a microplate 
reader as described previously (Ings et al., 2011; Gravel and Vijayan, 2007). Both glycogen 
and enzyme activity data were normalized to protein content of the tissue and the enzyme 
activity was expressed as µmol per minute (U) per gram protein. The individual enzyme 
assay conditions were as follows (final concentration in a well shown, all in 50 mM 
imidazole buffer, pH 7.4): 
 Hexokinase (HK: EC 2.7.1.1): 1 mM glucose, 5 mM MgCl2, 10 mM KCl, 0.24 mM 
NADH, 2 mM phosphoenolpyruvate (PEP), 20 U/mL lactate dehydrogenase (LDH) 
and 2.5U/mL pyruvate kinase (PK); reaction started with 1mM ATP. 
 Glucokinase (GK: EC 2.7.1.2): 20 mM glucose, 5mM MgCl2, 10mM KCl, 0.25 
mM NADH, 2 mM PEP, 20 U/mL LDH and 2.5 U/mL PK; reaction started with 1 
mM ATP. 
 Pyruvate kinase (PK: EC 2.7.1.40): 30 mM KCl, 10 mM MgCl2, 0.12 mM NADH, 
2.5 mM ADP, 10 U/mL LDH; reaction started with 2.5 mM PEP. 
 Lactate dehydrogenase (LDH: EC 1.1.1.27): 0.12 mM NADH and reaction 
initiated with 1 mM pyruvate Na. 
 
 62 
 Phosphoenolpyruvate carboxykinase (PEPCK: EC 4.1.1.32): 20 mM NaHCO3, 1 
mM MnCl2, 0.5 mM PEP,and 0.12 mM NADH; reaction started with 0.2 mM 
deoxyguanosine diphosphate. 
 Alanine aminotransferase (AlaAT: EC 2.6.1.2): 0.12 mM NADH, 200 mM L-
alanine, 0.025 mM pyridoxal 5-phosphate, and 12 U/mL LDH; reaction started with 
10.5 mM α-ketoglutarate. 
 Aspartate aminotransferase (AspAT: EC 2.6.1.1): 7 mM α-ketoglutarate, 0.025 
mM pyridoxal 5-phosphate, 0.12 mM NADH,and 8 U/mL malate dehydrogenase; 
reaction started with 40 mM aspartic acid. 
 Sodium-Potassium ATPase (NKA: EC 3.6.3.9): 45 mM NaCl, 10 mM KCl, 2.5 
mM MgCl2, 2 mM PEP, 0.5 mM ATP, 0.16 mM NADH, 1 mM NaN3, 1 mM 
EGTA, 5 U/ml PK, 5 U/ml LDH. For inhibition, add 0.5 mM ouabain. 
3.3.7 SDS-PAGE and immunodetection 





 ATPase expression. The procedure for SDS-PAGE and western blotting followed 
established protocols (Boone et al., 2002). In brief, samples containing 40 µg of total protein 




 ATPase, respectively) 
with Precision Plus protein molecular marker (BioRad, Hercules, CA, USA). The proteins 
were transferred onto a nitrocellulose membrane (20 V for 25 min) in transfer buffer (25 mM 
Tris pH 8.3, 192 mM glycine and 10% (v/v) methanol) using a semidry transfer unit 
(BioRad). Membranes were blocked for one hour at room temperature in 5% skim milk with 
0.05% sodium azide in TTBS (20 mM Tris pH 7.5, 300 mM NaCl, 0.1% (v/v) Tween 20). 
This was followed by incubation with either polyclonal rabbit anti trout GR antibody 




 ATPase (Wilson et al., 
2007; 1:1000 dilution) for one hour at room temperature. Subsequently, membranes were 
washed in TTBS (3× for 10 min) and probed with secondary antibody (goat anti-rabbit IgG 




 ATPase) conjugated to horseradish peroxidase 
(1:3000; BioRad) for one hour at room temperature. Membranes were washed 3x10 min with 
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TTBS and washed 1x10 min with TBS (20 mM Tris pH 7.5, 300 mM NaCl). Band detection 
was carried out using ECL+ Western Blotting Detection System and imaged with a Typhoon 
scanner (GE Healthcare Life Sciences, Piscataway, NJ, USA). Bands were quantified with 
AlphaEase software (Alpha Innotech, CA, USA) and equal loading was confirmed by 
probing the blots with β-actin (Cy3-coupled monoclonal antibody from mouse 1:1000; 
Sigma-Aldrich).   
3.3.8 RNA isolation and cDNA synthesis 
 Total RNA was extracted from liver (0 h time point, prior to acute stressor) and head 
kidney (all time points) with TRIzol reagent (Invitrogen Corp., San Diego, California, USA) 
according to the manufacturer’s instructions. Briefly, samples were lysed with the reagent, 
chloroform was added, and cellular RNA was precipitated by isopropanol. After washing 
with 70% ethanol, the RNA pellet was dissolved in nuclease-free water. RNA was quantified 
by NanoDrop spectrophotometer (Thermo Scientific, Nepean, ON, CAN) at 260 nm. RNA 
samples were DNase treated to avoid genomic contamination. 1 µg of total RNA per sample 
was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s protocol. 
3.3.9 Quantitative real-time polymerase chain reaction (qPCR) 
Gene-specific primers designed for rainbow trout StAR, P450scc, GLUT2, and EF1α 
cDNA sequences were used to amplify ~100 bp products in real-time quantitative PCR. 
EF1α was used as housekeeping gene for data normalization because its relative abundance 
was unchanged between treatment groups. The primer sequences and their accession 
numbers are presented in Table 3-1. Briefly, a master mix containing 2.5 μL of cDNA, 2.5 
μL of 10 μM primer pair, 40 μL of SYBR green supermix (BioRad) and 35 μL of nuclease-
free water was prepared for each sample and 25 μL was added to three wells (all samples 
assayed in triplicate). The following conditions were used for amplification: initial 
denaturation for 2 min at 94°C, followed by 40 cycles of 20 s at 94°C, 20 s at annealing 
temperature (Table 3-1); 95°C for 1 min; 55°C for 1 min followed by melt curve analysis 
starting at 55
°
C and increasing in 0.5
°
C increments to 95°C every 10 s. Threshold cycle 
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values were calculated using iCycler iQ real-time detection software (BioRad). Relative 
standard curve method was used to determine relative transcript abundance exactly as 
described previously (Aluru and Vijayan, 2004).  
3.3.10 Statistical Analysis 
 As there were no significant tank effects, the fish from duplicate tanks for each 
treatment were pooled for statistical comparison. A Student’s t-test was used to determine 
significant treatment effect after a 7-d exposure to venlafaxine for gill sodium-potassium 
ATPase activity and protein expression, while a two-way analysis of variance (ANOVA) was 
used to determine significant treatment (control, 0.2 and 1 µg/L), time (0, 1, 4 and 24 h after 
stressor exposure) and interaction effects (treatment x time) after stressor exposure. Tukey’s 
post-hoc test was used to identify significant differences. Data from our ex vivo head kidney 
experiment was analyzed with one-way repeated measures ANOVA to assess effects of in 
vitro stimulation on cortisol production in control tissues. Effect of in vivo venlafaxine 
exposure on in vitro-stimulated cortisol production was analyzed with two-way repeated 
measures ANOVA (one factor repetition). Holm-Sidak post hoc was used to identify 
significant differences. All data were log transformed when necessary to meet the 
assumptions of normality and equal variance; non-transformed data are shown in the tables 
and figures. All statistical analyses were performed using Sigmaplot 11 software (Systat 
Software). Significance level was set to P-value < 0.05 in all cases.  
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Table 3-1. Primers used in real-time quantitative RT-PCR. Sequences (forward and reverse), 
accession numbers, annealing temperatures and product sizes are indicated. Primers include 
elongation factor 1 alpha (EF1α), steroidogenic acute regulatory protein (StAR), cytochrome 















AB047032 60 101 
R: 5′-AGGGTTCCAGTCTCCCATCT-3′ 
P450scc 
F: 5′-GCTTCATCCAGTTGCAGTCA -3′  
S57305.1 60 140 
R: 5′-CAGGTCTGGGGAACACATC -3′  
GLUT2 
F: 5’-GGCCATCTTCCTGTTTGTGT-3’ 















3.4.1 Plasma glucose and cortisol levels 
A 7-d venlafaxine exposure did not significantly affect basal plasma cortisol levels 
(Fig. 3-1A; 0 h time point) in the present study. Handling disturbance significantly elevated 
plasma cortisol at 1 h, after which the levels dropped significantly at 3 h, but did not return to 
basal levels, and this cortisol level was maintained over the 24 h period post-stressor 
exposure (Fig. 3-1A). There was no significant effect of venlafaxine on the secondary 
stressor-induced plasma cortisol levels (Fig. 3-1A).  
Venlafaxine exposure also did not significantly affect basal plasma glucose levels 
(Fig. 3-1B; 0 h time point).  There was an interactive effect between venlafaxine treatment 
and time post-stressor exposure. The temporal glucose profile in the control and 1.0 µg/L 
venlafaxine groups showed significant elevation at 1 and 4 h compared to 0 and 24 h post-
stressor exposure (Fig. 3-1B; see inset), while in the 0.2 µg/L venlafaxine group the glucose 
level was significantly higher only at 1 h but not at other time-points post-stressor exposure 
(Fig. 3-1B; see inset). While a secondary stressor significantly increased glucose levels 
within each treatment group following the acute secondary stressor challenge, the magnitude 
of response at 1 h was significantly lower in the 1.0 µg/L, but not in the 0.2 µg/L, 
venlafaxine group compared to the control (Fig. 3-1B). At 4 h post-stressor, the 1.0 µg/L 
group maintained their 1 h plasma glucose levels while the levels dropped significantly lower 
in the 0.2 µg/L group compared to the controls (Fig. 3-1B). At 24 h, glucose returned to basal 



















Figure 3-1. Plasma cortisol and glucose levels. Effect of a 7-day venlafaxine exposure on 
plasma cortisol (A) and glucose (B) levels prior to an acute stressor (0 h) and 1, 4 and 24 h 
after stressor exposure. Bars represent means ± SEM (n = 8 fish). There were only time 
effects, but no treatment effects for cortisol (indicated by different uppercase letters), while 
for glucose a significant interaction was detected: treatment effects within a time point are 
indicated with asterisks and time effects within treatments are shown inset (within 
treatments) (P < 0.05, two-way ANOVA). 
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3.4.2  Head kidney steroidogenic capacity  
Exposure to 1.0 µg/L venlafaxine significantly increased the basal (0 h time point) 
P450scc mRNA abundance compared to the control and 0.2 µg/L treatment groups (Fig. 3-
2A). Additionally, exposure to 0.2 µg/L but not 1.0 µg/L venlafaxine increased P450scc 
mRNA abundance compared to the control at 24 h post-stressor exposure (Fig. 3-2A). 
Temporally, stressor exposure affected the P450scc mRNA abundance in the venlafaxine 
groups but not in the control group (Fig. 3-2A). In the 0.2 µg/L venlafaxine group the 
P450scc mRNA levels were significantly higher at 24 h compared to all other time points 
(Fig. 3-2A), while in the 1.0 µg/L venlafaxine group the levels were significantly lower at 1,4 
and 24 h post-stressor exposure compared to the pre-stress levels (Fig. 3-2A). There was a 
significant venlafaxine treatment effect on StAR mRNA abundance in the present study (Fig. 
3-2B). Both concentrations of venlafaxine were significantly lower than the control 
regardless of time post- stressor exposure (Fig. 3-2B). There was also a time effect, 
independent of treatment effects, with the pre-stress StAR mRNA levels significantly higher 




Figure 3-2. Head kidney steroidogenic capacity. Effect of a 7-day venlafaxine exposure on 
head kidney cytochrome P450 side chain cleavage (P450scc; A) and steroidogenic acute 
regulatory protein (StAR; B) mRNA levels prior to an acute stressor (0 h) and 1, 4 and 24 h 
after stressor exposure. Bars represent means ± SEM (n = 6 fish). A significant interaction 
was detected for P450scc: treatment effects within a time point are indicated with asterisks 
and time effects within treatments are shown as inset (within treatment). Significant overall 
treatment effects for StAR are shown as inset, while overall time effects are indicated by 
different uppercase letters (P < 0.05, two-way ANOVA). 
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3.4.3 Ex vivo head kidney study – cortisol production 
As expected, both 8-Br-cAMP and ACTH stimulation significantly increased cortisol 
production in kidney pieces from the control fish (no drug) (Fig. 3-3A). There was ~ 20-fold 
increase in cortisol production in response to these treatments compared to the unstimulated 
cortisol production (Fig. 3-3A).Venlafaxine treatment in vivo did not significantly affect the 
interrenal tissue response to 8-Br-cAMP stimulation compared to the control fish (Fig. 3-3B). 
However, ACTH-stimulated cortisol production was significantly higher (~47%) in the head 
kidney tissues from fish exposed to 1.0 μg/L venlafaxine compared to the control and 0.2 
μg/L venlafaxine groups (Fig. 3-3B). While for the control and 0.2 μg/L venlafaxine groups 
there were no differences between 8-Br-cAMP and ACTH stimulated responses, amplitude 
of cortisol response was significantly higher with ACTH treatment than 8-Br-cAMP in the 




Figure 3-3. In vitro-stimulated cortisol production. Stimulation of cortisol secretion by 
ACTH and 8-Br-cAMP in the control head kidney tissue (A) and effect of a 7-day in vivo 
venlafaxine (VEN) exposure on in vitro cortisol production in response to ACTH and 8-Br-
cAMP stimulation in the head kidney tissue slices of rainbow trout (B). Data shown as means 
± SEM (n = 5-6 fish). In (A), different letters indicate significant differences between in vitro 
treatments (P < 0.05, one-way repeated measures ANOVA). In (B), insets indicate in vitro 
treatment effect for each VEN group, and different letter indicate differences between 
venlafaxine exposure groups within an in vitro treatment group (P < 0.05, two-way repeated 
measures ANOVA, Holm-Sidak post hoc).  
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3.4.4 Liver metabolic capacity 
Venlafaxine treatment had no significant effect on liver glycogen content (Table 3-2). 
There was a temporal drop in liver glycogen content, irrespective of venlafaxine treatment, 
with the levels at 24 h significantly lower than the values prior to stress (Table 3-2). 
Venlafaxine treatment did not significantly alter the activities of the glycolytic enzymes in 
the present study (Table 3-2). However, there were time effects observed in enzyme 
activities, independent of venlafaxine treatment, in response to secondary stressor exposure. 
For instance, the pre-stressor HK and GK activities were significantly higher compared to all 
subsequent time points (Table 3-2). PK and LDH activities were significantly lower at 1 h 
compared to 24 h post-stressor exposure, but not at any other time points (Table 3-2). 
Basal activity of PEPCK, a key gluconeogenic enzyme, was not affected by a 7-d 
exposure to venlafaxine. However, there was a significant interaction between venlafaxine 
treatment and time after stressor exposure on this enzyme activity (Table 3-2). At 4 h post-
stressor exposure the PEPCK activity was significantly higher in the venlafaxine groups 
compared to the control group (Table 3-2). There was also a temporal change in PEPCK 
activity to stressor exposure that was treatment dependent. In the control, this enzyme 
activity significantly dropped at 1 and 4 h but not at 24 h post-stressor exposure compared to 
the pre-stress values (Table 3-2). The 0.2 µg/L venlafaxine group also showed a PEPCK 
response similar to that of the control group except that the reduced activity recovered at 4 h 
post-stressor exposure (Table 3-2). There was no time effect on PEPCK activity in the 1.0 
µg/L venlafaxine group in the present study (Table 3-2).  
Enzymes involved in amino acid catabolism were also affected by venlafaxine. Fish 
exposed to 1.0 µg/L of venlafaxine, but not 0.2 µg/L venlafaxine, had significantly higher 
AlaAT activity compared to the control group (Table 3-2). There was also a significant time 
effect, regardless of treatments, with the activity significantly lower at 1, 4 and 24 h post 
stressor exposure compared to the pre-stress values (Table 3-2). Venlafaxine exposures did 
not significantly affect basal or stress-mediated AspAT activity (Table 3-2).  There was a 
significant time effect with the activity lower at 1 h compared to either the pre-stress or 24 h 
post-stressor values (Table 3-2). 
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Table 3-2. Liver metabolic capacity. Changes seen in glycogen content (µmol glucosyl 
units/g protein) and enzyme activities (µmol/min/g) of hexokinase (HK), glucokinase (GK), 
pyruvate kinase (PK), lactate dehydrogenase (LDH), phosphoenolpyruvate carboxykinase 
(PEPCK), alanine aminotransferase (AlaAT), and aspartate aminotransferase (AspAT) in 
response to an acute stressor (0, 1, 4, and 24 h post-stressor) in trout exposed to venlafaxine 
concentrations (0, 0.2, 1.0 µg/L). Values are mean ± SEM (n = 7-8 fish); significant 
treatment (bold) and time effects are shown in the last column. For significant interactions, 
an asterisk (*) indicates a significant difference from the control within a time point while 
different letters indicate time effects within a treatment group (P < 0.05, two-way ANOVA). 
 
 Venlafaxine  
(µg/L) 
Post-acute stressor exposure (h) Significance 
P < 0.05   0  1  4  24  
Glycogen 
0 4160 ± 269 2714 ± 430 2622 ± 188 2112 ± 145 
0 h > 24 h 0.2 3007 ± 414 2686 ± 338 3270 ± 345 2942 ± 362 
1.0 3441 ± 451 2973 ± 327 3215 ± 336 2059 ± 390 
HK 
0 12.9 ± 0.6 8.5 ± 0.9 7.7 ± 0.7 7.5 ± 0.9 
0h > 1h, 4h, 24h 0.2 12.2 ± 0.6 9.0 ± 0.6 8.5 ± 0.7 8.1 ± 0.8 
1.0 11.6 ± 0.9 9.6 ± 0.8 9.1 ± 0.5 9.3 ± 0.8 
GK 
0 13.3 ± 0.5 9.5 ± 0.8 8.2 ± 0.6 8.4 ± 1.1 
0h > 1h, 4h, 24h 0.2 12.8 ± 0.6 9.7 ± 0.7 8.3 ± 1.0 8.2 ± 0.7 
1.0 12.5 ± 0.8 9.7 ± 0.9 9.7 ± 0.5 9.5 ± 0.9 
PK 
0 7.92 ± 0.62 5.17 ± 1.22 7.31 ± 0.89 7.11 ± 1.04 
24h > 1h 0.2 8.18 ± 1.32 5.15 ± 0.32 8.85 ± 1.02 8.34 ± 0.70 
1.0 6.85 ± 0.52 6.41 ± 1.05 6.75 ± 0.68 7.70 ± 0.93 
LDH 
0 323 ± 20 281 ± 21 322 ± 13 274 ± 26 
24h > 1h 0.2 330 ± 10 272 ± 31 329 ± 19 353 ± 16 
1.0 317 ± 30 307 ± 19 316 ± 16 368 ± 9 
PEPCK 
0 0.43 ± 0.04
a
 0.24 ± 0.04
b
 0.19 ± 0.01
b





0.2 0.38 ± 0.03
a
 0.22 ± 0.02
b
 0.34 ± 0.04
a* 0.26 ± 0.03ab 
1.0 0.35 ± 0.03
a
 0.26 ± 0.03
a
 0.33 ± 0.02
a* 0.25 ± 0.04a 
AlaAT 
0 43 ± 6 24 ± 5 18 ± 2 17 ± 2 
0h > 1h, 4h, 24h 
1.0 > 0 
0.2 41 ± 4 19 ± 2 29 ± 4 25 ± 4 
1.0 39 ± 4 25 ± 3 30 ± 5 26 ± 2 
AspAT 
0 52 ± 5 44 ± 4 41 ± 3 43 ± 6 
0h, 24h > 1h 0.2 48 ± 3 36 ± 4 42 ± 3 52 ± 3 
1.0 50 ± 2 43 ± 3 46 ± 2 56 ± 4 
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3.4.5 Gill glycolytic capacity 
Venlafaxine exposure for a 7-d period did not significantly affect either basal or 
stressor-mediated HK and PK activities (Table 3-3). While the pre-stress LDH activity was 
also not significantly affected by venlafaxine exposure, there was a significantly higher 
activity in the 1.0 µg/L of venlafaxine group at 24 h post-stressor exposure compared to the 
control group (Table 3-3).  There was a significant time effect, regardless of treatments, on 
HK and PK activities post-stressor exposure. HK activity was significantly higher at 24 h 
compared to 0, 1 and 4 h post-stressor exposure, while PK activity was significantly lower at 
24 h compared to the other time-points (Table 3-3). The PK activity at 4 h post stressor 
exposure was also significantly higher than the pre-stress values (Table 3-3). 
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Table 3-3. Gill metabolic capacity. Changes seen in enzyme activities (µmol/min/g) of 
hexokinase (HK), pyruvate kinase (PK), and lactate dehydrogenase (LDH) in response to an 
acute stressor (0, 1, 4, and 24 h post-stressor) in trout exposed to venlafaxine concentrations 
(0, 0.2, 1.0 µg/L). Values are mean ± SEM (n = 6-8 fish); significant time effects are shown 
in the last column. For significant interactions, an asterisk (*) indicates a significant 
difference from the control within a time point (P < 0.05, two-way ANOVA). 
 
 Venlafaxine  
(µg/L) 
Post-acute stressor exposure (h) Significance 
P < 0.05  0 1 4 24 
HK 
0 17.0 ± 0.8 17.0 ± 0.6 16.5 ± 0.7 17.2 ± 0.6 
24 > 0, 1, 4 0.2 16.2 ± 1.1 15.3 ± 0.5 14.8 ± 1.0 18.4 ± 1.1 
1.0 14.9 ± 0.7 16.1 ± 0.8 14.0 ± 0.7 18.9 ± 1.5 
PK 
0 114 ± 8 114 ± 5 137 ± 6 87 ± 2 
0, 1, 4 > 24 
4 > 0 0.2 
107 ± 6 130 ± 12 136 ± 10 95 ± 5 
1.0 114 ± 10 123 ± 6 127 ± 9 119 ± 13 
LDH 
0 56 ± 4 53 ± 1 57 ± 2 43 ± 1 
significant 
interaction 0.2 
50 ± 2 51 ± 2 56 ± 4 46 ± 2 












 ATPase activity and protein expression in the gills were measured only in the 
1.0 µg/L venlafaxine exposure group prior to the acute stressor challenge (Fig. 3-4). Activity 





 ATPase protein expression was significantly higher in the 1.0 µg/L 






























 ATPase activity and protein expression. Effects of a 7-d 




 ATPase activity (µmol/min/g; A) and protein expression 
(B). A representative western blot is shown for protein expression and the values are shown 
as % control in the bar graph (B). Bars represent means ± SEM (n = 6-8 fish). Asterisks 
indicate significant differences (P < 0.05, Student’s t-test). 
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3.4.7 Brain GR protein expression 
Brain GR protein expression was not affected following 7-d venlafaxine exposure 
(Fig. B1-A; Appendix B).  
3.4.8 Liver GR protein expression and GLUT2 mRNA abundance  
GR protein expression was not altered following a 7-d venlafaxine exposure in the 
liver tissue (Fig. B1-B; Appendix B). GLUT2 mRNA abundance (Fig. B2; Appendix B) was 
also unchanged.  
3.5  DISCUSSION  
The results demonstrate that environmentally relevant concentrations of venlafaxine 
can compromise the adaptive metabolic response to an acute stressor in rainbow trout. An 
essential component of the metabolic response is an elevation in circulating glucose levels to 
provide the fuel required to drive the energy demanding processes that are essential to regain 
homeostasis. Our results suggest that nominal levels of venlafaxine detected in MWWEs 
have the potential to disrupt metabolic performances essential to cope with stress in fish. 
Circulating plasma glucose levels were transiently elevated in response to the netting 
and crowding stressor and this is a conserved adaptive response that allows the animal to 
metabolically cope with stress (Vijayan et al., 2010; Wendelaar Bonga, 1997; Iwama et al., 
2006). The liver is an essential organ for glucose regulation, critical for the synthesis, storage 
and release of glucose, especially in response to stress (Mommsen et al., 1999). Hepatic 
glycogen is a major source for rapid glucose output during acute stress, which involves 
catecholamine-mediated glycogenolysis (Vijayan et al., 2010). The drop in liver glycogen 
content at 24 h supports the mobilization of this substrate as a contributing factor for the 
observed hyperglycemia after stressor exposure in trout (Wiseman and Vijayan, 2011; Gravel 
and Vijayan, 2007; Andersen et al., 1991). 
The elevation in plasma glucose levels following stress was attenuated in 
venlafaxine-exposed fish suggesting a disruption in liver metabolism. One possible mode of 
action of venlafaxine in suppressing stressor-mediated glucose output may involve 
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modulation of target tissue responsiveness to catecholamines. The rapid mobilization of 
glucose from the liver after acute stressor exposure is primarily mediated by the 
phosphorylation of glycogen phosphorylase and subsequent glycogenolysis by epinephrine-
mediated activation of beta-adrenoreceptor signalling (Fabbri et al., 1998). Any disruption in 
catecholamine synthesis and/or activation of beta-adrenergic signalling will lead to a 
reduction in stressor-induced acute plasma glucose response (Perry et al., 1988; Wright et al., 
1989). Recently, venlafaxine (1 µM) exposure in vitro was shown to inhibit epinephrine-
stimulated, but not basal, glucose release in isolated trout hepatocytes (Ings et al., 2012). 
This suggests that the venlafaxine impact on stressor-induced plasma glucose elevation may 
involve inhibition of epinephrine signalling.  Whether this is a direct effect of venlafaxine 
acting as a beta-blocker (Ings et al., 2012) and/or an indirect effect through the alteration of 
brain monoamine levels [Chapter 2; Melnyk-Lamont et al., submitted] needs to be 
determined. Another possibility may involve venlafaxine-mediated beta-adrenoreceptor 
desensitization in fish, since in mammalian studies it is established that chronic 
administration of some noradrenergic antidepressant causes a desensitization of the beta-
adrenoreceptor coupled adenylate cyclase system (Manier et al., 2002). 
The higher liver PEPCK and AlaAT activities suggest that environmental levels of 
venlafaxine exposure may increase the metabolic demand in response to stress, and this is 
exacerbated given that the fish were food-deprived during the experimental period. Also, the 
increased liver gluconeogenic capacity at 4 h post-stressor exposure may be due to the 
reduced plasma glucose levels, as studies have shown that lower extracellular glucose will 
enhance gluconeogenesis in fish liver (Plagnes-Juan et al., 2008). The lack of changes in the 
glucose transporter 2 (GLUT2), a low-affinity transporter (Polakof et al., 2007; Krasnov et 
al., 2001), along with hexokinase and glucokinase activities suggests that the liver capacity 
for glucose import and export may not be impacted by venlafaxine exposure. Consequently, a 
reduction in stress-induced blood glucose may not be attributed to compromised transport 
from liver, suggesting an enhanced liver metabolic demand and increased endogenous use of 
fuel associated with venlafaxine exposure.  
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 While catecholamines are responsible for the rapid hyperglycemia in acutely stressed 
trout, cortisol is thought to be a key player in maintaining the fuel in circulation for longer 
periods and for repletion of the liver glycogen stores (Vijayan et al., 2010; Mommsen et al., 
1999). This cortisol response, at least in part, is due to GR-mediated gluconeogenesis 
(Vijayan et al., 2010; Aluru and Vijayan, 2007). Venlafaxine exposure did affect the liver 
metabolic capacity of trout in the present study. Specifically, the drug increased the activity 
of liver PEPCK, a key enzyme in gluconeogenesis (Mommsen et al., 1999). This was further 
supported by increased activity of AlaAT, an enzyme that converts amino acids into C3 
precursors (i.e. alanine into pyruvate) for gluconeogenesis in fish (Mommsen et al., 1999). 
Stress-induced cortisol plays a role in increasing liver gluconeogenic capacity by increasing 
the activities of PEPCK and transaminases (Mommsen et al., 1999). In this study, 
venlafaxine exposure did not modify either plasma cortisol levels or the target tissue GR 
expression in the liver or in the brain, where it mediates negative feedback actions of cortisol 
on the HPI axis, suggesting other possible factor(s) modulating circulating glucose levels. A 
similar lack of effect on cortisol response to stress was also observed in trout exposed to 
environmentally relevant levels of fluoxetine (Stroud, 2012).  
Despite a lack of effects on basal plasma cortisol levels, venlafaxine exposure 
disrupted the interrenal cortisol biosynthetic capacity as evidenced by the reduced transcript 
levels of StAR, a key rate-limiting step in steroidogenesis. Also, the transcript levels of the 
key rate-limiting enzyme in steroid biosynthesis, P450scc (orthologous to mammalian 
CYP11A1), was elevated prior to and at 24 h after stressor exposure suggesting disturbances 
in interrenal steroidogenic capacity. Indeed, studies have shown that StAR and P450scc are 
targets for impact by xenobiotics, including AhR agonists, heavy metals, salicylate, 
pesticides, and municipal wastewater effluent (Ings et al., 2011; Sandhu and Vijayan, 2011; 
Gravel and Vijayan, 2007; Aluru et al., 2005; Walsh et al., 2000). Our results add 
venlafaxine to the list of contaminants with the potential to disrupt steroidogenesis. However, 
the changes in mRNA levels of steroidogenic genes by venlafaxine did not translate into 
modulation of basal or stressor-stimulated plasma cortisol levels in trout in vivo. While the 
reason for this is unclear, previous studies have also shown a similar mismatch between 
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steroidogenic gene expression and corticosteroid output in trout (Aluru et al., 2005; Geslin 
and Auperin, 2004; Kusakabe et al., 2002).  
Interestingly, the results of our ex vivo head kidney experiment indicate that 
venlafaxine increases the magnitude of cortisol response to in vitro challenge with ACTH, 
suggesting that at the interrenal level, tissue sensitivity to stressors may actually be increased. 
Stimulation of ex vivo head kidney tissues with 8-Br-cAMP, a cAMP analogue that can 
stimulate membrane signal cascades while bypassing MC2R receptor ligand binding and 
adenylate cyclase activation in the interrenal cells, did not reveal differences in cortisol 
production response between the tissues from different venlafaxine exposure groups. This 
leads us to propose that venlafaxine effect on cortisol production may be mediated by 
mechanism upstream of intracellular cAMP signalling cascade. Although the acute stressor 
challenge in vivo did not reveal significant effects of venlafaxine exposure on stressor-
mediated plasma cortisol response in the present study, we have shown previously that this 
drug exposure significantly amplified cortisol response to a social stress in trout [Chapter 2, 
Melnyk-Lamont et al., submitted]. Consequently, effects of venlafaxine exposure on plasma 
cortisol response may vary with different types of stressors and/or the nutritional/metabolic 
state of the animal and this warrants further investigation.  
 While liver is a key organ for glucose production, the gill is a key target for glucose 
utilization in fish (Hemre and Kahrs, 1997; Soengas et al., 1995). An increase in LDH 
activity in the gill at 24 h in the 1.0 µg/L group suggests enhanced glycolytic capacity 
associated with drug exposure. The gill is essential for gas exchange and hydromineral 
homeostasis (Wendelaar Bonga, 1997) and the sodium pump activity is critical in 










is located on the basal membrane of the chloride cells and actively maintains ion balance by 
exporting sodium ions into the blood in exchange for potassium ions (Wendelaar Bonga, 
1997). In brook trout brain synaptosomes, activity of this ATPase is downregulated by 
SSRIs, which is in agreement with our results but the mechanism is far from clear 




 ATPase protein expression in response to 
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venlafaxine exposure suggests a compensatory mechanism to offset the reduced activity, but 
this remains to be tested. The changes in sodium pump expression and activity along with 
changes in LDH activity suggest a dysregulation in gill metabolism in response to 
venlafaxine exposure. We propose that exposure to venlafaxine may disrupt the osmo- and 
iono-regulatory capacity of fish and this warrants further investigation. 
From an ecotoxicological standpoint, it is important to assess the effects of 
pharmaceutical contaminant exposure at environmentally realistic levels in order to estimate 
the impact on the organisms exposed in the wild. Since little is known about effects of 
venlafaxine on fish, exposure studies utilizing individual drug as opposed to complex 
effluent mixtures can elucidate its mechanism of action in these non-target animals. Overall, 
frequent or chronic aquatic contaminant exposures may lead to longer-term repartitioning of 
energy resources away from vital processes important to fitness, including growth, proper 
immune function, and reproduction (Iwama et al., 2006). As venlafaxine is typically found 
amid a cocktail of pharmaceuticals in municipal wastewater effluents along with other 
antidepressants that often have similar modes of action, the potential for additive, synergistic 
or antagonistic effects is an important consideration for environmental risk assessment.  
 
3.6 CONCLUSIONS 
Overall, this study demonstrates for the first time that environmental concentrations 
of venlafaxine can perturb the metabolic response to stress in rainbow trout. The importance 
of this work is underscored by using environmentally realistic concentrations for assessment 
of the impact of venlafaxine on stress physiology of fish. The reduced plasma glucose 
response to a secondary stressor suggests disruption in target tissue metabolic capacities. 
Indeed, the metabolic capacity of the liver, a key glucose producing tissue, was disrupted by 
venlafaxine exposure and this was evidenced by increased gluconeogenic and transaminase 
activities. The metabolic capacity of gills, a key glucose utilizing tissue, was also impacted 





ATPase activity and increased protein expression of this enzyme. Though no changes were 
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seen in cortisol levels or GR expression in the brain or liver, the capacity for steroidogenesis 
in interrenal tissue (transcript levels of StAR, P450scc) was altered by venlafaxine. 
Moreover, ex vivo head kidney tissues from venlafaxine-exposed fish exhibited increased 
production of cortisol in response to ACTH stimulation in vitro. Our results suggest that 
venlafaxine impacts the metabolic adjustments that are essential to cope with stress and re-
establish homeostasis in fish. The overall picture of venlafaxine effects on the functioning of 
the HPI axis and the disruption of cortisol response appears complex and warrants further 
study.  
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Attenuation of stressor-induced cortisol 




Venlafaxine, a commonly prescribed antidepressant drug that is frequently detected in 
aquatic systems across North America, impacts aspects of stress physiology in rainbow trout 
(Oncorhynchus mykiss), although effects on the functioning of the hypothalamus-pituitary-
interrenal (HPI) axis are far from clear. Utilizing a flow-through exposure system and 
maintaining a regular feeding schedule, we mimicked an environmentally relevant exposure 
scenario and tested the hypothesis that venlafaxine disrupts the functioning of the HPI axis. 
Fish were subjected to an acute stressor following a seven day exposure to 1.0 μg/L 
venlafaxine. We examined plasma parameters associated with stress physiology and gene 
expression levels of molecular markers associated with the HPI axis. Venlafaxine exposure 
led to an attenuated stressor-induced cortisol response. The interrenal capacity for cortisol 
production in response to ACTH-stimulation was not altered by this drug. However, mRNA 
levels of steroidogenic acute regulatory protein (StAR) and cytochrome P450 side chain 
cleavage (P450scc) were upregulated at the interrenal level. At the hypothalamus, 
venlafaxine exposure did not affect corticotropin releasing factor (CRF) or CRF binding 
protein transcript levels. At the pituitary, the drug exposure significantly reduced CRF 
receptor type 1 (CRF-R1), but not pro-opiomelanocortin (POMC) mRNA levels. There was 
no significant effect of the drug on plasma ACTH levels or on the mRNA levels of 
corticosteroid receptors, which are involved in mediation of negative feedback effects by 
cortisol in the pituitary and hypothalamus. Transcript levels of neuropeptide Y (NPY), an 
appetite-stimulating peptide that is also known to interact with the HPI axis, were 
upregulated by venlafaxine exposure. No significant changes were seen in the mRNA 
abundance of glucose transporter type 2, GLUT2, another player involved in energy 
homeostasis, in the hypothalamus. Collectively, these findings suggest that venlafaxine 
perturbs the highly conserved and adaptive cortisol response to stressor challenge in rainbow 
trout. We propose that the mode of action of this drug may involve disruption of HPI axis 




Stressor-mediated increase in plasma corticosteroids is an evolutionarily conserved 
response mechanism that allows animal to re-establish homeostasis (Sapolsky et al., 2000). 
Cortisol is a principal corticosteroid hormone in teleosts and it plays an essential role in the 
physiological adjustments associated with stress, including regulation of energy metabolism, 
hydromineral balance, and immune functions (Vijayan et al., 2005; Mommsen et al., 1999; 
Wendelaar Bonga, 1997). Plasma cortisol elevation in response to stressor in teleosts is 
regulated by the functioning of the hypothalamus-pituitary-interrenal (HPI) axis (Vijayan et 
al., 2010; Barton, 2002). Briefly, upon perception of stress stimuli, corticotropin releasing 
factor (CRF) is released form the hypothalamic neurosecretory cells in the nucleus preopticus 
(NPO) (Bernier et al., 2009). CRF stimulates cells in the anterior pituitary to produce 
adrenocorticotropic hormone (ACTH) from a precursor peptide pro-opiomelanocortin 
(POMC), and this hormone is released into the general circulation (Mommsen et al., 1999; 
Wendelaar Bonga, 1997). CRF mediates its actions via two types of receptors, CRF-R1 and 
CRF-R2 (Pohl et al., 2001). In teleosts, CRF-R1 is known to play a pivotal role in the stress 
response, while the second type is thought to be associated with a broad range of 
physiological and behavioural responses, including appetite regulation (Flik et al., 2006). 
ACTH is the primary cortisol secretogogue in teleosts and activates the melanocortin 2 
receptors (MC2R), a G-protein coupled receptor, present on the steroidogenic cells in the 
head kidney region (interrenal tissue), leading to cortisol biosynthesis (Aluru and Vijayan, 
2008). The first step in steroid biosynthesis involves delivery of cholesterol from the outer to 
the inner mitochondrial membrane, and this process is mediated by the steroidogenic acute 
regulatory protein (StAR) (Stocco, 2000). In the inner mitochondrial membrane, cytochrome 
P450 side chain cleavage (P450scc) converts cholesterol to pregnenolone and this is first 
rate-limiting enzymatic reaction for steroid biosynthesis (Payne and Hales, 2004). Cortisol 
mediates its actions in target tissues by binding to corticosteroid receptors, which are ligand-
activated transcription factors. There are multiple isoforms of corticosteroids receptors, 
including two isoforms of glucocorticoid receptors, GR1 and GR2, and one 
mineralocorticoid receptor (MR) in trout (Aluru and Vijayan, 2009).  
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Disruption of HPI axis functioning reduces the organism’s ability to cope with 
subsequent stressors and may lead to reduced fitness (Ings et al., 2011). The cortisol stress 
axis is a key target for endocrine disruptors, including polychlorinated biphenyls, metals and 
pharmaceuticals (Hontela and Vijayan, 2009). In rainbow trout, exposure to municipal 
wastewater effluent (MWWE), which exhibits a complex mixture of chemicals, impacts the 
cortisol stress response (Ings et al., 2011). Over the recent years, venlafaxine became a 
predominant antidepressant drug detected in the MWWE. 
Venlafaxine, a serotonin and norepinephrine reuptake (SNRI) inhibitor, is a 
commonly prescribed antidepressant drug for treatment of many depressive disorders 
(Roseboom and Kalin, 2000; Thase and Sloan, 2009). Due to its increased human 
consumption over the last decade and inadequacy of removal from the wastewater effluent 
(Corcoran et al., 2010), its detection levels in the aquatic systems are usually one of the 
highest among antidepressants, ranging from low ng/L to over 1000 ng/L (González Alonso 
et al., 2010; Metcalfe et al., 2010; Schultz and Furlong, 2008; Schultz et al., 2010). Our 
earlier acute stressor study conducted in a static experimental system revealed that 
venlafaxine exposure results in attenuated stressor-induced plasma glucose response [Chapter 
3; Best et al., accepted], while no effect on stressor-induced plasma cortisol response was 
detected in vivo, although at the level of the interrenal tissue, cortisol response to in vitro 
ACTH stimulation was amplified in the tissues from venlafaxine-exposed fish [Chapter 3].  
Static experimental systems utilizing daily water changes are commonly used in the 
fields of aquatic toxicology. However, during the acclimation period, habituation may occur 
to repeated handling associated with water exchanges and the animal may not respond to an 
additional stressor (Cyr and Romero, 2009). Repeated exposures to mild stressors can 
desensitize fish and attenuate neuroendocrine responses to subsequent stressors (Barton, 
2002). Also, the fish in the static system were not fed during the experimental period and this 
may have led to changes in the metabolic demand of the animal, leading to an altered 
response. To test this,  and to determine whether changes in the physiological stress response 
by VEN exposure involve alterations in HPI axis functioning, we exposed juvenile rainbow 
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trout to 1 μg/L venlafaxine in a flow-through water system with daily feed for seven days, 
followed by subjecting the fish to an acute stressor challenge.  
To test the hypothesis that exposure to environmental levels of venlafaxine disrupts 
functioning of the HPI axis, we examined plasma parameters of stress response (cortisol, 
ACTH, glucose, lactate) along with GR1, GR2 and MR transcript levels in the hypothalamus 
and pituitary, where cortisol mediates negative feedback regulation of the HPI axis (Aluru 
and Vijayan, 2009), following an acute stressor challenge. The drug exposure was considered 
as the primary stressor, and these fish were then subjected to a handling disturbance, which 
constituted the secondary stressor. Also, transcript levels of key molecular markers involved 
in HPI axis function, including CRF and its binding protein, CRF-BP, in the hypothalamus, 
pro-opiomelanocortin, POMCA and POMCB, and CRF-R1 and CRF-R2 in the pituitary and 
StAR, P450scc and MC2R in the interrenal tissue were measured to indicate central and 
peripheral endocrine disruption by venlafaxine. In addition, we investigated mRNA 
abundance of genes involved in appetite regulation, including hypothalamic neuropeptide Y 
(NPY) and bidirectional glucose transporter type 2 (GLUT2) (Polakof et al., 2011;Volkoff et 
al., 2005), and their modulation by acute stressor given that venlafaxine appeared to play a 
role in feed intake and energy homeostasis [Chapter 2; Melnyk-Lamont et al., submitted].  
4.3 MATERIALS AND METHODS 
4.3.1 Animals and experimental protocol 
Juvenile rainbow trout were purchased from Rainbow Springs Trout Hatchery 
(Thamesford, ON) and were kept at the aquatics facility at Wilfrid Laurier University in 200 
L polyethylene tanks with flowing fresh water (dechlorinated city tap water) at 700 ml/min at 
12
◦
C. Trout were fed 2% of body weight with commercial fish food (Bio Oregon Protein 
Inc., Warrenton, OR) once daily and a photoperiod (16 light : 8 dark) was maintained 
throughout the experiment. All experimental protocols were approved by the University of 
Waterloo and the Wilfrid Laurier University Animal Care Committees and conducted in 
accordance with the Canadian Council for Animal Care guidelines. 
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Rainbow trout (112 ± 6 g) were randomly distributed into four 200 L polyethylene 
tanks (32 fish per tank) where they were acclimated for two weeks prior to start of the 
experiment. In our drug exposure set-up, trout were exposed to either 0 (control) or 1.0 μg/L 
venlafaxine for seven days in a flow-through system. Venlafaxine concentration of 1.0 μg/L 
was chosen to approximate environmental levels (Metcalfe et al., 2010; Schultz and Furlong, 
2008) and this concentration was shown to affect brain monoamine levels [Chapter 2; 
Melnyk-Lamont et al., submitted]. Venlafaxine exposure involved metering (QG6 pump, 
Fluid Metering Inc., Oyster Bay, NY) of a concentrated stock solution (venlafaxine 
hydrochloride; Sigma Aldrich, St. Louis, MO; dissolved in water) into a mixing head tank 
before delivery to duplicate fish tanks (180 L volume of water in each tank). Exposures were 
initiated by spiking the tanks with appropriate volumes of concentrated stock solution of 
venlafaxine to achieve the target exposure concentration. Header and fish tanks were 
supplied with continuous aeration to ensure mixing. Fish were fed once daily throughout the 
exposure period and the feeding stopped 24 h prior to acute stressor exposure. 
Following the drug exposure period, pre-stress fish from each tank were sampled 
(represented by 0 h time point). Following the 0 h sampling, the remaining fish were exposed 
to a secondary acute stressor consisting of a 5 min handling disturbance as previously 
described (Ings et al., 2011) followed by sampling at 1, 4 and 24 h post-stressor exposure. At 
each sampling point, 8 fish (4 fish per replicate exposure tank) were sampled. 
4.3.2 Collection of tissue samples 
Fish were euthanized with an overdose of tricaine methanesulfonate (MS-222; Syndel 
Laboratories Ltd., Vancouver, BC; 0.6 g/L buffered with sodium bicarbonate) and were bled, 
by severing the caudal peduncle, into 1.5 ml centrifuge tubes containing 40 μl of 10 mg/mL 
EDTA in physiological saline as an anticoagulant. Blood samples were immediately 
centrifuged at 10,000 x g for 2 min and plasma was collected and stored at -30 °C for later 
analysis of cortisol, ACTH, glucose and lactate levels. Each brain was quickly removed and 
placed on a chilled petri dish. Hypothalamic tissue along with preoptic region (containing 
NPO) was dissected and pooled as one region. Trout brain regionalization diagram is shown 
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in [Fig. A1-A; Appendix A]. Pituitaries and head kidney tissue were also collected from all 
fish. All tissue samples were flash frozen in dry ice and stored at -80
o
C for later analysis of 
mRNA levels. 
4.3.3 Plasma measurements 
Plasma cortisol levels were measured by radioimmunoassay (RIA) using 
3
H cortisol 
as described previously (McMaster et al., 1995). Cortisol antibody was obtained from MP 
Biomedicals (MP Biomedicals, Irvine, CA, USA) and 
3
H cortisol was purchased from GE 
Healthcare (Waukesha, WI, USA). Plasma ACTH concentrations were measured using a 
double antibody (hACTH) 
125
I RIA kit (MP Biomedicals) as per the manufacturer’s 
instructions. This kit has been previously validated for ACTH measurements in trout plasma 
(Doyon et al., 2006; Craig et al., 2005). Plasma glucose was measured by the hexokinase and 
glucose-6-phosphate dehydrogenase enzymatic method (Bergmeyer et al., 1974), and plasma 
lactate was determined by lactate dehydrogenase and nicotinamide adenine dinucleotide 
enzymatic method (Gutmann and Wahlefeld, 1974) using a VersaMax microplate reader 
(Molecular Devices, Sunnyvale, CA, USA).  
4.3.4 Quantification of gene expression 
Total RNA was isolated from head kidney, pituitary, hypothalamic tissues using the 
RNeasy Mini Kit (Qiagen, Mississauga, ON) according to manufacturer’s instructions. RNA 
was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Nepean, ON) at 
260/280 nm and 1 μg of total RNA (DNase treated) was used for first-strand cDNA synthesis 
using high capacity cDNA reverse transcription kit (Applied Biosystems, Streetsville, ON, 
CAN) in 20 μl reaction volume. Real-time quantitative PCR (qPCR) was used for 
quantification of transcript levels using iCycler real-time PCR detection system (Bio-Rad, 
Hercules, CA). cDNA samples were used as template for amplification of target genes using 
gene-specific primers (Table 4-1). cDNA from the hypothalamic region was used for analysis 
of CRF, CRF-BP, GLUT2, NPY, GR1, GR2 and MR transcript expression (genes involved 
in HPI axis and energy balance regulation); the pituitary cDNA was used for expression 
analysis of CRF-R1 and CRF-R2, POMCA, POMCB, GR1, GR2, MR (genes involved in 
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HPI axis); and the head kidney cDNA was used for StAR, P450scc, and MC2R analysis 
(genes involved in cortisol biosynthesis).  
A master mix containing 2.5 μL of cDNA, 2.5 μL of 10 μM primer pair, 40 μL of 
SYBR green supermix (Bio-Rad) and 35 μL of nuclease-free water was prepared for each 
sample and run in triplicates. The following PCR conditions were used for amplification: 
initial denaturation for 3 min at 95
 
°C, followed by 40 cycles of 20 s at 95
 
°C, 20 s at 
annealing temperature (see Table 4-1); 95
 
°C for 1 min; 55
 
°C for 1 min followed by melt 
curve analysis starting at 55
 
°C and increasing in 0.5
 
°C increments to 95
 
°C every 10 s. Only 
PCR conditions for NPY amplification differed from the above stated, and were described 
previously (Conde-Sieira et al., 2010). Threshold cycle values were calculated using iCycler 
iQ real-time detection software (Bio-Rad).  All data were normalized to relative expression 
of a housekeeping gene EF1α since its expression did not change across treatments or time 
points. A relative standard curve method was used to determine relative transcript 
abundances according to established protocols (Sathiyaa and Vijayan, 2003). All transcript 
levels are shown as percent change from the control group of 0 h time-point.  
4.3.5 Statistical analysis 
All statistical tests were performed using Sigmaplot 11 (Systat Software Inc., San 
Jose, CA, USA). For plasma measurements and transcript levels, two-way analysis of 
variance (ANOVA) was used to examine venlafaxine treatment and time post-stressor 
exposure effects, and their interactions (treatment × stress), followed by Holm-Sidak post hoc 
test. Data were transformed when necessary to meet the assumptions of normality and 
homogeneity of variance, although non-transformed data are shown in figures. A significance 
level of α = 0.05 was used in all cases.  
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Table 4-1. Sequences (forward and reverse), amplicon size, accession number and annealing 
temperature for primers used in quantitative real-time RT-PCR. 
 
Gene Primer sequence 
Accession  
No. 








































AY495372.1 60 140 
R: 5’-CTCACCCCACAGATGGAGAT-3’ 
MR 






AB047032 60 101 
R: 5′-AGGGTTCCAGTCTCCCATCT-3′ 
P450scc 
F: 5′-GCTTCATCCAGTTGCAGTCA -3′  
S57305.1 60 140 
R: 5′-CAGGTCTGGGGAACACATC -3′  
MC2R 
F: 5'-GAGAACCTGTTGGTGGTGGT-3' 








NM_001124719.1 60 199 
R: 5'- CCTGCTGCCCTCCTCTACTGC-3' 
Gene abbreviations: EF1α, elongation factor 1α; CRF, corticotropin-releasing factor; CRF-BP,  
corticotropin-releasing factor binding protein; CRF-R1 and CRF-R2, corticotropin releasing factor receptor 1 and 
2,  respectively; GLUT2, glucose transporter type 2; NPY,  neuropeptide Y; GR1 and GR2, glucocorticoid 
receptor 1 and 2, respectively; MR, mineralocorticoid receptor; StAR, steroidogenic acute regulatory protein; 
P450scc, cytochrome P450 side chain cleavage; MC2R , melanocortin 2 receptor, POMCA and POMCB, pro-




4.4.1 Plasma measurements 
As expected, stressor-induced plasma cortisol response was affected by a significant 
stressor effect (P < 0.001, two-way ANOVA). There was a significant increase at the 1 h 
post-stressor time point (Fig. 4-1A), followed by a significant decrease at the 4 h time point 
and returning to basal (pre-stress) levels at 24 h post-stressor exposure Also, a significant 
treatment effect was present (P < 0.05, two-way ANOVA), demonstrating significant 
attenuation of plasma cortisol levels in the venlafaxine-exposed group compared to the 
control (Fig. 4-1A). Attenuation was most prominent at 1 h post-stressor time point, where 
cortisol levels were reduced by approximately 40% in the venlafaxine group compared to the 
control. There was no significant treatment effect on plasma ACTH levels (Fig. 4-1B), 
although a significant stressor exposure effect was detected (P < 0.05, two-way ANOVA), 
demonstrating that ACTH levels were significantly elevated at 24 h post-stress relative to 1 
or 4 h time-points regardless of treatments (Fig. 4-1B). Stress-induced glucose levels showed 
a profile similar to that of cortisol, with significant elevation at 1 h post-stressor and 
returning to pre-stress levels at 24 h post-stressor (Fig. 4-1C). There was no significant 
treatment effect on plasma glucose levels (Fig. 4-1C). Stressor exposure significantly 
increased plasma lactate levels at 1 h post-stressor exposure and the levels dropped to pre-
stress levels by 4 h post stressor exposure (Fig. 4-1D). There was a significant increase in 
plasma lactate levels at 24 h compared to the pre-stress levels. Venlafaxine exposure did not 





Figure 4-1.  Effect of a 7-day venlafaxine exposure (1.0 μg/L ) on plasma cortisol (A), 
adrenocorticotropic hormone, ACTH (B), glucose (C), and lactate (D) in rainbow trout prior 
to (0 h) and after an acute stressor (1, 4 and 24 h). Values represent mean ± SEM (n = 7-9 
fish). Capital letters indicate significant differences between stress time points, and insets 
show significant treatment effects. Data were analysed by two-way ANOVA, followed by 
Holm-Sidak post hoc test when significant effects were detected (P < 0.05). 
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4.4.2 Transcript levels - hypothalamic region 
In the hypothalamic region (including the preoptic area), overall CRF mRNA 
abundance was affected by stressor application (P < 0.05, two-way ANOVA), where 
transcript levels were significantly elevated at 4 h and 24 h relative to 1 h post-stress time 
point (Fig. 4-2A). No venlafaxine treatment effect on CRF mRNA abundance was present 
(Fig. 4-2A). Expression of CRF-BP, a binding protein that regulates CRF bioavailability, was 
not affected by either stressor application or venlafaxine exposure in this study (Fig. 4-2B).  
Analysis of transcript levels of the glucose transporter, GLUT2, detected a significant 
effect due to stressor application (P < 0.05, two-way ANOVA), where transcript levels were 
elevated at 4 h post-stress relative to other time points (Fig. 4-2C). No venlafaxine treatment 
effect on GLUT2 expression was observed (Fig. 4-2C). Statistical analysis of mRNA 
expression of NPY detected a significant interaction (P = 0.05, two-way ANOVA) between 
the drug treatment and stress factors. Comparison between the control and venlafaxine 
groups within each time point revealed that drug exposure significantly elevated NPY 
transcript levels (~1.8-fold) before acute stressor application at the 0 h time point, although 
no treatment effect was present at post-stress time points (Fig. 4-2D). There was an effect of 
stressor application on NPY expression in the control group; however, venlafaxine-exposed 
fish demonstrated a significant time effect, where expression levels were reduced 1h post-
stress relative to pre-stress levels (Fig. 4-2D).  
Expression levels of the corticosteroid receptor genes, important in the negative 
feedback regulation of the HPI axis, were also examined in the hypothalamic region. 
Transcript abundances of GR1 and GR2 genes were not affected by either venlafaxine 
treatment or stressor application (Fig. 4-2E and 4-2F, respectively). There was no treatment 
effect on MR mRNA levels, although a significant stressor effect was present (P < 0.001, 
two-way ANOVA), showing a gradual reduction in expression levels after acute stressor 







Figure 4-2.  Effect of a 7-day venlafaxine exposure (1.0 μg/L ) on the hypothalamic 
(including preoptic area) mRNA levels of corticotropin-releasing factor, CRF (A), its binding 
protein CRF-BP (B), glucose transporter type 2, GLUT2 (C), neuropeptide Y, NPY (D), 
glucocorticoid receptors, GR1 (E) and GR2 (F), and mineralocorticoid receptor, MR (G) in 
rainbow trout prior to (0h) and after an acute stressor (1, 4, and 24 h). All mRNA levels were 
normalized to EF1α and values are shown as percent of the control group (0 h), bars 
represent means ± SEM (n = 6 fish).  Capital letters indicate significant differences between 
stress time points. When significant interaction was detected (treatment × stress), small 
letters indicate differences between stress time points for an individual treatment group, and 
asterisks indicate significant treatment effect within a time point. Transcript abundances were 
analyzed with two-way ANOVA, followed by Holm-Sidak post hoc test when significant 






4.4.3 Transcript levels - pituitary 
In the pituitary, transcript levels of the two CRF receptor genes, CRF-R1 and CRF-
R2, were examined. Statistical analysis of CRF-R1 gene expression detected a significant 
interaction between venlafaxine treatment and stressor factors (P = 0.031, two-way 
ANOVA). Comparison between the control and venlafaxine-exposed groups, detected a 
significant reduction in CRF-R1 transcript abundance (~1.6 fold-change) in the venlafaxine 
group 1 h following stressor exposure (Fig. 4-3A). No treatment effect was detected within 0, 
4, or 24 h time-points. There was a significant stressor effect present in the control group, 
where CRF-R1 transcripts were significantly elevated 1 h post-stressor relative to other time 
points, whereas the venlafaxine-exposed group did not exhibit stress effects on CRF-R1 
expression (Fig. 4-3A). There was no treatment effect on CRF-R2 expression (Fig.4-3B), 
although a significant stressor effect was detected (P < 0.001, two-way ANOVA) 
demonstrating a reduction in CRF-R2 mRNA levels at the 4 and 24 h time-points relative to 
the 0 and 1 h time points (Fig. 4-3B). 
Analysis of the pituitary expression profiles of the genes encoding the pro-
opiomelanocortin peptides, POMCA and POMCB, did not identify significant effects of 
venlafaxine treatment or stressor exposure for either of the genes (Fig. 4-3C and Fig. 4-3D, 
respectively).  
Transcript abundances of GR1 and GR2 (Fig. 4-3E and 4-3F, respectively) were 
influenced by significant stressor effects (P < 0.05 in both cases, two-way ANOVA), where 
24 h post-stressor time point exhibited reduced GR1 (Fig. 4-3E) and elevated GR2 (Fig. 4-
3F) mRNA abundances in comparison to other time-points, although neither of the GR 
isoforms were affected by venlafaxine treatment. MR expression (Fig. 4-3G) was 
significantly affected by stressor application (P < 0.001, two-way ANOVA), demonstrating 
reduced expression at 4 and 24 h post-stress relative to the pre-stress levels. There was no 








Figure 4-3.  Effect of a 7-day venlafaxine exposure (1.0 μg/L ) on the pituitary mRNA levels 
of corticotropin-releasing factor receptors, CRF-R1(A) and CRF-R2 (B), pre-
opiomelanocortin genes, POMCA (C) and POMCB (D), glucocorticoid receptors, GR1 (E) 
and GR2 (F) and mineralocorticoid receptor, MR (G) in rainbow trout prior to (0 h) and after 
an acute stressor (1, 4, and 24 h). All mRNA levels were normalized to EF1α and values are 
shown as percent of the control group (0 h), bars represent means ± SEM (n = 6 fish). Capital 
letters indicate significant differences between stress time points. When significant 
interaction was detected (treatment × stress), small letters indicate differences between stress 
time points for an individual treatment group, and asterisks indicate significant treatment 
effect within a time point. Transcript abundances were analysed with two-way ANOVA, 







4.4.4 Transcript levels - interrenal tissue 
Statistical analysis of the gene expression levels of MC2R did not detect any 
significant treatment or stressor exposure effects (Fig. 4-4A). There were significant main 
treatment and stressor effects detected on the expression of the two steroidogenic genes – 
StAR and P450scc (Fig. 4-4B and 4-4C, respectively). Venlafaxine-exposed fish had higher 
expression of StAR and P450scc compared to the control fish (P < 0.05; two-way ANOVA). 
Transcript levels for both genes showed significant elevations at 24 h relative to 1 h post-









Figure 4-4. Effect of a 7-day venlafaxine exposure (1.0 μg/L ) on the head kidney mRNA 
levels of melanocortin 2 receptor, MC2R (A), steroidogenic acute regulatory protein, StAR 
(B), and cytochrome P450 side chain cleavage, P450scc (C) in rainbow trout prior to (0 h) 
and after an acute stressor (1, 4, and 24 h). All mRNA levels were normalized to EF1α and 
values are shown as percent of the control group (0 h), bars represent means ± SEM (n = 6 
fish). Capital letters indicate significant differences between stress time points, and insets 
show significant treatment effects. Transcript abundances were analysed with two-way 


































Our study demonstrates that sub-chronic exposure to an environmentally relevant 
concentration of venlafaxine perturbs the organismal cortisol response in rainbow trout, 
which is a highly conserved mechanism essential for the metabolic adjustments required for 
re-establishing homeostasis (Aluru and Vijayan, 2009). Reduced capacity to evoke a proper 
physiological cortisol response may impair the animal’s stress performance, which can 
translate into reduced fitness in fish exposed to environmental levels of venlafaxine.  
Venlafaxine exposure did not affect basal cortisol levels after the seven day exposure 
period, and this is in agreement with our previous findings [Chapters 2, 3]. However, our 
results demonstrate that venlafaxine impaired the ability to respond to a secondary stressor 
(handling disturbance), as the amplitude of the stressor-induced cortisol response was 
reduced by the drug exposure. So what is the mechanism leading to the attenuation of 
stressor-included cortisol response by venlafaxine?  
Analysis of plasma ACTH, a primary secretagogue for cortisol in fish produced by 
the pituitary gland, did not provide evidence for its involvement in attenuation of the cortisol 
response. Typically application of an acute stressor (e.g. handling, confinement, heat stress) 
leads to elevation of plasma ACTH in conjunction with elevation of plasma cortisol levels 
(Aluru and Vijayan, 2008; Balm and Pottinger, 1995; Sumpter et al., 1986). In the present 
study, we did not observe a peak in plasma ACTH concentrations at the 1 h time point 
following the acute stressor. Plasma ACTH concentrations may peak as early as 5 min 
following stressor application (preceding the rise in plasma cortisol), and the duration and 
amplitude of the response may be stressor-specific (Sumpter et al., 1986; Cook et al., 1973). 
Thus, it is possible that in our experimental animals the stressor-induced ACTH levels may 
have peaked prior to the 1 h sampling point.  
Signalling of CRF and CRF-related peptides is mediated by two main G-protein 
coupled receptor types, CRF-R1 and CRF-R2, which are widely expressed in the central 
nervous system, as well as peripherally (Pohl et al., 2001). CRF-R1 is known to be 
associated with the stress axis activation, while CRF-R2 is involved in a wide range of 
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physiological and behavioural responses (Flik et al., 2006). In the pituitary corticotrophs, 
CRF-R1 is the major subtype and is responsible for regulating the synthesis and secretion of 
ACTH (Kageyama and Suda, 2009). In the present study, the control fish exhibited a 
significant elevation of the pituitary CRF-R1 transcripts 1 h after the acute stressor challenge 
and returned to the resting levels at the later time points, and this is in agreement with the 
finding that CRF stimulation of pituitary CRF-R1 leads to subsequent downregulation of 
CRF-R1 mRNA levels (Kageyama and Suda, 2009; Rabadan-Diehl et al., 1996). 
Interestingly, the venlafaxine-exposed group did not exhibit the same temporal profile, 
demonstrating significantly lower transcript levels of this receptor type 1 h post-stressor 
exposure. This suggests that venlafaxine exposure may reduce the sensitivity of the pituitary 
corticotroph cells to CRF stimulation, but this remains to be tested. Despite the reduced CRF-
R1 transcript levels post-stressor in the venlafaxine group, there was no significant effect on 
the expression levels of either of the two pro-opiomelanocortin encoding genes, POMCA and 
POMCB, although the venlafaxine group exhibited a high degree of variation at this time 
point for both genes. POMC is a precursor molecule for several biologically active peptides 
and it undergoes post-translational processing in the corticotrophs, resulting in the production 
of ACTH and teleost fish have two gene isoforms due to a genome duplication event in 
salmonids (Salbert et al., 1992). Although there was no significant downstream effect on 
POMC transcript abundance due to alteration in CRF-R1 transcript levels by venlafaxine, it 
remains to be determined whether the drug affected the translational/post-translational 
processing and secretion of this peptide in trout pituitaries.  
While examining the most upstream element of the HPI axis, the hypothalamic 
region, we did observe an overall upregulation of CRF transcripts in the hypothalamic area at 
4 and 24 h, but not at 1 h time-points, consistent with the idea that stress-induced CRF gene 
expression increases in response to depletion of the stored CRF neuropeptide (Imaki et al., 
1992). Venlafaxine treatment affected neither CRF mRNA abundance nor CRF-BP 
transcripts, encoding the protein that regulates CRF bioavailability (Flik et al., 2006). Our 
previous findings [Chapter 2; Melnyk-Lamont et al., submitted] demonstrated that 
venlafaxine exposure significantly increased basal CRF mRNA in the hypothalamus, but not 
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in the preoptic area. In this current study, the preoptic area was pooled together with the 
hypothalamic region and this may have a played a role in the lack of change in CRF 
transcript levels with venlafaxine, as the brain responses are very region-specific. In the fish 
brain, CRF-neurons from nucleus preopticus (in the preoptic area) and hypothalamic nucleus 
tuberalis are thought to be involved in the regulation of pituitary ACTH production and 
secretion (Yulis and Lederis, 1987). However, nucleus preopticus plays a more pivotal role in 
stressor-mediated ACTH regulation compared to the tuberal hypothalamus in fishes (Bernier 
et al., 2008; Flik et al., 2006). 
While the hypothalamic brain region is an integral neuroendocrine element of the HPI 
stress axis, this region also plays a central role in the control of food intake, integrating 
sensory information from peripheral signals of appetite, satiation, and long-term energy-
balance (Kalra et al., 1999). The pre-stress levels (0 h) of NPY transcript were elevated due 
to venlafaxine treatment and this observation can be related to the feeding behaviour. Similar 
to mammals, NPY is an orexigenic peptide in fish involved in energy balance regulation by 
stimulating appetite (Volkoff et al., 2005). Previous studies demonstrated that fasted fish 
exhibit higher expression of NPY transcripts in the hypothalamus and preoptic area 
(MacDonald and Volkoff, 2009; Silverstein et al., 1998).  Our results from behavioural study 
[Chapter 2; Melnyk-Lamont et al., submitted] suggested that fish exposed to venlafaxine 
consumed less food compared to the control fish. If a similar venlafaxine effect on food 
intake occurred in the present study (although food consumption was not evaluated), it might 
have resulted in reduced nutritional status in the venlafaxine-exposed fish leading to 
transcriptional activation of the appetite-stimulating NPY. Thus, the elevated levels of 
hypothalamic NPY mRNA observed in the venlafaxine group may be related to the feeding 
behaviour. In addition to its role in appetite regulation, NPY is also involved in complex 
interactions with the hypothalamus-pituitary-adrenal (HPA) axis based on mammalian 
studies, and NPY is known to stimulate ACTH release in mammals [reviewed in (Krysiak et 
al., 1999)]. Studies in fish also suggest that NPY may participate in the activation of the HPI 
axis in trout, possibly through interaction with CRF (Doyon et al., 2006; Doyon et al., 2003). 
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Consequently, we propose that venlafaxine-mediated changes in NPY transcript levels may 
also be involved in the impaired HPI axis regulation, in addition to appetite-related effects.  
Another potential mechanism associated with altered cortisol production may involve 
changes in the cortisol-mediated negative feedback regulation. However, no significant 
changes were seen in the mRNA levels of genes encoding corticosteroid receptors GR1, 
GR2, MR by venlafaxine exposure in either the hypothalamic tissue or the pituitary arguing 
against perturbation in the negative feedback regulation.  Investigation of steroidogenic 
capacity at the interrenal level did show interesting results. Overall, venlafaxine-exposed fish 
demonstrated higher transcript levels of the steroidogenic genes StAR and P450scc, while the 
mechanism leading to this effect remains unknown. As mentioned earlier, the stimulation of 
steroid biosynthetic pathway in the interrenal tissue involves binding of ACTH to MC2R 
receptor, which leads to increased adenylate cyclase activity, leading to elevation of 
intracellular levels of cAMP and activation of protein kinase A (PKA), which in turn 
phosphorylates protein targets including StAR (Stocco, 2000). While some researchers have 
shown an increase in the expression of these genes to ACTH or a handling disturbance 
stressor (Aluru and Vijayan, 2008; Aluru and Vijayan, 2006), others saw no change in 
transcript levels of these genes following ACTH stimulation or stressor (Alderman et al., 
2012; Gravel and Vijayan, 2007). Transcript response of the steroidogenic genes in the 
interrenal appears to be related to the magnitude of cortisol response. For instance, high 
intensity stressor resulted in elevation of StAR and P450ssc transcripts in the interrenal tissue 
of trout; however, no change in expression of these genes was present following a low 
intensity stressor (Geslin and Auperin, 2004). Moreover, transcriptional regulation of these 
genes seems to be rapid and transient− for instance, transcripts of the steroidogenic genes 
showed a significant elevation 10 min of in vitro ACTH stimulation of the head kidney tissue 
and dropped back at the 30 min time point (Conde-Sieira et al., 2013). We hypothesize that 
the decreased transcript levels of StAR and P450scc in the control fish may reflect higher 
turnover of pre-existing mRNA pools to support higher cortisol output. Previous in situ 
hybridization results showed presence of substantial StAR mRNA pool in the interrenal cells 
in non-stressed trout that may be readily translatable (Kusakabe et al., 2002). 
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In the present study, the reduced cortisol response to a handling disturbance in the 
venlafaxine exposure group did not translate into effects at the metabolic level. To this end, 
we examined plasma glucose and lactate levels post-stressor exposure and they did not show 
any significant treatment effects. However, in the previous study [Chapter 3; Best et al., 
accepted], when fish were held in static water system and food was withheld during the 
experiment, venlafaxine exposure caused attenuation of stressor-mediated plasma glucose 
levels, but not plasma cortisol. Nutritional status has been shown to modulate stress response 
in salmonids (Barton et al., 1988); moreover, food deprivation in rainbow trout is associated 
with more severe metabolic effects to acute handling stress (Vijayan and Moon, 1992). In the 
current study, fish were fed for the duration of the experiment. The discrepancy in our 
findings from previous and current studies may stem from the fact that nutritional status can 
influence the rate of metabolic recovery, offsetting the effect of venlafaxine on the stressor-
mediated physiological cortisol response. Also, timing, duration and magnitude of these 
plasma indicators of stress vary with animal model and stressor type and intensity (Iwama et 
al., 2006; Barton, 2002). 
4.6 CONCLUSIONS 
Our study provides evidence that venlafaxine is a neuroendocrine disruptor in fish 
and interferes with the physiological stress response. Although a significant attenuation of 
stressor-mediated cortisol response was evident in the venlafaxine-exposed fish, no treatment 
effects were detected in either glucose or lactate concentrations, suggesting a lack of 
metabolic effects. Examination of individual components of the HPI axis at mRNA level 
revealed that expression of CRF-R1, a key receptor type involved in stress response, was 
reduced by venlafaxine in the pituitary, suggesting that venlafaxine exposure may lead to 
changes in ACTH production and/or secretion. No treatment effects were seen on 
hypothalamic CRF or pituitary POMC gene expression levels, although venlafaxine exposure 
significantly increased basal expression of hypothalamic NPY – a neuropeptide involved in 
interaction with the HPI axis and appetite regulation. At the interrenal tissue level, 
venlafaxine treatment resulted in higher transcript levels of StAR and P450scc, while this 
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corresponded with attenuation in stressor-induced cortisol response. Taken together, 
venlafaxine is an endocrine disruptor in trout and impairs the highly conserved cortisol 
response that is essential to allow animal to cope with stress. We propose that venlafaxine 
may exert its effect centrally and peripherally, at the level of the interrenal tissue, but the 
mechanisms remains to be elucidated.  
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Chapter 5  
 
Venlafaxine disrupts the hypothalamus, 





There is an increasing body of evidence suggesting that venlafaxine acts as a 
neuroendocrine disruptor affecting the cortisol stress axis in rainbow trout. Venlafaxine is a 
pharmaceutical compound that is widely distributed in the aquatic environment due the high 
rates of human consumption for treatment of depressive disorders. However, the mode of 
action of this selective serotonin and norepinephrine reuptake inhibitor in non-target 
organisms like fish is less understood. We tested the hypothesis that venlafaxine directly 
affects the functioning of the hypothalamus, pituitary and interrenal tissues in rainbow trout. 
We utilized an in vitro approach using hypothalamus, pituitary and head kidney tissues from 
rainbow trout (Oncorhynchus mykiss) to tease out the mode of action of venlafaxine in 
disrupting neuroendocrine/endocrine function. Venlafaxine exposure in vitro disrupted 
hypothalamus and pituitary function in trout. These tissues were exposed to 0, 0.3 and 3 nM 
venlafaxine either in the presence or absence of a specific 5-HT1A receptor antagonist, NAN-
190, to determine whether serotonin signalling is involved in venlafaxine-mediated 
endocrine/neuroendocrine disruption. In the hypothalamus, venlafaxine reduced expression 
of phosphorylated form of cAMP response element binding protein (CREB). Also, 
venlafaxine treatment disrupted the transcript abundance of genes involved in hypothalamus-
pituitary-interrenal axis functioning and appetite regulation, including CRF, NPY,  
glucocorticoid receptors (GR1 and GR2), pro-opiomelanocortins (POMCA and POMCB), 
neuropeptide Y (NPY), and glucose transporter type 2 (Glut2). The venlafaxine effect on 
CRF and NPY transcript abundance may involve disruption in serotonin signalling. In the 
pituitary, higher venlafaxine concentration resulted in a significant increase in basal ACTH 
production, but reduced the CRF-stimulated ACTH production. At the head kidney level, 
neither unstimulated nor ACTH-induced cortisol production were altered in response to 
tissue exposure to a range of venlafaxine concentrations (0.1 – 1000 nM), although our result 
from ex vivo study demonstrated that venlafaxine significantly increased interrenal cortisol 
response to ACTH stimulation in the presence of serotonin. Collectively, our findings 
demonstrate that venlafaxine is a neuroendocrine disruptor in fish, primarily affecting key 
genes in the hypothalamus and pituitary involved in stress axis and appetite regulation. We 
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propose that the mode of action of venlafaxine, at least in some aspect of HPI axis function 
and appetite regulation, may involve disruption in serotonin signalling.  
5.2 INTRODUCTION 
Vertebrates have evolved complex adaptive physiological mechanisms that enable 
them to maintain their normal homeostatic state in a challenging environment. In teleosts, a 
key aspect of stress response involves activity of the neuroendocrine stress axis − the 
hypothalamus-pituitary-interrenal (HPI) axis, with cortisol as its primary end product in 
teleosts (Vijayan et al., 2010; Wendelaar Bonga, 1997). Over the last decade, evidence has 
accumulated demonstrating the presence of endocrine disrupting chemicals in the aquatic 
environments that compromise the functioning the HPI axis in fish (Norris, 2000; Hontela 
and Vijayan, 2009). Any alteration or disruption of the HPI axis activity due to contaminant 
exposure may be maladaptive and can undermine the stress performance, leading to reduced 
fitness in fish (Ings et al., 2011). 
Upon perception of stress stimuli, corticotropin releasing factor (CRF) is released 
from the hypothalamus (Mommsen et al., 1999). Several intracellular signalling cascades are 
known to participate in the regulation of CRF gene transcription, and the most significant one 
involves the activation of cAMP-dependant protein kinase A (PKA), resulting in the 
phosphorylation of cAMP response element binding protein (CREB) at a conserved serine 
residue and this occurs within minutes following stressor exposure (Denver, 2009). CRF 
stimulates corticotroph cells in the anterior pituitary to secrete adrenocorticotropic hormone 
(ACTH), which is produced from a precursor peptide pro-opiomelanocortin (POMC) 
(Vijayan et al., 2010; Wendelaar Bonga, 1997), encoded by two gene isoforms in trout, 
POMCA and POMCB (Leder and Silverstein, 2006). ACTH is released into the circulation 
and activates melanocortin 2 receptor (MC2R) leading to cortisol biosynthesis and secretion 
from the steroidogenic cells dispersed in the head kidney region of teleosts (Vijayan et al., 
2010). In the target tissues, cortisol mediates its effects via glucocorticoid (GR) and 
mineralocorticoid (MR) receptors, which are also involved in the negative feedback 
regulation of the HPI axis at the level of hypothalamus and pituitary (Aluru and Vijayan, 
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2009). Similarly to most teleost species, rainbow trout have one MR and two GR genes (GR1 
and GR2) (Alsop and Vijayan, 2008).   
In mammals, it is well established that the serotonergic system is involved in the HPA 
(hypothalamus-pituitary-adrenal) axis regulation leading to cortisol production (Chaouloff, 
1993). In fish, as in mammals, studies suggests that serotonin (5-hydroxytryptamine; 5-HT) 
plays a key role in HPI axis activation and downstream cortisol production, and evidence 
suggests that 5-HT1A receptor is the primary mediator of serotonergic effects on the HPI axis 
(Medeiros et al., 2014; Höglund et al., 2002; Winberg et al., 1997). In addition to its 
neurotransmitter role, 5-HT can induce corticosteroid secretion from the adrenocortical cells 
(analogous to fish interrenal cells) via paracrine action in many vertebrate species (Contesse 
et al., 2000) and the presence of 5-HT in the head kidney has been demonstrated in fish 
species (Reid et al., 1998). 
Venlafaxine is a drug designed to modulate levels of the brain monoamines 5-HT and 
norepinephrine (NE) by blocking their respective reuptake transporters, thus increasing 
synaptic availability of these neurotransmitters, with a stronger effect on 5-HT reuptake 
(Roseboom and Kalin, 2000), and it is a commonly prescribed antidepressant. In recent 
years, it has become a predominant antidepressant detected in urban wastewater effluent and 
aquatic systems (Rúa-Gomez and Püttmann, 2012; Metcalfe et al., 2010; Schultz et al., 
2010). Although detection of pharmaceuticals, including antidepressants, in the aquatic 
environment has received a lot of attention, their effects on non-target animals, including 
fish, are not very clear. We have previously demonstrated that rainbow trout (Oncorhynchus 
mykiss) exhibit an attenuated plasma cortisol response to an acute handling stressor following 
exposure to environmentally realistic levels of venlafaxine [Chapter 4]. However, the 
mechanism involved in this attenuation of stressor-induced cortisol response by this drug 
remains unclear. We hypothesized that the impact of venlafaxine on the HPI axis activity 
involves disruption of neuroendocrine/endocrine responses at multiple levels, including the 
functioning of the hypothalamus, pituitary and internal tissue in rainbow trout. This was 
tested using an in vitro approach with head kidney, pituitary and hypothalamic tissues 
exposed to venlafaxine. Specifically our objective was to determine the mode of action of 
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this drug in disrupting hypothalamus, pituitary and interrenal function in trout. This was 
carried out by assessing the phosphorylation of CREB and the transcript levels of genes 
involved in HPI axis functioning and appetite regulation, including CRF and its binding 
protein (CRF-BP), pro-opiomelanocortin (POMCA and POMCB), glucocorticoid receptors 
(GR1, GR2), mineralocorticoid receptor (MR), glucose transporter type 2 (Glut2), in the 
hypothalamus in response to venlafaxine exposure. Also, the drug effect on pituitary function 
was ascertained by measuring either the unstimulated or CRF-stimulated ACTH content in 
the tissue and medium. We used a specific 5-HT1A antagonist NAN-190 in our studies with 
hypothalamic and pituitary tissues in order to determine whether the effects of venlafaxine 
exposure are mediated by this receptor. Similarly, the effect of venlafaxine on interrenal 
function was determined by measuring either the unstimulated or ACTH-stimulated cortisol 
production in trout head kidney pieces in vitro. In order to test whether this drug can alter 
responsiveness of the interrenal tissue to stimulation in the presence of 5-HT, we used 
isolated head kidney tissues from trout exposed to venlafaxine in vivo and examined ACTH-
stimulated cortisol production in the presence of 5-HT.   
5.3 MATERIAL AND METHODS 
5.3.1 Animals 
Sexually immature rainbow trout (average body weight ~200 g) were used for 
experiments in this study. Fish were purchased from Alma Aquaculture Research Station 
(Alma, ON, CAN) and maintained at the University of Waterloo Aquatic Facility. Fish were 
acclimated for a month in 2000-L tanks with continuous running well water at 13 °C and 12-
h light: 12-h dark photoperiod before experimentation. The fish were fed to satiety once daily 
with a commercial trout chow (Martin Feed Mills, Elora, ON, CAN). Experimental protocols 
were approved by the Animal Care Committee at the University of Waterloo and conducted 
in accordance with the Canadian Council for Animal Care guidelines. During sampling, fish 
were netted quickly and euthanized with an overdose of 2-phenoxyethanol (1:1000 dilution; 
Sigma-Aldrich, St. Louis, MO). Fish that were sampled for the head kidney tissue 
(containing interrenal cells) were bled and then the tissue was immediately dissected. Fish 
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used for collection of pituitaries and hypothalami were rapidly decapitated, brains and 
pituitaries were immediately removed.    
5.3.2 Treatments 
Venlafaxine hydrochloride (VEN) and serotonin hydrochloride (5-HT) were initially 
dissolved in water, and NAN-190 hydrobromide (5-HT1A receptor antagonist) was dissolved 
in 1:10 solution of DMSO and then further diluted in water (vehicle). NAN-190 control 
group represents vehicle control. The above listed chemicals were obtained from Sigma-
Aldrich (St. Louis, MO). Modified Hank’s medium (136.9 mM NaCl, 5.4 mM KCl, 0.8 mM 
MgSO4∙7H20, 0.33 mM Na2HPO4∙7H2O, 0.44 mM KH2PO4, 5.0 mM HEPES, 5 mM 
HEPES∙Na, 5mM NaHCO3, 5mM glucose, pH 7.63) was used in our all tissue incubations. 
Peptide hormones used in this study were porcine ACTH
1–39 
(Sigma-Aldrich) and tilapia 
(Oreochromis mossambicus) CRF, which was a kind gift form Dr. D.A. Lovejoy (University 
of Toronto). All stock solutions of experimental treatments were diluted in modified Hank’s 
medium to achieve the appropriate working concentrations. Concentration of 5-HT was 100 
nM (10
-7 




M have stimulatory role on 
CRF release (Nakagami et al., 1986), and a preliminary experiment with rainbow trout 
hypothalami incubations demonstrated that this concentration upregulated CRF mRNA after 
2 h incubation (Fig. C1-B, Appendix C). Concentration of CRF (10 nM) for stimulation of 
ACTH secretion was selected based on a previous study, where human/rat CRF was effective 
in 1-1000 nM dose range on ACTH secretion by trout pituitary (Baker et al., 1996). ACTH 
concentration (0.5 IU/mL) was based on previous work in our laboratory (Sandhu and 
Vijayan, 2011; Aluru and Vijayan, 2008). Venlafaxine concentrations for experiments with 
the pituitary and hypothalamic tissues were 0, 0.3 and 3 nM. We selected 3.0 nM venlafaxine 
concentration since it approximates 1.0 μg/L concentration used in our previous studies, and 
0.3 nM – an order of magnitude lower. Tissue viability was determined by measuring the 
release of lactate dehydrogenase (LDH) into the media according to established protocols 
(Boone et al., 2002). 
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5.3.3 In vitro experiment with hypothalami 
The hypothalamic region from each brain was separated by making transverse cuts 
immediately anterior to the optic chiasm, posterior to saccus vasculosus, followed by 
longitudinal cuts along the boundary of the optic tectum (Fig.C1-A; Appendix C), in order to 
include nucleus preopticus and nucleus lateral tuberalis − the major nuclei of CRF-ergic 
neurons that are thought to be involved in the regulation of pituitary ACTH production and 
secretion (Yulis and Lederis, 1987). This fragment was minced in a Petri dish with ice-cold 
modified Hank’s medium and transferred into a sterile 24-well culture plate (Sarstedt, 
Newton, NC, USA) containing 500 μl of modified Hanks buffer (hypothalamic region from 1 
fish per well). Our experimental set-up included three venlafaxine exposure groups (0, 0.3 
and 3 nM), and each either in the absence or presence of 5-HT1A antagonist NAN-190 (1 
μM). In addition, to assess whether the changes seen with VEN are mediated by 5-HT, we 
also had control groups (not exposed to venlafaxine) exposed to either 5-HT (100 nM) alone 
or in combination with NAN-190. Six hypothalami were used (n = 6, independent samples) 
per treatment group. Initially, the tissues were equilibrated for 1 h with gentle rocking at 
13
o
C. Next, the tissues were incubated in fresh buffer containing venlafaxine treatments for 1 
h. Antagonist treatments (control or NAN-190) were added to the appropriate wells and 
tissues were allowed to incubate for 30 min. Then 5-HT treatments were added to the 
appropriate wells and the tissues were allowed to incubate for 2 h in order to assess treatment 
effects on hypothalamic transcript levels. At the end of the incubation period, samples were 
quickly collected, centrifuged at 9,000 x g for 20 s and then the supernatant an the tissues 
were separated, snap-frozen on dry ice and stored at -80
o
C for further analysis. This 
experiment was repeated exactly as described above with identical treatments groups, where 
the final incubation point (after 5-HT addition) was 10 min instead of 2 h, for assessment of 
rapid phosphorylated CREB expression.  
5.3.4 In vitro experiment with pituitaries 
After tissue collection, each pituitary was rinsed with ice-cold modified Hanks, sliced 
into 4 fragments and transferred into a well of a sterile 96-well plate with 75 μl of modified 
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Hank’s buffer supplemented with 0.5% bovine serum albumin (BSA). Our experimental set-
up included three venlafaxine exposure groups (0, 0.3 and 3 nM), and each either in the 
absence or presence of 5-HT1A antagonist NAN-190 (1 μM). One set of tissues was treated 
with CRF (10 nM), and one set did not receive CRF stimulation (no CRF). In addition, to 
assess whether the changes seen with venlafaxine mimic 5-HT-mediated effects, we also had 
control groups (no venlafaxine treatment) exposed to 5-HT (100 nM), with either absence or 
presence of CRF (10 nM CRF or no CRF). Initially, the tissues were equilibrated for 1 h with 
gentle rocking at 13
o
C. After equilibration, the tissues were incubated in fresh buffer 
containing venlafaxine treatments (0, 0.3, 3 nM) for 1 h. This was followed by addition of 
antagonist (control or 1 μM NAN-190) and allowing the tissues to incubate 30 min. Then, 
CRF treatments were added (10 nM CRF or no CRF). After a 4 h incubation period, media 
and pituitaries were collected separately, snap-frozen on dry ice, weight of the tissues 
recorded, and stored at -30
o
C for later ACTH analysis.  
5.3.5 In vitro experiment with head kidney tissue   
Effect of in vitro venlafaxine exposure on cortisol production was determined using a 
well-established head kidney tissue preparation method (Sandhu and Vijayan, 2011; Aluru 
and Vijayan, 2006). Head kidney tissue was finely minced (~1 mm
3
 pieces) in a Petri dish 
with ice-cold modified Hank’s medium and cleaned of blood clots. After rinsing, tissue was 
distributed equally (500 μL of buffer with ~50 mg of tissue per well) into 24-well culture 
plates (Sarstedt, Newton, NC, USA). The tissues were left to equilibrate for 2 h at 13°C with 
gentle rocking. After 2 h, the buffer was replaced with fresh medium containing a range of 
venlafaxine concentrations (0, 0.1, 1, 10, 100, 1000 nM). After 1 h incubation period, media 
was collected for determination of basal cortisol levels, and replaced with fresh aliquot with 
appropriate venlafaxine concentration containing either no ACTH (control) or 0.5 IU/mL 
ACTH. The experiment was repeated with tissues from six independent fish (n = 6). At the 
end of the incubation period, samples were collected, quickly centrifuged (13,000 x g for 1 
min), and the supernatant was collected and stored at -30
o
C for later cortisol determination.  
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5.3.6 Ex vivo head kidney study with serotonin 
Head kidney tissues were isolated from rainbow trout exposed to venlafaxine in vivo 
for a 7-day period (control or 1.0 μg/L venlafaxine) exactly as previously described [Chapter 
4]. Head kidney tissue preparation was done exactly as described above. Tissue were pre-
incubated for 2 h at 13 °C, then medium was replaced with fresh medium with control, low 
(10
-8 
M) and high (10
-7 
M) 5-HT treatments in combination with ACTH stimulation (0.5 
IU/mL) or in the absence of stimulation  (no ACTH). At the end of the 4 h incubation period, 
media and tissues were collected as described above. 
5.3.7 Cortisol analysis 
Media cortisol levels were measured from the head kidney experiments by 
radioimmunoassay (RIA) using 
3
H cortisol as previously described [Chapter 4]. Cortisol 
antibody (rabbit antiserum) and scintillation cocktail (Universol™) were obtained from MP 
Biomedicals (Irvine, CA, USA) and 
3
H cortisol was purchased from GE Healthcare 
(Waukesha, WI, USA). All cortisol samples were measured in one assay with intra-assay 
variability of 3.6%. 
5.3.8 ACTH analysis 
ACTH concentrations in the incubation media and the tissue samples were measured 
using a double antibody (hACTH) 
125
I RIA kit (MP Biomedicals) as described previously 
[Chapter 4]. Tissue homogenates were prepared by sonication of pituitary fragments in 50 μL 
of ice-cold 50 mM Tris buffer (pH 7.5) with protease inhibitor cocktail (Roche, Mannheim, 
Germany). The validity of this RIA kit, previously established for trout plasma (Craig et al., 
2005; Doyon et al., 2006), was confirmed by observation of parallel dilution curves for 
media and tissue homogenate samples. Media and homogenate samples were analyzed in two 
RIA runs; the intra-assay variation was 4.7% and 3.8%, respectively.  
5.3.9 Quantification of gene expression 
Total RNA was isolated from the hypothalamic tissue using Ribozol RNA extraction 
reagent (Amresco, Solon, OH, USA) according to manufacturer’s instructions. Briefly, 500 
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μl of Ribozol was added to 30-50 mg of frozen tissue. Samples were homogenized on ice, 
chloroform was added (100 μl) and the aqueous phase (containing RNA) was collected 
following centrifugation at 12,000 x g for 15 min. RNA was recovered by isopropanol 
precipitation and reconstituted in nuclease-free water. RNA was then DNase-treated as per 
manufacturer’s instructions (Fermentas, Pittsburgh, PA, USA) and one microgram of total 
RNA was reverse-transcribed with high capacity cDNA reverse transcription kit (Applied 
Biosystems, Streetsville, ON, CAN). Hypothalamic cDNA samples were used for 
transcriptional analysis by quantitative real-time PCR exactly as described earlier [Chapter 2, 
3, 4]. Expression levels of the following genes were investigated: corticotropin releasing 
factor (CRF) and its binding protein (CRF-BP), glucocorticoid receptors 1 and 2 (GR1 and 
GR2), mineralocorticoid receptor (MR), pre-opiomelanocortin A and B (POMC A and B), 
neuropeptide Y (NPY) and glucose transporter type 2 (Glut2). All gene expression data is 
shown as percent change from control of venlafaxine control (0) group for presentation 
purposes. Specific information for the primers used in this study was previously listed in 
Table 5-1. 
5.3.10  Immunoblotting 
Hypothalamic tissues were homogenized in ice-cold lysis buffer (50 mM Tris-Cl, 5 
mM EDTA, 150 mM NaCl, 5 mM NaF, 5 mM NEM, 2 mM Na3VO3, 1% SDS, 1% Nonidet-
P40, 1x protease inhibitor cocktail (Roche). Protein concentration was measured using the 
bicinchoninic acid (BCA) method using BSA as the standard. Samples were diluted in 
Laemmmli’s sample buffer (1 M Tris-HCl, pH 6.8, 60 mM, 25% glycerol, 2% SDS, 14.4 
mM β-mercaptoethanol, 0.1% bromophenol blue) and 40 μg of total protein was separated on 
a 10% SDS-PAGE at 180 V. Proteins were transferred onto 0.45 μM nitrocellulose 
membrane (Bio-Rad, Hercules, CA, USA) in a semi-dry transfer unit (Bio-Rad) with transfer 
buffer (25 mM Tris, pH 8.3, 192 mM glycine, and 20% methanol) at 20 V for 25 min with 
using. Following 1 h blocking with 5% solution of non-fat dry milk in 1xTTBS (2 mM Tris, 
30 mM NaCl, 0.01% Tween, pH 7.5) at room temperature, membranes was incubated 
overnight at 4
o
C with either monoclonal rabbit phospho-CREB (ser133) or total CREB (Cell 
Signalling technology, Beverly, MA) antibodies diluted 1:1000 in 5% BSA in TTBS. 
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Following washing, blots were probed with anti-rabbit horseradish peroxidase (HRP)-
conjugated secondary antibody (Bio-Rad, diluted 1:3000 in 5% skim milk in TTBS). Protein 
bands were detected with Luminata Crescendo
 
Western HRP Substrate (Millipore, Billerica, 
MA, USA) and imaged using Pharos FX molecular Imager (Bio-Rad). Total band intensity 
was quantified using AlphaEase Software (Alpha Innotech, Santa Clara, CA, USA) and 
densitometric values were normalized to a reference sample ran on each blot for inter-blot 
comparisons. All membranes were also probed with Cy3-conjugated monoclonal mouse β-
actin antibody (1:1000; Sigma-Aldrich) for 1 h at room and protein loading was normalized 
based on β-actin expression.  
5.3.11 Statistics 
All analyses were conducted using Sigmaplot 11 (Systat Software Inc., San Jose, CA, 
USA). For the hypothalamus experiment, one-way ANOVA was used for comparison 
between treatment groups in the control tissues (not exposed to venlafaxine), and two-way 
ANOVA was used for venlafaxine exposed tissues (venlafaxine and NAN-190 treatments).  
For the pituitary experiment, two-way ANOVA was used for non-stimulated (no CRF) and 
CRF-stimulated groups (venlafaxine and NAN-190 treatments), for control and NAN-190 
groups (CRF and venlafaxine treatments). For the in vitro head kidney experiment, paired t-
test was used to assess effect of ACTH stimulation in the control tissues, and one-way 
repeated measures analysis of variance (ANOVA) was used to assess effect of venlafaxine 
treatments on basal and ACTH-stimulated cortisol production. For ex vivo head kidney study, 
two-way repeated measures ANOVA was used to analyse cortisol response (5-HT and 
venlafaxine variables). Significant differences between treatment groups were compared 
using Holm-Sidak post hoc test. Data were log transformed when necessary to meet the 
assumptions of normality and homogeneity of variance, although non-transformed data are 
shown in figures (mean ± SEM). A significance level of α = 0.05 was used in all cases.  
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Table 5-1. Sequences (forward and reverse), amplicon size, accession number and annealing 
temperature for primers used in quantitative real-time RT-PCR. 
 




































AY495372.1 60 140 
R: 5’-CTCACCCCACAGATGGAGAT-3’ 
MR 










NM_001124719.1 60 199 
R: 5'- CCTGCTGCCCTCCTCTACTGC-3' 
Gene abbreviations: EF1α, elongation factor 1α; CRF, corticotropin-releasing factor; CRF-BP, 
corticotropin-releasing factor binding protein; Glut2, glucose transporter type 2; NPY,  neuropeptide 
Y; GR1 and GR2, glucocorticoid receptor 1 and 2, respectively; MR, mineralocorticoid receptor; 
POMCA and POMCB, pro-opiomelanocortin A and B, respectively.  
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5.4 RESULTS  
5.4.1 In vitro experiment with hypothalami: phosphorylation of CREB 
In our experiment involving in vitro incubations of trout hypothalamic tissues, 
treatments with either 5-HT, NAN-190 or a combination of both did not significantly affect 
CREB phosphorylation in the present study (Fig. 5-1A). In the tissues exposed to venlafaxine 
treatments (Fig. 5-1B), 3.0 nM venlafaxine significantly reduced phosphorylation of CREB 
(expressed as the ratio of phosphorylated to total CREB protein) compared to 0 or 0.3 nM 
venlafaxine groups (P < 0.05, two-way ANOVA), but there was no significant effect in 








Figure 5-1. Rapid phosphorylation of cAMP response element binding protein (CREB) in 
rainbow trout hypothalami (not exposed to venlafaxine; VEN) in response to response to 
incubation with serotonin, 5-HT (100 nM), 5-HT1A receptor antagonist, NAN-190 (1 μM), or 
combination of NAN-190 and 5-HT (A). Effect of in vitro venlafaxine exposure on phospho-
CREB response in hypothalami treated with NAN-190 or vehicle control (B). Samples (40 
μg of protein) were probed with monoclonal rabbit phospho-CREB (133) and total-CREB 
antibodies (Cell Signalling Technology, Beverly, MA) and protein loading was confirmed by 
normalizing to β-actin (monoclonal mouse antibody, Sigma, St. Louis, MO). Values plotted 
represent mean ± SEM of the ratio of phosphorylated to total CREB densitometric values and 
are shown as percent control  (n = 6 independent fish), insets indicate significant venlafaxine 












5.4.2 In vitro experiment with hypothalami: transcript abundances  
Transcript responses in the control tissues (not exposed to venlafaxine) for all the 
genes examined, with the exception of CRF, were not significantly affected by 5-HT, NAN-
190 or their combination (Fig. C2; Appendix C). 
CRF and CRF-BP 
5-HT significantly increased CRF transcript abundance (1.3-fold increase from the 
control) in the present study and this effect was completely abolished in the presence of 
NAN-190 (Fig. 5-2A). In the tissues exposed to venlafaxine, a significant interaction was 
detected between venlafaxine and antagonist treatments (P < 0.001; two-way ANOVA). 
Venlafaxine at 3.0 nM concentration significantly increased CRF transcript abundance 
compared to venlafaxine control (0) group (1.4-fold) but not the 0.3 nM venlafaxine 
concentration (Fig. 5-2B). This effect of 3.0 nM venlafaxine on CRF mRNA level was 
completely abolished by NAN-190. In the 0.3 nM VEN group, NAN-190 exposure 
significantly increased CRF mRNA levels compared to the control (1.5-fold) (Fig. 5-2B). 
Analysis of CRF-BP mRNA levels (Fig. 5-3C) did not reveal any significant effects of any in 









Figure 5-2. Transcript levels of corticotropin releasing factor, CRF, in rainbow trout 
hypothalami in response to incubation with serotonin, 5-HT (100 nM), 5-HT1A receptor 
antagonist, NAN-190 (1 μM), or combination of NAN-190 and 5-HT (A). Effect of in vitro 
venlafaxine (VEN) exposure on CRF (B) and its binding protein, CRF-BP (C), transcript 
levels in hypothalami treated with NAN-190 or vehicle control. In (A), different letters 
indicate significant differences (P < 0.05, one-way ANOVA) between treatments. In (B), 
significant interaction was detected (P < 0.05; two-way ANOVA) between venlafaxine and 
antagonist treatments. Letters indicate significant differences between venlafaxine groups 
within control or NAN-190 treatments, and asterisks demonstrate differences between 
control and NAN-190 treatments for individual venlafaxine groups. All values were 
normalized to EF1α and represent percent control. Bars show means ± SEM (n = 6 






GR1, GR2 and MR 
 Examination of transcript abundances of the corticosteroid receptor genes revealed 
similar overall effects of venlafaxine exposure on GR1 and GR2 mRNA levels (Fig. 5-3A 
and 5-3B, respectively), where 0.3 nM and 3.0 nM venlafaxine groups had significantly 
attenuated transcript levels (approximately 1.5-fold change) in comparison to venlafaxine 
control (0) group (P < 0.001 in both cases, two-way ANOVA). There were no differences 
between the control and NAN-190 treatments. MR mRNA levels were not affected by 


























Figure 5-3. Effect on in vitro venlafaxine (VEN) exposure on mRNA levels of 
glucocorticoid receptor 1 and 2, GR1 and GR2 (A and B, respectively) and mineralocorticoid 
receptor, MR (C) in rainbow trout hypothalami in response to incubation with either control 
or 5-HT1A receptor antagonist (NAN-190; 1 μM) treatments. Insets indicate significant 
venlafaxine effects (P < 0.05; two-way ANOVA). All values were normalized to EF1α and 
represent percent control. Bars show means ± SEM (n = 6 independent fish).  
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POMCA and POMCB 
Expression analyses of the pro-opiomelanocortin encoding genes determined main 
venlafaxine exposure effects (P < 0.05 in both cases, two-way ANOVA). POMCA mRNA 
levels (Fig. 5-4A) were approximately 3- and 2.3-fold reduced in 0.3 and 3.0 nM venlafaxine 
groups, respectively, compared to venlafaxine control (0). POMCB expression (Fig. 5-4B) 
was strongly diminished in 0.3 and 3.0 nM venlafaxine groups by approximately 9.6- and 
7.2-fold, respectively, relative to venlafaxine control (0) group. There was no overall effect 

























Figure 5-4. Effect on in vitro venlafaxine (VEN) exposure on mRNA levels of pro-
opiomelanocortin genes A and B, POMCA and POMCB (A and B, respectively) in rainbow 
trout hypothalami in response to incubation with either control or 5-HT1A receptor antagonist 
(NAN-190; 1 μM) treatments. Insets indicate significant venlafaxine effects (P < 0.05; two-
way ANOVA). All values were normalized to EF1α and represent percent control. Bars show 
means ± SEM (n = 6 independent fish). 
 
 132 
Glut2 and NPY 
Examination of Glut2 transcript levels detected a significant main effects of in vitro 
venlafaxine exposure (Fig. 5-5A), where 0.3 and 3.0 nM venlafaxine groups had significantly 
reduced transcript levels (approximately 8.8-fold) in comparison to venlafaxine control (0) 
group (P < 0.001, two-way ANOVA), although there was no differences between the control 
and NAN-190 treatments. Analysis of NPY mRNA levels (Fig. 5-5B) revealed a significant 
interaction between venlafaxine and 5-HT1A antagonist treatments (P < 0.05; two-way 
ANOVA). Within the control group, exposure to 3.0 nM venlafaxine reduced NPY 
transcripts relative to venlafaxine control (0) group by 2.2-fold, although no venlafaxine 
effects were present within the NAN-190 treatment group. Comparison between the control 


























Figure 5-5. Effect on in vitro venlafaxine (VEN) exposure on mRNA levels of glucose 
transporter type 2, Glut2 (A) and neuropeptide Y, NPY (B) in rainbow trout hypothalami in 
response to incubation with either vehicle control or 5-HT1A receptor antagonist (NAN-190; 
1 μM) treatments. Insets indicate significant venlafaxine effects (P < 0.05; two-way 
ANOVA). Significant interaction was detected for NPY (P < 0.05; two-way ANOVA); 
letters indicate significant differences between venlafaxine groups within control treatment. 
All values were normalized to EF1α and represent percent control. Bars show means ± SEM 
(n = 6 independent fish).  
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5.4.3 In vitro experiment with pituitaries: tissue ACTH levels 
In the control pituitary tissues (not exposed to venlafaxine), CRF stimulation 
significantly increased (3.8-fold) ACTH levels in trout pituitary pieces (Fig. 5-6A). Neither 
5-HT nor NAN-190 had any significant effect on unstimulated ACTH levels in trout control 
pituitaries. However, both 5-HT and NAN-190 completely abolished the CRF-induced 
ACTH production (Fig. 5-6A). Analysis of ACTH content in the pituitaries exposed to 
venlafaxine demonstrated that in the absence of CRF stimulation, 3.0 nM venlafaxine 
resulted in significantly higher ACTH content compared to 0 or 0.3 nM venlafaxine (5.4-fold 
change from venlafaxine control (0), and this was abolished by NAN-190 (Fig. 5-6B). 
Production of ACTH in the tissues stimulated with CRF did not demonstrate significant 
effects of venlafaxine exposure, however NAN-190 reduced ACTH production in the 









Figure 5-6. Tissue ACTH levels (in vitro static incubation experiment with rainbow trout 
pituitaries). Effect of CRF stimulation on ACTH levels in pituitaries treated with 5-HT1A 
receptor antagonist (NAN-190; 1 μM) and serotonin (5-HT, 100 nM) (A). Effect of in vitro 
venlafaxine (VEN) exposure and NAN-190 treatment on ACTH production without (no 
CRF) or with 10 nM CRF stimulation (B). In (A), asterisks show a significant CRF effect 
within a treatment group and different letters indicate a significant treatment effects for 
individual CRF group. In (B), different letters indicate significant venlafaxine effects, 
asterisks indicate significant NAN-190 effects for individual venlafaxine group, and hash 
signs demonstrate a significant change resulted by CRF stimulation for individual 
venlafaxine treatments (P < 0.05). All values were normalized to the tissue weight and bars 
show means ± SEM (n = 5-6). Tilapia CRF peptide was used for stimulations (4 h), 





5.4.4 In vitro experiment with pituitaries:  ACTH levels in incubation medium 
ACTH analysis in the medium from the non-exposed (not exposed to venlafaxine) 
pituitary incubations did not detect any effect of either CRF stimulation or NAN-190 or 5-HT 
treatments (Fig. 5-7A). Media for non-stimulated (no CRF) tissues did not show changes 
with venlafaxine exposure or NAN-190 treatment (Fig. 5-7B). No venlafaxine effects were 
detected in in the absence of CRF. Analysis of ACTH content in the medium from the 
stimulated (10 nM CRF) incubations demonstrated ACTH levels were higher in 0.3 nM 
venlafaxine relative to 0 and 3.0 nM venlafaxine in the control group (2.3-fold change from 
venlafaxine control), and this effect was abolished with NAN-190 treatment.  NAN-190 
treatment had an opposite effect in 3.0 nM venlafaxine group, where ACTH levels were 
elevated by the antagonist. Stimulation with CRF produced significant effect only for 0.3 nM 











Figure 5-7. Medium ACTH levels (in vitro static incubation experiment with rainbow trout 
pituitaries). Effect of CRF stimulation on ACTH released in medium by pituitaries treated 
with 5-HT1A receptor antagonist (NAN-190; 1 μM) and serotonin (5-HT, 100 nM) (A). Effect 
of in vitro venlafaxine (VEN) exposure and NAN-190 treatment on ACTH secretion without 
(no CRF) or with 10 nM CRF stimulation (B). In (B), different letters indicate significant 
venlafaxine effects, while asterisk indicate significant NAN-190 effects for individual 
venlafaxine group, and hash sign demonstrates a significant change resulted by CRF 
stimulation for individual venlafaxine treatment (P < 0.05). All values were normalized to 
the tissue weight and bars show means ± SEM (n = 5-6). Tilapia CRF peptide was used for 
stimulations (4 h), pituitaries were incubated in modified Hank’s medium supplemented with 
0.5% bovine serum albumin. 
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5.4.5  In vitro experiment with head kidney: cortisol production 
In this experiment we examined whether in vitro venlafaxine exposure effects basal 
or ACTH-stimulated cortisol production. ACTH stimulation resulted in approximately 11-
fold increase (paired t-test, P < 0.05) in cortisol production in the control trout head kidney 
tissues (Fig. 5-8A). Venlafaxine concentrations (0.1, 10, 100, or 1000 nM) did not 
significantly affect unstimulated cortisol production compared to the venlafaxine control (0) 
group (Fig. 5-8B). There was also no significant effect of venlafaxine on ACTH-induced 







Figure 5-8. In vitro cortisol production in rainbow trout head kidney tissues. Basal and 
ACTH-stimulated (0.5 IU/mL) cortisol production in the control head kidney tissues (A). 
Effect of in vitro venlafaxine exposure (0.1, 10, 100, 1000 nM) on basal cortisol production 
(B) and ACTH-induced cortisol production − expressed as percent control of the control 
group (C). Data are shown as mean ± SEM (n = 5 fish); asterisk indicates a significant 




5.4.6 Ex vivo head kidney study: cortisol production 
Cortisol production by the interrenal tissue from venlafaxine exposed fish was 
examined to determine whether basal or stimulated  (ACTH) response was affected by 5-HT. 
Unstimulated (basal) cortisol production was not affected by 5-HT treatments (Fig. 5-9A). 
Stimulated cortisol levels (Fig. 5-9B) revealed a significant interaction between 5-HT and 
venlafaxine variables (P < 0.005, two-way repeated measures ANOVA). In presence of the 
higher 5-HT concentration, cortisol output was approximately 4-fold elevated in the tissues 
from the venlafaxine exposed fish relative to the control tissues. Presence of 5-HT did not 




Figure 5-9. Effect of in vitro serotonin (5-hydroxytryptamine, 5-HT) treatments on basal (A) 
and ACTH-stimulated (shown as magnitude of change) (B) cortisol production in the head 
kidney tissues exposed to venlafaxine in vivo (1.0 μg/L) for 7-day period. For 5-HT 
treatments, low corresponds to 10
-8 
M and high 10
-7 
M. Values are shown a mean ± SEM, (n 
= 8-6 independent fish from each drug exposure group). An asterisk shows a significant 
effect of venlafaxine exposure on cortisol production within individual 5-HT group, while 
different small letters indicate a significant 5-HT effect within individual venlafaxine 
exposure group (P < 0.05, two-way repeated measures ANOVA). 
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5.5  DISCUSSION 
This study demonstrates that venlafaxine can act as a neuroendocrine disruptor at the 
upstream elements of the HPI axis in rainbow trout. Specifically, this drug disrupts transcript 
levels of key genes involved in HPI axis function and appetite regulation in the 
hypothalamus, disrupts activation of CREB transcription factor in the hypothalamus, affects 
production of ACTH in the pituitary, and may alter interrenal cortisol response. This is in 
agreement with our previous finding from an in vivo study where venlafaxine exposure 
disrupted plasma cortisol response to an acute stressor [Chapter 4]. Overall, our results 
demonstrate that venlafaxine exposure can lead to disruption of endocrine pathways involved 
in cortisol stress axis functioning in fish. Disruption of any elements of the HPI axis may 
result in the impairment of physiological stress response, which may translate into reduced 
ability of an organism to cope with subsequent stressors. In fish, 5-HT plays a key role in the 
HPI axis activation and downstream cortisol production (Winberg et al., 1997). 5-HT1A 
receptors are primary mediators of 5-HT effects on HPI axis regulation (Medeiros et al., 
2014; Höglund et al., 2002; Winberg et al., 1997), especially at the level of the hypothalamus 
and/or pituitary (Höglund et al., 2002). Our results suggest that the mode of action of 
venlafaxine in impacting stress axis function and appetite regulation may at least in part 
involve disruption in 5-HT signalling.  
Hypothalamus 
Results of our in vitro experiment with hypothalamic fragments demonstrated that 5-
HT treatment increases expression of CRF mRNA, and pre-treatment with 5-HT1A antagonist 
abolishes this 5-HT effect, thus supporting the role of 5-HT1A receptors in stress activation at 
the level of hypothalamus. This is also in agreement with a recent study in Gulf toadfish 
(Opsanus beta), demonstrating that in vivo administration of 5-HT1A receptor agonist (8-OH-
DPAT) resulted in increased CRF mRNA abundance in the hypothalamic region (Medeiros 
et al., 2014). In the hypothalamic tissues exposed to 3.0 nM venlafaxine, a similar increase in 
CRF transcripts was observed in the presence of 5-HT and this was abolished in the presence 
of 5-HT1A antagonist NAN-190, suggesting that the venlafaxine effect may be mediated by 
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changes in 5-HT levels. On the other hand, 0.3 nM venlafaxine by itself had no effect on 
CRF mRNA abundance, but in the presence of the antagonist NAN-190, CRF transcript 
levels were elevated, suggesting that venlafaxine may also exert an inhibitory effect on CRF 
synthesis but this remains to be verified. Monoamine analysis in our previous study 
demonstrated that hypothalamic and preoptic areas (both pooled as one region for the present 
study) in the trout brain have relatively high 5-HT content [Chapter 2; Melnyk-Lamont et al., 
submitted].  Hypothalamic tissues have endogenous 5-HT, thus venlafaxine may inhibit 
cellular reuptake of this monoamine after it has been leaked into the incubation media. In the 
present study with hypothalamic fragments, we did not utilize additional in vitro treatment 
with 5-HT in the tissues exposed to venlafaxine based on the reasoning that the hypothalamic 
tissues contain sufficient endogenous 5-HT, in order to keep experimental conditions 
physiologically relevant.  
CRF is a 41-amino acid peptide with a remarkably conserved sequence similarity in 
mammals, fish, and amphibians (Hauger et al., 2006; Lovejoy and Balment, 1999). Cyclic 
AMP response element binding protein (CREB) is known to be one of the mediators of 
stress-induced increases in CRF gene expression, and the promoter region of CRF gene 
contains cAMP response element (CRE), which regulates its transcription (Yao and Denver, 
2007). Transcription activity of CREB is determined by phosphorylation at the conserved 
serine 133 residue in response to variety of neuronal stimuli (Denver, 2009). In this study, 
3.0 nM venlafaxine treatment significantly decreased phosphorylation of CREB (pCREB) in 
the hypothalamus in vitro. The mechanism responsible for venlafaxine effect on 
phosphorylation of CREB remains unclear. In addition, significantly reduced pCREB was 
detected in nuclear lysates of cortex after chronic but not acute venlafaxine administration in 
rats (Rossby et al., 1999), although another study demonstrated that chronic low dose (but 
not high dose) of venlafaxine increased expression of pCREB in the hippocampus of rats 
exposed to chronic unpredictable stress (Li et al., 2011). Venlafaxine effect on CREB 
phosphorylation observed in our experiment is intriguing since this transcription factor 
strongly influences expression of various genes that contains CREs in their regulatory 
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regions, and it has diverse functions in various tissues. Whether venlafaxine affects CREB 
phosphorylation levels in other fish tissues remains to be elucidated.  
Our gene expression results from in vitro study with hypothalamic tissue provided 
more evidence that venlafaxine may act as a neuroendocrine disruptor. Physiological effects 
of cortisol on target tissues are mediated by corticosteroid receptors – glucocorticoid and 
mineralocorticoid types (GR and MR, respectively). Cortisol can mediate negative feedback 
regulation of the HPI axis activity via corticosteroid receptors at the level of hypothalamus 
and pituitary. Our results suggest that venlafaxine (both 0.3 nM and 3.0 nM treatments) 
significantly reduced transcript abundances of GR1 and GR2 (but not MR). In our in vivo 
exposure study with acute stressor challenge [Chapter 4], venlafaxine did not alter GR1, GR2 
or MR mRNA expression in hypothalamus or pituitary. Also, another in vivo exposure study 
[Chapter 3, Best et al., accepted] did not detect venlafaxine effects on GR protein expression 
in the whole brain or liver. Taken together, these finding suggest that the effect of in vitro 
venlafaxine treatment on GR gene expression is a short-term/acute exposure effect, although 
reduction in GR1 and GR2 in hypothalamus could lead to decreased tissue sensitivity to the 
negative feedback regulation by cortisol. It should be noted that in humans, many 
antidepressants are known to modulate the HPA axis hyperactivity, which is often associated 
with depressive symptoms, by modulating GR expression (Anacker et al., 2011). In rats, it 
has been shown that even a short-term treatment with venlafaxine affects both GR and MR 
expression in the hippocampus (Yau et al., 2001).   
Our gene expression analyses in the hypothalamus also demonstrated that venlafaxine 
exposure alters the expression of several molecular markers involved in regulation of food 
intake, adding to our in vivo observations that venlafaxine exposure reduced food intake in 
rainbow trout [Chapter 2, Melnyk-Lamont, et al. submitted]. The mRNA levels of two pro-
opiomelanocortin encoding genes, POMCA and POMCB were significantly reduced by 
venlafaxine exposure. POMC undergoes tissue-specific post-translational processing and 
serves as a precursor molecule for several biologically active peptides, including the opioid, 
β-endorphin, and the melanocortin-related peptides, ACTH, α-melanocyte stimulating 
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hormone (α-MSH), β-MSH, and γ-MSH (Tanaka, 2003). In addition to its role in stress 
response, hypothalamus also plays a central role in energy homeostasis, integrating 
peripheral signals of appetite, satiation, and long-term energy-balance and coordinating food 
intake responses (Kalra et al., 1999). Hypothalamus contains neurons that produce numerous 
appetite-stimulating and inhibiting neuropeptides, including neuropeptide Y (NPY) and 
POMC-derived β-endorphin with orexigenic properties, and POMC-derived α-MSH is an 
anorexin (Volkoff et al., 2005; Lin et al., 2000) . Thus, reduction in POMC transcripts may 
lead to a reduction in the formation of POMC-derived peptides by venlafaxine.  
We also detected a reduction of NPY transcripts in the hypothalamic tissues exposed 
to 3.0 nM venlafaxine. As mentioned earlier, NPY is a known appetite stimulator in both 
mammals and fish. Also, NPY is involved in complex interactions with hypothalamus-
pituitary-adrenal (HPA) based on mammalian studies [reviewed in Krysiak et al. (1999)]. 
Doyon et al., (2006) suggested that NPY may participate in activation of the HPI axis, 
possibly through interaction with CRF in trout.  It should be noted that venlafaxine effect on 
NPY mRNA expression was not present in NAN-190 treatment group, but only in the control 
group.  In mammals, many feeding related peptides are known to be modulated by 5-HT, 
including NPY, and there is an antagonistic relationship between 5-HT and NPY (Halford et 
al., 2007). 5-HT1A receptor immunoreactivity has been directly demonstrated in the 
hypothalamic NPY-producing neurons, suggesting that this receptor type is involved in 
mediation of 5-HT effects on the release of this orexigenic peptide (Collin et al., 2002). 
Therefore, the observed downregulation of NPY transcript by venlafaxine may be related to 
alterations in 5-HT signalling similar to that seen with CRF gene expression. We propose 
that the venlafaxine mediated increase in 5-HT levels negatively regulate NPY expression 
and this involves 5-HT1A signalling in trout.  
Reliance of the brain on glucose for meeting energy demands suggest that central 
glucosensing mechanisms play a vital role in energy homeostasis. Hypothalamus contains 
glucosensing neurons, and their firing rates can be either excited or inhibited by circulating 
glucose concentration (Polakof et al., 2011). Glut2 plays a crucial role in glucosensing, and a 
role for Glut2 in feeding regulation has also been suggested (Stolarczyk et al., 2010). 
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Reduced hypothalamic transcript abundance of Glut2 in response to venlafaxine treatment 
may also be playing a role in the drug effect on appetite regulation in trout. 
Pituitary 
In our in vitro experiment with rainbow trout pituitaries, whole pituitaries were used 
(fragmented) as opposed to using only pituitary pars distalis (containing corticotrophs) or 
dispersed pituitary cell culture in order to preserve as much physiological integrity as 
possible. For example, the pituitary neurointermediate lobe contains endogenous arginine 
vasotocin (AVT), which can potentiate response of corticotrophs to CRF stimulation (Baker 
et al., 1996). The purpose of this study was to study the effects on in vitro venlafaxine 
exposure on ACTH production and release in the pituitary. In the pituitary corticotrophs, 
CRF stimulates pro-opiomelanocortin transcription and ACTH secretion through the cAMP-
protein kinase A (PKA) pathway, and although CRF stimulates secretion of ACTH via its 
CRF-R1 receptor, the mechanism of ACTH secretion via the receptor is not fully understood 
(Moriyama et al., 2005). 
Stimulation of rainbow trout pituitary fragments with 10 nM tilapia CRF did 
significantly elevate tissue ACTH levels, but did not show any corresponding changes in 
ACTH released into the incubation medium. Static in vitro incubation systems using pituitary 
tissue fragments are widely used to characterize endocrine physiology (Tsai and Wang, 1997; 
Baker et al., 1996; Yu and Peter, 1992; Yu et al., 1991). However, a potential drawback of 
this system arises due to receptor desensitization as a result of continuous contact with the 
released peptides. This could account for the lack of an effect of CRF on ACTH release in 
the present study. Overall, venlafaxine did affect ACTH production in the trout pituitary, 
although concentration effects or effects of ACTH released in to the medium was unclear. 
This experiment demonstrated some evidence that 5-HT1A receptor may be involved in 
mediation of some of the observed venlafaxine effects. This in vitro venlafaxine effect at the 
level of the pituitary corresponds with our previous results from in vivo exposure study where 
expression of CRF-R1 was altered in the pituitaries of venlafaxine exposed fish following a 
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stressor challenge [Chapter 4], suggesting reduced sensitivity of corticotrophs to CRF 
stimulations due to drug exposure.  
 
Interrenal 
Neither basal nor ACTH-induced cortisol production were altered in head kidney 
pieces exposed to a range of venlafaxine concentrations (0.1 – 1000 nM). Such in vitro 
exposure model represents short-term or acute effects of drug exposure on tissue suggesting 
that venlafaxine exposure does not affect interrenal cortisol biosynthetic capacity in response 
to ACTH stimulation. The results of our ex vivo head kidney revealed that ACTH-induced 
cortisol response was significantly elevated in the presence of high 5-HT (10
-7 
M) in the 
venlafaxine exposed fish. 5-HT is known to play a prominent role as a paracrine factor in 
peripheral tissues involved in various aspects of fish physiology. Recent studies revealed a 
direct stimulatory effect of 5-HT on cortisol secretion by the interrenal tissue in fish (Lim et 
al., 2013; Medeiros and McDonald, 2012). Although in our study 5-HT treatments did not 
significantly stimulate cortisol response, the observed elevation of ACTH-stimulated cortisol 
production in the tissues from venlafaxine exposed fish with high 5-HT treatment suggests 
that this drug may impact endocrine/paracrine interactions that control corticosteroid 
biosynthesis, but this needs further validation.  In addition, our previous ex vivo head kidney 
study [Chapter 3] demonstrated the venlafaxine can alter responsiveness of steroidogenic 
cells to ACTH stimulation, and the mode of action appears to involve pathways upstream of 
the intracellular cAMP signalling cascade. A potential link between venlafaxine and 
paracrine or paracrine/endocrine interactions in the head kidney should be investigated in 
more detail in future studies. Taken together, venlafaxine exposure may alter the functioning 
of the interrenal tissue by eliciting effects on the upstream regulatory elements of the HPI 
axis.  
5.6 CONCLUSIONS 
Overall, this study demonstrated several lines of evidence suggesting that venlafaxine 
is a neuroendocrine disruptor in fish, and it directly affects the functioning of the 
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hypothalamus, pituitary and interrenal tissues in rainbow trout. Venlafaxine reduced 
phosphorylation of CREB transcription factor, which is involved in the regulation of a wide 
array of genes involved in cellular metabolism and hormone production. Venlafaxine altered 
expression of key molecular markers involved in HPI axis regulation, including CRF and GR 
transcript levels. Moreover, mRNA abundances of several peptides involved in energy 
homeostasis/food intake regulation, including POMC, Glut2, and NPY, were also affected by 
venlafaxine exposure. Effects of 3.0 nM venlafaxine treatment on CRF and NPY involve 
disruption in serotonergic activation. Venlafaxine also disrupted CRF-mediated ACTH 
production in trout pituitaries. Interrenal cortisol biosynthesis capacity was not affected by in 
vitro venlafaxine exposure in the present study, although finding of our head kidney ex vivo 
study indicated that interrenal tissues from venlafaxine exposed fish have higher cortisol 
production in response to ACTH stimulation in the presence of serotonin. Altogether, 
venlafaxine impacts the functioning of each component of the HPI axis and the mode of 
action involves disruption in serotonin signalling. 
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Summary of key findings 
 
The overall goal of this thesis was to characterize the impact of environmentally 
relevant venlafaxine exposure on the stress performance in rainbow trout (Oncorhynchus 
mykiss), as well as to investigate the mechanisms of action of venlafaxine in disrupting the 
functioning of the hypothalamus pituitary interrenal (HPI) axis. Altogether, the findings 
support our primary hypothesis that venlafaxine at environmentally relevant concentrations is 
a neuroendocrine disruptor in rainbow trout. Specifically, the studies provide evidence for the 
first time that venlafaxine exposure: 
1. Alters monoamine levels and their turnover rates, with significant changes occurring 
in the midbrain and hindbrain regions of the trout brain [Chapter 2]. 
2. Impacts appetite regulation [Chapter 2] and this involves changes in the expression 
levels of key neuropeptides associated with food intake/energy homeostasis [Chapter 
2, 4, 5]. 
3. Alters liver and gill metabolic capacities [Chapter 3]. 
4. Disrupts adaptive stressor-mediated plasma cortisol and glucose responses [Chapter  
2 , 3, 4], where specific effects on these plasma parameters are influenced by several 
factors, including type of stress (e.g. social or handling), overall 
sensitivity/responsiveness state of the HPI axis, and nutritional status of animals 
[Chapter 2, 3, 4]. 
These findings are summarized in Fig. 6-1. 
In an attempt to elucidate potential mechanisms involved in disruption of the HPI axis 
functioning, our studies established that venlafaxine targets multiple 
neuroendocrine/endocrine components involved in its functioning (summary presented in 
Figure 6-2). In the hypothalamus, venlafaxine alters expression of the key neuropeptides 
involved in the HPI axis regulation (corticotropin releasing factor, CRF, and neuropeptide Y, 
NPY). In the pituitary, ACTH response to CRF stimulation is disrupted and this may involve 
alteration in CRF receptor type 1 (CRF-R1) transcript levels. At the interrenal tissue level, 
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the responsiveness of steroidogenic cells to ACTH stimulation appears to be affected by 
venlafaxine and the mode of action appears to involve disruption of pathways upstream of 
cAMP production. Also, our results suggest the venlafaxine effects on the interrenal tissue 
may be mediated via interactions with paracrine factors in the head kidney. In general, the 
mode of action of this drug may include disruptions of specific responses via serotonergic 
actions and pathways involved in CREB signalling, while the exact mechanism of action 




Figure 6-1. Overview of adaptive responses affected by venlafaxine exposure in rainbow 
trout, as demonstrated over the course of the studies included in this thesis (affected 
responses indicated by red bolts). Monoamine levels were mostly altered in the midbrain and 
hindbrain regions (highlighted in orange). Hypothalamic region (highlighted in grey) 
participates in regulation of various neuroendocrine responses, and receive monoaminergic 
innervation (represented by arrows) from the affected areas. Trout brain is in sagittal view; 
enlarged window shows hypothalamic region (with preoptic area) and pituitary. 
Abbreviations: HPI – hypothalamic pituitary interrenal axis, CREB – cAMP response 






Figure 6-2. Overview of venlafaxine exposure effects on individual components of the 
hypothalamus-pituitary-interrenal (HPI) axis in rainbow trout, as demonstrated by our in vivo 
and in vitro studies presented this thesis. Abbreviations: VEN – venlafaxine, CRF- 
corticotropin releasing factor, ACTH – adrenocorticotropic hormone, CREB – cAMP 
response element binding protein, 5-HT- serotonin. Numbers: 1- hypothalamic region, 2 - 




Limitations and future directions 
Results from our in vivo exposure study with acute stressor challenge [Chapter 4] 
demonstrated that venlafaxine-exposed fish exhibited reduced transcript abundance of CRF 
receptor CRF-R1, which is the primary type involved in regulation of the HPI axis. While no 
changes in mRNA levels of CRF were detected, it is not known whether CRF protein levels 
remained unchanged. CRF has been shown to downregulate CRF-R1 mRNA levels via a 
cAMP-PKA mediated mechanism (Moriyama et al., 2005). Thus, further investigation into 
how venlafaxine affects hypothalamic CRF protein levels and cAMP-PKA signalling 
cascades in the pituitary will help to elucidate mechanisms of venlafaxine effects on the 
pituitary corticotrophs.  
CREB is a key transcriptional regulator of many genes that function in cellular 
metabolism. For instance, CREB has been proposed to regulate hepatic enzymes involved in 
gluconeogenesis including phosphoenol pyruvate carboxykinase (PEPCK) (Mayr and 
Montminy, 2001). Our past results from in vivo exposure study [Chapter 3, Best et al., 
accepted] demonstrated that venlafaxine exposure increased activity of liver PEPCK. Thus, 
future investigation into how venlafaxine affects rapid CREB phosphorylation in liver could 
provide a link to a possible mechanism responsible for effect of this drug on glucose 
production in response to stress in trout.  
Our in vitro studies with the pituitary fragments were performed in a static system 
and this may have inhibited the ACTH secretion response, possibly due to desensitization of 
secretion responses mediated by CRF. Therefore, perfusion studies with trout pituitaries 
would offer a better system for evaluation of venlafaxine effect on ACTH secretion. In 
addition, it would be interesting to investigate whether venlafaxine exposure affects cortisol 
mediated negative feedback on the hypothalamus and/or pituitary using in vitro approach 
with glucocorticoid receptor antagonists.  
Work presented in this thesis was mainly aimed at teasing out serotonin-associated 
venlafaxine effects, and investigation of potential norepinephrine and dopamine mediated 
effects due to venlafaxine exposure remains a subject for future studies. Specifically, a 
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potential focus of future studies can be directed towards elucidating venlafaxine effects on 
stressor-induced rapid catecholamine responses. 
 
Relevance / significance 
Most aquatic biomonitoring studies involving controlled exposures are conducted 
with concentrations that are greatly exceeding environmentally realistic levels in order to 
increase chances of detecting and quantifying exposure effects. To our knowledge, very few 
studies have looked at the effects of venlafaxine exposure at environmentally relevant levels, 
which range from low ng/L to low μg/L, and none have evaluated the effects on the 
physiology of stress response. The work presented in this thesis underscores the need to 
conduct detailed studies in non-target species involving individual pharmaceutical 
components associated with wastewater effluent mixtures. This will assist in extrapolating 
potential effects of a wide range of pharmaceutical compounds that share similar 
pharmacological modes of action. From an ecotoxicological standpoint, it is important to 
study the effects of the wastewater effluent and its components on aquatic organisms in order 
to estimate their impact on the ecosystem. In addition to contributing to the body of literature 
on neuroendocrine disruptive compounds affecting stress physiology of fish, the results from 
our studies underscore the need to develop and employ effective risk management strategies 
to minimize environmental contamination with pharmaceuticals. For example, since overall 
pharmaceutical consumption is not likely to be reduced with growing population levels and 
increasing prescription trends, employment of drug disposal programs and public education 
in proper disposal would help to reduce entry of unused medicines into the environment. 
Development of advanced wastewater treatment processes with higher pharmaceutical 
removal efficiencies and investment in wastewater infrastructure is also important. Another 
additional risk management approach that should gain more emphasis in the near future is 
development of “green pharmacy”. In accordance with its principles, drug design should not 
only be based on the functionality of a chemical necessary for its therapeutic application, but 
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Figure A1. Schematic representation of the rainbow trout brain showing different regions 
[hypothalamus (Hyp), telencephalon (Tel), preoptic area (POA), optic tectum (OT), midbrain 
(MB), cerebellum (Cer) and hindbrain (HB), olfactory bulbs (OB), and pituitary (Pit)] (A), 
and levels of 5-hydroxyidndoleacetic acid, 5-HIAA (B) and 3,4- dihydroxyphenylacetic acid, 
DOPAC (C) in these brain regions (excluding OB) after a 7-day exposure to venlafaxine. 






Figure A2. Transcript levels of corticotropin-releasing factor binding protein, CRF-BP (A), 
pro-opiomelanocortin A, POMCA (B), and neuropeptide Y, NPY (C)  in selected regions of 
rainbow trout brain (see methods for details) following a 7-day venlafaxine exposure. Values 
were normalized to EF1α and represent percent hypothalamus control; bars represent means 
± SEM (n = 5). Abbreviations: hypothalamus (Hyp), preoptic area (POA), midbrain (MB), 
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Figure B1. Glucocorticoid receptor (GR) protein expression. Effect of 7 day venlafaxine 
exposure on GR protein expression levels in liver (A) and brain (B) of rainbow trout.  A 
representative western blot image of GR expression is shown above the bar graph. Values are 
shown as % control (normalized to β-actin) and represent means ± SEM (n = 6 fish). There 







Figure B2. Liver glucose transporter 2 (GLUT2) mRNA abundance. Effect of a 7-day 
venlafaxine exposure on liver GLUT2 mRNA abundance in rainbow trout. Values are shown 
as % control (normalized to EF1α) and represent means ± SEM (n = 6 fish). There were no 






























Figure C1. Schematic representation of rainbow trout brain in sagittal view, depicting the 
way the brain was sectioned to separate hypothalamic region from the rest of the brain. 
Dashed lines indicate where the cuts were made, and numbers represent their order (A) 
(Abbreviations: OB - olfactory bulb,  ON - optic nerve, T - telencephalon, OT - optic tectum, 
Cer - cerebellum, HB - hindbrain, Hyp - hypothalamus). Effect of serotonin treatments (5-
hydroxytryptamine, 5-HT) on transcript abundance of corticotropin releasing factor (CRF) in 
hypothalamic tissue (B) following 2 h incubation period. Bars represent means ± SEM (n = 5 
independent samples), values were normalized to elongation factor 1 alpha (eF1alpha). 




















Figure C2. Transcript levels in rainbow trout hypothalami in response to incubation with 
serotonin, 5-HT (100 nM), 5-HT1A receptor antagonist, NAN-190 (1 μM), or combination of 
NAN-190 and 5-HT. All values were normalized to EF1α and represent percent change from 
the control group. Bars show means ± SEM (n = 6 independent fish). Gene abbreviations: 
EF1α, elongation factor 1α; CRF-BP, corticotropin-releasing factor binding protein; Glut2, 
glucose transporter type 2; NPY,  neuropeptide Y; GR1 and GR2, glucocorticoid receptor 1 
and 2, respectively; MR, mineralocorticoid receptor; POMCA and POMCB, pro-
opiomelanocortin A and B, respectively. No significant treatment effects were detected on 
transcript abundances of the above mentioned genes (P > 0.05, one-way ANOVA). 
